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Abstract
T-cells expressing chimeric antigen receptors (CARs) can elicit dramatic clinical responses in CD19+
malignancies; however, therapeutic options for acute myeloid leukemia (AML) and solid tumors remain
limited. Folate receptor beta (FRβ) is a myeloid-lineage antigen expressed in 70% of AML. Here, we tested
the hypothesis that FRβ could be an effective new CAR T-cell target in AML. Low affinity FRβ CAR T-cells
displayed specific reactivity for FRβ+ cells in vitro and delayed human AML outgrowth in mice but were
unable to completely eliminate the tumor. An optimized higher affinity CAR exhibited drastically increased
anti-leukemic activity in vitro and in vivo. Further, we assessed the potential for toxicity caused by
recognition of non-tumor tissues, the primary concern for new CAR target antigens. As many cell-surface
markers are shared between AML blasts and healthy hematopoietic stem cells (HSCs), we measured CAR
recognition of FRβ on HSCs. Neither low nor high affinity CAR T-cells showed reactivity against bone
marrow HSCs. However, we noted high surface FRβ on mature monocytes and found that they were lysed
when cultured with high affinity CAR T-cells. To minimize the potential for toxicity, we investigated
transient CAR expression via mRNA electroporation. High affinity mRNA CAR T-cells retained effective
anti-tumor activity while posing a decreased risk for long-term myeloid toxicity.
In addition to AML, FRβ is also expressed on tumor associated macrophages (TAMs) in human patients
and mouse models of cancer. Since TAMs help promote tumor growth and correlate with worse
prognosis, we hypothesized that redirecting CAR T-cells to target FRβ+ TAMs could be an effective way to
improve CAR T-cell therapy in epithelial cancers. We developed a mouse FRβ-specific CAR for use in
implantable murine ovarian tumor models. Our preliminary data suggest that adoptive transfer of FRβ
CAR T-cells results in destruction of FRβ+ TAMs, a mild delay in tumor growth, and systemic immune
activation. However, transient toxicity and on-target depletion of macrophages in non-tumor tissues was
also observed, warranting caution when translating FRβ CARs for clinical use. Our results suggest that
safe application of FRβ CAR T-cells could contribute to tumor elimination in AML and solid tumors.
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ABSTRACT
FRβ-DIRECTED CAR T CELLS FOR IMMUNOTHERAPY OF CANCER
Rachel C. Lynn
Daniel J. Powell Jr
T-cells expressing chimeric antigen receptors (CARs) can elicit dramatic clinical responses in
CD19+ malignancies; however, therapeutic options for acute myeloid leukemia (AML) and solid
tumors remain limited. Folate receptor beta (FRβ) is a myeloid-lineage antigen expressed in 70%
of AML. Here, we tested the hypothesis that FRβ could be an effective new CAR T-cell target in
AML. Low affinity FRβ CAR T-cells displayed specific reactivity for FRβ+ cells in vitro and
delayed human AML outgrowth in mice but were unable to completely eliminate the tumor. An
optimized higher affinity CAR exhibited drastically increased anti-leukemic activity in vitro and
in vivo. Further, we assessed the potential for toxicity caused by recognition of non-tumor tissues,
the primary concern for new CAR target antigens. As many cell-surface markers are shared
between AML blasts and healthy hematopoietic stem cells (HSCs), we measured CAR
recognition of FRβ on HSCs. Neither low nor high affinity CAR T-cells showed reactivity against
bone marrow HSCs. However, we noted high surface FRβ on mature monocytes and found that
they were lysed when cultured with high affinity CAR T-cells. To minimize the potential for
toxicity, we investigated transient CAR expression via mRNA electroporation. High affinity
mRNA CAR T-cells retained effective anti-tumor activity while posing a decreased risk for longterm myeloid toxicity.
In addition to AML, FRβ is also expressed on tumor associated macrophages (TAMs) in human
patients and mouse models of cancer. Since TAMs help promote tumor growth and correlate with
worse prognosis, we hypothesized that redirecting CAR T-cells to target FRβ+ TAMs could be an
v

effective way to improve CAR T-cell therapy in epithelial cancers. We developed a mouse FRβspecific CAR for use in implantable murine ovarian tumor models. Our preliminary data suggest
that adoptive transfer of FRβ CAR T-cells results in destruction of FRβ+ TAMs, a mild delay in
tumor growth, and systemic immune activation. However, transient toxicity and on-target
depletion of macrophages in non-tumor tissues was also observed, warranting caution when
translating FRβ CARs for clinical use. Our results suggest that safe application of FRβ CAR Tcells could contribute to tumor elimination in AML and solid tumors.
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CHAPTER 1: Introduction
Cancer
Cancer is currently the second leading cause of death in the United States; a close second behind
heart disease1. Nearly 1 in 2 men and 1 in 3 women will receive a cancer diagnosis in their
lifetime. In 2015, approximately 1.6 million new cases will be diagnosed and more than 500,000
people will die from this disease2. The term cancer is used to encompass a large, diverse group of
malignancies stemming from the uncontrolled growth of one’s own cells. This unrestricted
expansion results from multiple acquired genetic mutations that cooperate to overcome a cell’s
intrinsic checkpoints designed to regulate proliferation. Hanahan and Weinberg’s now famous
review from 15 years ago outlines the basic requirements needed for cancer to manifest 3.

Cancer Inflammation and the Tumor Microenvironment
In the 1860s, the German physician Rudolph Virchow, heralded by many as the father of modern
pathology, noted the prevalence of white blood cell infiltration into tumors. His “chronic irritation
theory” proposed that cancer was caused by inflammation at the site of the tumor4. While only
about 15% of cancer can be directly linked to inflammatory stimuli (e.g. cigarette smoking and
lung cancer, Hepatitis infections and hepatocellular carcinoma, and Crohn’s disease and
colorectal cancer), it is now well-established that nearly all types of cancer, particularly solid
tumors, contain stroma with a large component of infiltrating immune cells. The tumor cells and
associated non-tumor cells are collectively referred to as the tumor microenvironment (TME). In
1986, Harold Dvorak’s review highlighted similarities between stromal compartments in tumors
and those involved in normal wound healing, and first popularized the notion of tumors as
“wounds that do not heal.”5 Tumors can co-opt several of the body’s wound-healing capabilities
1

to promote tumor cell growth and metastasis: angiogenesis, remodeling of extracellular matrix,
and recruitment of immune cells. The importance of inflammation in cancer is now highlighted as
a major underlying factor in an updated Hanahan and Weinberg Hallmarks of Cancer review
published in 20116.

Anti-Cancer Immunity
The adaptive immune system has evolved primarily to help protect the host from foreign
pathogens including bacteria, viruses, and parasites. For this reason, T cells with T cell receptors
(TCRs) specific for self-antigens are deleted in the thymus during development. Because cancers
derive from normal cells, the presence of tumor-specific T cells is thought to be quite low. Escape
of self-reactive T cells does happen and can contribute to the development of autoimmune
diseases. However, for proper activation and proliferation, T cells must encounter antigen in the
presence of “licensed” antigen presenting cells (APCs) which are activated via recognition of
foreign “danger signals” in the setting of a microbial infection. Tumors generally promote an
immunosuppressive environment with impaired APC function. Inducing proper T cell responses
against tumor cells would require breaking central tolerance (or escape of self-reactive T cells),
presentation of self-antigen within MHC molecules of activated APCs, and finally, survival
within a hostile TME.
In 1893, William Coley began administering a mixture of bacterial products to patients with
sarcoma after his research uncovered a connection between infections and cancer regression.
“Coley’s toxins” were given to patients for more than 50 years, but have largely been abandoned
in modern medicine for lack of clear efficacy7. While bacterial infections do not cure cancer, they
do produce potent immune activation, something generally missing in the steps to activation of
tumor-reactive T cells. It is possible that Coley’s toxins provided innate immune activation,
2

which led to increased ability to prime an anti-tumor T cell response. Analogous strategies are
now being employed as components of cancer vaccines in preclinical and clinical use.
While the theory of adaptive cancer immunity dates back to the early twentieth century, the idea
was highly controversial due to lack of appropriate model system in which to test the hypothesis.
In the last two decades, seminal work from the Schreiber group was finally able to show
definitive evidence for increased tumor growth in immunocompromised mice8,9. Either
lymphocyte deficient or interferon-gamma (IFNg) receptor deficient mice were at greater
susceptibility to carcinogen-induced and spontaneous tumor formation. In addition, when
carcinogen-induced tumors from immunocompromised mice were transferred into
immunocompetent hosts, a large percentage of mice rejected the tumor9. These finding suggested
that the immune system can directly eliminate cancer and that tumors expanded in
immunocompetent hosts are antigenically or otherwise phenotypically different from those in
immunosuppressed hosts. These and other similar findings led to the “Three Es” hypothesis of
cancer immunoediting10 (Elimination -> Equilibrium -> Escape). This hypothesis posits that early
during tumor formation, the immune system is alerted and cancer is eliminated. Any cells
surviving the initial elimination phase enter a long equilibrium phase in which the immune
system puts significant selective pressure on developing tumors, so that when tumors finally
become clinically detectable (escape phase) they have evolved to avoid immune-mediated
destruction.
Even though tumors in cancer patients have likely evolved over time to evade anti-tumor T cell
responses, the presence of T cells does still seem to be beneficial. The presence of intratumoral T
cells, particularly CD8+ cytotoxic T cells (CTLs) or gene signatures associated with activated T
cells, correlates with better prognostic factors or improved response to therapy in a wide array of
cancer patients including melanoma11, breast12, ovarian13, head and neck14, lung15,16, and
3

gallbladder17. This suggests that the elimination phase of anti-cancer immunity could be ongoing,
with the tumor ultimately winning out. Stimulation of tumor-reactive T cells could tip the balance
of cancer immunity towards elimination. However, a productive CTL response in the TME
requires the T cells to survive the hostile immunosuppressive elements that help the tumor cells
thrive.

Suppressive elements of the inflammatory tumor microenvironment
Myeloid cells
The innate immune compartment represents the first line of defense against invading pathogens
and its activation is critical for subsequent adaptive immune responses in B and T cells. Myeloid
cells, composed of monocyte/macrophages, dendritic cells (DCs), and neutrophils, are a major
component of the innate immune system and play a vital role in promoting tumor growth.
Macrophages are probably the most well-characterized myeloid component of the TME.
Although likely oversimplified, the M1/M2 paradigm of macrophage polarization posits that
macrophage phenotype is highly plastic and that the functional activity of macrophages is context
dependent. This paradigm defines proinflammatory macrophages as M1 and immunosuppressive
macrophages as M218. Tumor associated macrophages (TAMs), largely thought to differentiate
from infiltrating monocytes, can in theory mediate both tumor destruction (M1 phenotype) and
promotion of tumor growth (M2 phenotype). However, the soluble chemokines and cytokines
(CCL2, MCSF, IL4, IL10, and TGFβ) in the TME favor the recruitment and M2-like polarization
of TAMs19. Macrophages at tumor sites can secrete growth factors, matrix metalloproteases, proangiogenic factors like VEGF, and express inhibitory ligands or immunosuppressive cytokines to
directly promote tumor growth, angiogenesis, metastasis, and evasion of immune recognition. In
the majority of cancer patients, the presence and density of TAMs correlates with poorer
4

prognoses20. Strategies to block myeloid recruitment21-23 or differentiation24, promote TAM
depletion25-27, or TAM repolarization28-31 have shown promising results in preclinical studies.
Tumor-associated dendritic cells also show dysfunctional tumor-promoting characteristics
compared to their proinflammatory counterparts. DCs function as professional antigen presenting
cells (APCs) that uptake and present antigens to promote adaptive immunity32. For this reason,
the presence of DCs within tumors is generally associated with better prognosis33. Upon pathogen
encounter, DCs sense foreign danger signals that promote maturation and maximal functional
capacity for antigen presentation. Possibly due to the lack of appropriate danger signals and other
immunosuppressive cytokines in the TME, tumor localized dendritic cells tend to have a more
immature phenotype with defects in antigen presentation compared to normal tissue DCs34,35.
Although less well-studied, tumor associated neutrophils (TANs) may also display polar
phenotypes affected by the TME36. In a mouse model, researchers recently identified the role of
TGFβ in inducing a pro-tumor “N2” TAN phenotype, and show that depletion of TANs can
decrease tumor growth37.
Immature myeloid cells that heavily infiltrate tumors in both mouse models and human disease
also have suppressive functions. Both monocytic and granulocytic myeloid-derived suppressor
cells (MDSCs) have been described. While these compartments may contribute to the more
mature TAM and TAN compartments, respectively, immature MDSCs can also secrete
immunosuppressive cytokines and inhibit T cell activity through production of prostaglandin-E2
(PGE2), arginase, and iNOS38-40.

Lymphocytes
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Lymphocytes, including B and T cells, comprise the adaptive arm of the immune system. Both B
and T cells are found in tumors, albeit at lower frequencies compared to myeloid cells. There are
conflicting reports of the activity of B cells in the TME in various mouse models of cancer,
although the majority of studies in humans generally support a favorable relationship between the
presence of CD20+ B cells and prognosis41. However, this subset is grossly understudied
compared to T cells, and much remains to be discovered about the role of B cells in cancer. T
cells are comprised of CD8+ CTLs and CD4+ helper T cells (Th). Much like myeloid cells, CD4+
T cells are polarized in the TME towards an anti-inflammatory (Th2) phenotype that counteracts
a productive immune response. In particular, a subset of CD25-high, FoxP3+ regulatory T cells
(Tregs) are commonly described in cancer. Tregs are particularly potent producers of IL10 and
TGFβ and contribute to the impediment of anti-tumor immunity and are correlated with worse
prognosis in cancer42.
As noted above, activated CD8+ T cells have the capacity for potent cytotoxic effects against
antigen-expressing target cells, and strategies to overcome immunosuppression and stimulate
tumor-reactive T cells could result in clinically beneficial anti-tumor immunity.

Tumor Immunotherapy
Cytokine therapy
Cytokines are small secreted protein messengers that bind to receptors on target cells and mediate
downstream signaling changes. Cytokines are key mediators of both innate and adaptive
immunity, and as discussed above, the cytokine milieu in a given microenvironment can
dramatically affect the proinflammatory or immunosuppressive polarization of local immune
cells. Therefore, modulation of the tumor cytokine milieu became of great interest in tumor
therapy. It was reasoned that provision of proinflammatory cytokines could have direct cytotoxic
6

effect on tumor cells or activate a proinflammatory anti-tumor response from tumor associated
myeloid cells and/or tumor-reactive T cells. Interleukin-2 (IL2) became the first cytokine therapy
approved by the United States Food and Drug Administration (FDA) in 1992 for treatment of
metastatic melanoma and renal cell carcinoma. Interferon-α (IFNα) is also approved for single
use in high risk melanoma and some hematologic malignancies43. Among other cytokines,
interferon-γ (IFNg) and interleukin-12 (IL12) have been broadly evaluated in preclinical models
with some promising effects. Clinical application of these cytokines has not been as
rewarding44,45. For the majority of single agent cytokines used for clinical application, including
FDA approved IL246 and IFNα47, systemic toxicity related to high serum cytokine levels is the
limiting factor for clinical use. Paired with low to moderate anti-tumor activity43,48, systemic
toxicity of cytokine therapy has greatly limited its widespread use in the clinic. The field is
developing new ways to locally deliver high concentrations of cytokines to the tumor
microenvironment. These approaches49,50 may allow for beneficial use of cytokine therapy
without systemic toxicity in the future.

Tumor vaccines
Like common vaccines for infectious diseases, tumor vaccines aim to generate anti-tumor
immunity by injecting the patient with tumor antigen. With the exception of a few viral tumor
antigens (like E6/E7 HPV viral proteins involved in the pathogenesis of cervical cancer) the vast
majority of targeted tumor antigens are self-proteins. As discussed above, tumor vaccine
strategies must provide an extra “danger signal” to break central tolerance to self-antigens. GMCSF is widely used in vaccine strategies due to its potent activation of APCs like dendritic cells
and macrophages51. The tumor antigen component can be derived from selected tumor antigen
peptides, DNA or viral vectors encoding tumor antigens, or non-selected whole tumor cell
7

vaccine approaches52. The first FDA-approved tumor vaccine, Provenge, was approved for
prostate cancer in 2010. Other vaccine strategies are proving efficacious, particularly when used
in combination with T cell immunomodulatory antibodies.

Immunomodulatory antibodies
Costimulation
T cells in the tumor microenvironment likely encounter multiple immunosuppressive elements.
One strategy to boost anti-tumor immunity is to provide positive costimulation in the form of
monoclonal antibodies (mAbs). CD28 provides the classic second signal of T cell activation in
the setting of foreign antigen encounter on activated APCs. Unfortunately, provision of
“superagonist” anti-CD28 mAb resulted in severe cytokine storm and related toxicity in
humans53. Agonistic antibodies for T cell costimulatory receptors of the TNF receptor
superfamily are also currently under evaluation in the clinic. Agonistic antibodies against CD137
(4-1BB)54,55, CD134 (OX40) and CD27 have been evaluated in clinical trials. Anti-CD137
antibody therapy yielded response rates of about 6%, although hepatotoxicity did occur at higher
doses55. Anti-OX40 therapy demonstrated evidence of immune activation in patients with
advanced cancer; however, the development of human anti-mouse antibodies precluded further
use56. New humanized OX40 antibodies are in development to reduce potential immunogenicity.
Anti-CD27 therapy resulted in one complete response and stable disease in a few additional
patients with hematological malignancies57. Agonistic antibodies for TNF receptor family
members are generally well tolerated, and response rates will likely improve in combination with
other immunomodulatory regimens.

Checkpoint Blockade
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Like costimulatory receptors, inhibitory receptors are also present on the surface of T cells
following activation to serve as a checkpoint to prevent over-activation and resulting immune
pathology. T cell inhibitory receptors cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and
programmed cell death protein 1 (PD-1) are important components driving the retraction phase
following clearance of microbial pathogens. CTLA-4 outcompetes CD28 in binding shared
ligands CD80 and CD86, effectively blocking CD28 costimulation in T cells, while also
propagating inhibitory signaling upon ligation58. PD-1, upon binding its ligands PD-L1 or PD-L2,
activates the inhibitory phosphatase SHP2, which mediates inhibition of TCR activating
signals59,60. Tumors take advantage of these pathways and commonly upregulate expression of
ligands for inhibitory receptors as a means to evade T cell-mediated destruction. The expression
of PD-1 ligand PD-L1 is inversely correlated with survival in many different types of cancer61.
Blocking the interaction of inhibitory receptors and their respective ligands is showing great
promise in recent clinical trials. In 2011, ipilimumab, an antibody for CTLA-4, received FDA
approval for the treatment of advanced melanoma62, although efficacy in other types of cancer has
been minimal. A second CTLA-4 antibody showed early promise but failed to show
improvements over standard chemotherapy in Phase III trials. A comparison of the isotypes led to
the now well-accepted hypothesis of a second means of action of ipilimumab involving depletion
of CTLA-4+ suppressive Tregs. The anti-PD-1 antibodies nivolumab and pembrolizumab were
also recently granted FDA approval for advanced melanoma and non-small-cell lung carcinoma
(NSCLC). Initial trials blocking PD-163,64 and PD-L165 have provided exciting response rates in a
number of different types of cancer. A comparison of ipilimumab and nivolumab or combination
provided direct evidence for the greater efficacy of PD-1 blocking antibody therapy in melanoma
patients. PD-1 directed therapies have lower side effects, broad efficacy across multiple tumor
types, and better efficacy as single use agents66. For these reasons, PD-1 blocking strategies are
currently being built into a wide range of preclinical and clinical studies as single use agents or in
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combination with traditional chemotherapy, radiation therapy, and other immunotherapies such as
cancer vaccines and adoptive T cell therapies.

Adoptive T cell Therapy
TIL
Cytokine therapy, tumor vaccines and immunomodulatory antibodies share the common goal of
inducing expansion and improving functional reactivity of tumor-specific T cells in the patient.
Instead of relying on in vivo activation and proliferation, tumor infiltrating lymphocyte (TIL)
therapy involves the isolation and ex vivo expansion of tumor-reactive T cells which are then reinfused into the patient. TIL can be activated non-specifically or pulsed with autologous tumor or
antigen-specific peptides. TIL therapy trials have been conducted for melanoma since 198867. In
this time, more than 200 patients with metastatic melanoma have been treated with TIL after
lymphodepleting preconditioning, and objective response rates range from 49-75% with 22% of
patients achieving a complete tumor regression68. Response rates increased with the strength of
lymphodepleting conditioning, now well accepted to increase engraftment and activity of
transferred T cells69. This likely works through depletion of suppressive Tregs and other
lymphocytes that serve as sinks for homeostatic T cell cytokines70,71. While the vast majority of
trials have been conducted in melanoma, clinical studies in other types of cancer are currently
recruiting patients. Early results using TIL for HPV-related cancers recently reported encouraging
results in patients with metastatic cervical cancer72.
A common theme from the evolution of tumor immunotherapy, particularly strategies attempting
to harness the power of naturally-occurring tumor reactive T cells, is that not all patients respond
and certain types of cancer are much more amenable to these therapies than others. Melanoma,
for example, seems to be particularly responsive to tumor immunotherapeutic strategies. Unlike
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other tumors, T cells make up a large percentage of tumor infiltrating immune cells in
melanoma73. Incidentally, melanoma also has the highest mutation rate compared to other types
of cancer74, suggesting that it may be a particularly immunogenic tumor. This hypothesis is
strengthened by recent identification of tumor mutation-specific T cell clones in the infused TIL
product in some patients with positive responses to TIL therapy75,76. Other types of cancer with
lower mutational load and lower incidence of tumor-reactive T cells may be less affected by
immunomodulatory therapies.

Engineered Tumor-Specific T cells
Recent advances in DNA manipulation techniques and development of safer viral vector
technology have advanced the efficiency and safety of gene transfer into lymphocytes. Instead of
relying on the endogenous presence of tumor reactive T cell clones, tumor specificity can be
engineered into patient T cells ex vivo before reinfusion into the patient. This approach has the
potential to broaden the opportunity for effective T cell therapy in patients with cancer that does
not naturally induce T cell immunity. One method of introducing tumor specificity is through
gene transfer of tumor antigen specific TCRs. For this method, alpha and beta TCR genes are
cloned from tumor-reactive clones and transferred into patient T cells using viral vectors. The
first engineered TCR to enter the clinic was specific for melanoma antigen MART-177 and
provided evidence for the safety and potential of genetically engineered lymphocytes in
melanoma patients. Affinity-enhanced MART-1 TCRs improved the response rate in melanoma
but also resulted in destruction of healthy melanocytic tissue78. The cancer testis antigen NYESO-1 is rarely expressed in adult tissue outside of the testes and is commonly re-expressed in a
wide variety of cancers79. TCRs specific for NY-ESO-1 displayed in vitro reactivity against a
panel of melanoma as well as non-melanoma cell lines of epithelial and sarcoma origin80. Initially
tested in melanoma and synovial sarcoma, the NY-ESO-1 TCR became the first platform to
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safely and successfully treat non-melanoma cancer with TCR gene-engineered cells81. Long-term
follow-up of 38 patients revealed >50% response rate in both melanoma and synovial cell
sarcoma82. Clinical responses using an affinity-enhanced NY-ESO TCR have also been recently
reported in multiple myeloma83.
Even when high functioning engineered TCRs can be isolated and applied to patients with many
types of cancer, they are inherently restricted to use in only some subsets of the population. TCRs
recognize peptide antigen within the context of specific HLA molecules. For example, both the
MART-1 and NY-ESO-1 TCRs are restricted to use in patients with HLA-A0201 alleles. Even as
one of the most widely represented HLA serotypes, HLA-A0201+ individuals only make up 2050% of the US population84. Like natural tumor-reactive T cells, gene-engineered TCRs also rely
on tumor cell antigen processing and presentation on surface MHC molecules. Downregulation of
MHC-class I and abnormalities in antigen processing machinery are common mechanisms used
by tumors to evade immune recognition85. Provision of exogenous α and β chains into open
repertoire T cells has the potential to create autoantigen specificity by mispairing with
endogenous TCR α and β chains. While this theoretical concern has not yet resulted in any
observed toxicity, mispairing with endogenous TCR chains also likely leads to decreased surface
bioavailability of functional transferred TCR.

CAR T cells take the driver’s seat
T cells engineered to express chimeric antigen receptors (CARs) share the benefits of tumorspecific TCR engineered cells and overcome many of their limitations. With credited
development by Zelig Eshhar and colleagues in 1989, CARs are chimeric proteins composed of a
tumor antigen recognition domain coupled to intracellular T cell activation signaling domains 86,87
(see Figure 1.1 for a simplified schematic representation). The tumor antigen recognition
12

domain is most often derived from the single-chain variable fragment (scFv) of a tumor-specific
monoclonal antibody, although ligand/receptor-based chimeric immune receptors have also been
developed to target the respective ligand/receptor expressed on tumor cells (ex: CD27/CD7088,
NKG2D/NKG2DL89,90, IL13/IL-13Ra291, FSH/FSHR92). CAR T cells recognize native surface
protein expressed on the tumor cell surface and do not rely on functioning tumor cell antigen
processing and presentation in MHC complexes. In principle, CAR T cells can also be applied to
any patient with antigen-positive tumor regardless of HLA serotype. CAR T cell constructs
contain both antigen recognition and T cell activation domains, so mispairing with endogenous
TCR components is not a major concern. Although the original constructs published by Eshhar
utilized constant regions from the TCR α and β chains, most modern CARs utilize signaling
domains from CD3ζ chain to modulate T cell activation (Figure 1.1).

Figure 1.1 Schematic representation of CAR design and functional activity.
mAb – monoclonal antibody, V – Variable heavy chain, VL– variable light chain, TCR – T cell
receptor.
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The possibility of utilizing tumor-redirected chimeric T cell receptors was quickly realized using
T cells recognizing the ovarian cancer antigen FRα93,94. Early clinical application of FRα-specific
CAR T cells was well tolerated but their efficacy was disappointing due to the poor survival of
CAR T cells after infusion in patients95. Decreasing T cells numbers coincided with the
development of inhibitory factors in the serum. Responses in other early CAR T cell trials for
CD171+ glioblastoma96 and CD20+ lymphoma97 were also minimal with relatively short CAR T
cell persistence. These early trials all used CAR constructs with only CD3ζ signaling. In the
meantime, research in preclinical CAR T cell models suggested that inclusion of CD28
costimulatory signaling domains in CAR constructs greatly enhanced T cell cytolytic capacity,
cytokine secretion, and in vivo efficacy98-101. These platforms were coined “second generation”
CAR T cell constructs due to the inclusion of additional costimulatory signaling domains.
Following CD28, incorporation of costimulatory domains from TNF receptor family members 41BB102,103 and OX40102,104 were incorporated into second generation and third generation CAR
constructs utilizing both CD28 and TNFR costimulation104-108. Consensus shows that any
costimulation greatly improves the in vivo persistence and efficacy of CAR T cells compared to
CD3ζ signaling alone, and some studies suggest TNFR costimulation is particularly important for
long term persistence106,107,109,110. The greatly improved performance of second and third
generation costimulated CAR T cells in preclinical mouse models quickly led to incorporation of
these domains in CARs designed for clinical protocols.

CAR T cells in the clinic
First generation “zetakine” IL13Rα2-redirected CAR T cells showed evidence of transient antitumor activity in 3 glioblastoma patients. T cells were well tolerated with manageable transient
CNS inflammation. However, poor CAR T cell persistence and disease progression was observed
in all patients. Noted decreased expression of IL13Rα2 target antigen in one patient’s tumor
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suggested antigen escape could be a possible concern in future patients treated with zetakine T
cells111.
Similarly, clinical use of PSMA-specific first generation CAR T cells for prostate cancer only
resulted in transient anti-tumor effects which were not sustained long term112,113. Additional trials
are underway for PSMA (NCT01140373).
First generation GD2 CAR T cells showed safety and activity in some neuroblastoma patients
(3/11 patients achieved complete remission) and longer persistence was associated with clinical
response114. A new trial using third generation CD28-OX40 costimulated CAR T cells is
currently recruiting with the hopes that costimulation will improve T cell persistence and increase
overall response rates in patients (NCT02107963).
Second generation 4-1BB costimulated mesothelin-specific CAR T cells have been used to treat
solid tumors. For safety concerns, the first trials were conducted with RNA CAR T cells where
the CAR construct was introduced via mRNA electroporation for transient CAR expression.
Encouraging safety and activity of RNA mesothelin CAR T cells115 led to the development of
lentivirally transduced mesoCAR T cells (NCT02159716) and preliminary reports suggest no
long term toxicity and some suggestion of anti-tumor activity116.
12 patients with metastatic renal cell carcinoma were treated with carboxy-anhydrase-IX (CAIX)
specific CAR T cells. Liver toxicity was noted in the lowest dose cohort, and biopsies confirmed
expression of CAIX on bile duct epithelial cells, suggesting “on-target, off-tumor” toxicity in
these patients117.
By far the most promising clinical experience with CAR therapy has been the dramatic success of
CD19-directed CAR T cells in B-cell leukemia and lymphoma patients. One of the first
indications of CD19 CAR T cell efficacy was reported in 2011 when two patients with refractory
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chronic lymphocytic leukemia (CLL) had a complete response following T cell transfer118,119.
Similar results were reported in clinical trials at other institutions120,121. Since then, CD19 CAR
therapy has been applied to other B-cell malignancies, with common reports of complete
responses in heavily pretreated patients. Acute lymphoblastic leukemia (ALL) patients appear to
have a particularly favorable response to CD19 CAR therapy, with response rates over 90%122-124.
The selection of the CD19 target likely plays a role in the success of CAR therapy for these
patients. CD19 is highly restricted to normal and neoplastic B cells125, eliminating the concern for
recognition of antigen in healthy organs. Normal B-cell depletion is managed through
immunoglobulin replacement infusions. In addition, CD19 is expressed at high surface levels and
on a high percentage of all cancerous cells, decreasing the likelihood for antigen-negative escape
although this phenomenon has been reported122. Depletion of normal B cells could also hinder an
antibody response against foreign elements in the CAR, such as the murine antibody portion,
thereby increasing CAR T cell persistence and activity. The enormous clinical success in heavily
pretreated ALL patients led to FDA breakthrough therapy designation to CD19 CAR therapy for
relapsed/refractory ALL in 2014.

Safety concerns with CAR T cells
Clinical experience with CAR T cells in the last 10-15 years has taught the field some valuable
lessons. While CAR T cells can exert potent activity against antigen-positive tumor cells, they
also have the potential to target antigen on healthy tissues. One major concern is the development
of “on-target, off-tumor” toxicity. Indeed, one of the most serious adverse advents in clinical
CAR T cell therapy was the death of a patient treated with third generation Her2-specific CAR T
cells which was attributed to recognition of low levels of Her2 antigen in the lung126. Evidence of
on-target liver toxicity was also observed in renal cell carcinoma patients treated with carboxyanhydrase-IX (CAIX) CAR T cells117. Transfer of CEA-specific TCR-transduced T cells induced
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severe colitis in colorectal cancer patients due to recognition of normal colonic epithelium127. For
this reason, trial designs are now incorporating inducible suicide genes, low dose escalation
strategies, or transient CAR expression techniques to test new CAR target antigens.
Development of humoral and cellular immune responses against transferred CAR T cells have
been observed in some patients95,128,129. The immune-mediated elimination of transferred cells
will severely limit the persistence and overall efficacy of CAR T cell therapy. In addition to
decreased efficacy, anaphylaxis was observed in one patient receiving mesothelin RNA CAR T
cells which was likely related to IgE CAR-specific antibodies binding to foreign elements of the
scFv129.
Many groups using the CD19 CAR or other CARs have observed side effects related to cytokine
release syndrome (CRS), a systemic side effect of massive CAR T cell activation in the patient.
This toxicity ranges from mild to life threatening, and seems to correlate with the tumor burden at
the time of T cell infusion. IFNg, presumably released from activated transferred T cells is often
highly present. IFNg can induce chemokines like CXCL9 and CXCL10 also elevated in one of
the first reported cases in CD19 CAR T cell treated patient118. IL6 is often highly expressed, and
treatment of CRS using tocilizamab, an anti-IL6R antibody, has decreased CRS toxicity in CD19
CAR T cell treated patients130. The mechanism of CRS is still not well understood. CRS
following CAR T cell therapy has many similar clinical similarities to macrophage activation
syndrome (MAS), suggesting activation of macrophages may contribute to the cytokine storm in
these patients. Although toxicity can be severe, the benefit of CAR T cells in heavily pre-treated
patients can be lifesaving. As more patients are treated with a larger diversity of CAR platforms
lessons learned in the clinic will continue to inform safer and more effective T cell therapies for a
large array of cancers.
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Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a type of cancer originating from poorly differentiated
myeloid precursors in the bone marrow. In 2015, an estimated 20,830 new cases of AML will be
diagnosed and an estimated 10,460 patients will die due to AML. The 5 year survival rate remains
dismally low at only 25.9% of patients living more than 5 years beyond their diagnosis131.
Standard treatment for AML includes induction chemotherapy, usually with cytarabine, which
results in complete remission (CR) in 65-75% of patients. Many patients go on to receive
consolidation and/or maintenance therapy involving more rounds of intensive chemotherapy after
a CR has been achieved. Despite induction of initial CR, the vast majority of AML patients will
relapse following induction chemotherapy, and patients usually go on to receive additional rounds
of intensive chemotherapy, however, there is no standard of care for relapsed AML, and
outgrowth of chemotherapy resistant disease is common132. Allogeneic hematopoietic stem cell
transplant (HSCT) can produce cures in a small minority of patients following a second CR,
however, long-term cures are still rare. In one trial following over 1000 patients, HSCT
moderately reduced the risk of relapse, however, did not produce an overall survival advantage133.
Therefore, newer more potent therapies are urgently needed for AML patients to improve long
term survival following diagnosis.

Folate Receptors and Cancer
The folate receptor (FR) family is composed of three known members, designated FRα, FRβ, and
FRγ. The cDNAs were cloned by independent groups in 1989134-136. The two isoforms later
designated FRα and FRβ are bound to the cell surface via glycosylphosphatidylinositol (GPI)
linkages, whereas the truncated isoform, FRγ, lacks a GPI signal sequence and is secreted from
the cell137. FRα and FRβ bind and uptake folate via receptor-mediated endocytosis. Folate is an
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essential dietary vitamin and its derivatives are utilized during nucleic acid synthesis and
methionine production; therefore, folate is important in DNA replication and cell division138. It is
perhaps unsurprising, then, that FR isoforms were subsequently found to be highly upregulated
on cancer cells139. FRα is selectively expressed in epithelial tissues and is substantially increased
in tumor cells of epithelial origin139-142. The high expression on tumor cells and the concurrent
finding that folate-linked proteins could be used to selectively target FR+ cells143 led to the rapid
exploitation of this pathway for targeted delivery of therapeutic and imaging agents to FR+
cancer. Strategies have included directly linking folate to toxic compounds144, folate-conjugated
liposomal drug delivery145, and immunization146. In addition, FRα was one of the first tumor
antigens exploited for CAR T cell therapy in oncology93,94.

FRβ expression in myeloid cancer
While FRα is selectively expressed in epithelial tissues, FRβ also shows restricted expression
only in cells of the hematopoietic myeloid lineage and myeloid cancer147,148. In 1999, Manohar
Ratnam’s lab showed using immunocytochemistry that many human AML patient blasts
expressed FRβ148. This was also the first description of FRβ co-expression with myeloid lineage
antigens CD11b, CD13, and/or CD14 in normal peripheral blood and bone marrow. Using a
larger patient sample size, this same group showed that 68% of all AML bone marrow specimens
across different subtypes expressed FRβ149, making the beta isoform an attractive target in
myeloid leukemia. As observed with FRα+ tumor cells, folate-conjugated liposomal doxorubicin
was able to selectively target FRβ+ AML. This group also discovered that all-trans retinoic acid
(ATRA) specifically enhanced FRβ expression in AML150, and pretreatment with ATRA was able
to enhance FRβ-targeted drug liposomal drug delivery149. The FRβ-inducing activity of ATRA
was independent of its role in promoting differentiation of acute promyelocytic leukemia (APL),
and subsequent investigation revealed direct activity at the FRβ promoter151, which could be
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enhanced with histone deacetylase (HDAC) inhibitors152. ATRA was unable to induce FRβ
expression in FRβ- cells. Combining FRβ-targeted therapies with antigen upregulation via ATRA
is an attractive strategy for AML.

Imaging studies with labeled folic acid highlight the low expression of
FR in healthy organs
Imaging experiments with radiolabeled folate conjugates were initially used to assess the safety
profile of FR-targeted therapies by identifying the biodistribution of folate uptake in animal
models. These studies reproducibly demonstrated strong uptake by FR+ tumor cells, with little to
no retention in healthy tissues outside the kidneys153-156. Encouragingly, results were reproducible
in human subjects157. Of note, background uptake in the liver was also noted in mice158 and
patients157, however, the FR-specific nature of this signal has been questioned. The favorable
biodistribution profile of folate imaging agents suggests the low expression of FR+ cells in
healthy tissues and provides rationalization for FR-targeted cancer therapy.

FRβ expression in pathologic macrophages
In investigating the mechanism of action of methotrexate (an antifolate drug) in rheumatoid
arthritis (RA), Takami Matsuyama’s group demonstrated the selective high expression of FRβ in
synovial macrophages from the inflamed joints of RA patients.159 Soon after, Philip Low and
colleagues described folate uptake in inflamed joints of rats with experimental adjuvant-induced
arthritis160 and later in both canine and human patients with arthritis161. These reports highlight
the cross-species finding that activated macrophages at sites of inflammation highly express FRβ
compared to healthy animals without inflammation. In addition, the imaging from both rats and
dogs suggested that macrophages in the spleen and liver of arthritic (but not healthy) animals also
exhibited increased folate uptake, suggesting inflammatory conditions induce activated FRβ+
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macrophages systemically as well as locally. Both the Matsuyama and Low groups have
developed preclinical models targeting FRβ+ macrophages in RA using vaccination162 and
immunotoxin strategies163-165.
FRβ has also been described as a marker of M2 macrophages166 and is expressed on tumor
associated macrophages (TAMs) in many different kinds of cancer166-169. The Low group noted
that TAMs from murine ovarian cancer ascites could selectively endocytose folate-conjugated
liposomes170. In addition Matsuyama’s lab used their FRβ immunotoxin to deplete FRβ+ TAMs
and slow tumor growth in a mouse model of glioma171. The general consensus from all these
studies reveals high expression of FRβ in activated macrophages at sites of inflammation,
including both inflammatory diseases and tumor microenvironment, with low expression in
healthy tissues.

A Rationale for FRβ-directed CAR T cell Development
The tissue restriction of FRβ, broad expression in AML and pathologic macrophages, vast
preclinical and clinical studies demonstrating the safety of FR-targeted therapy, and demonstrated
clinical efficacy of CAR T cell therapy for cancer rationalizes the preclinical development and
evaluation of FRβ-specific CAR T cells. The goals of this thesis can be summarized in two major
aims:
Aim1: Create and assess the functional activity and safety of human FRβ-specific CAR T cells in
vitro and in vivo to test the central hypothesis that FRβ is a promising target for CAR T cell
therapy for AML.
Aim2: Create and assess the functional activity and safety of mouse FRβ-specific CAR T cells in
vitro and in vivo to test the hypothesis that FRβ-directed CAR T cells could be applied for
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immunotherapy of solid tumors by eliminating TAMs, a major contributor to the tumor
microenvironment.
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CHAPTER 2: Targeting of folate receptor-beta on acute myeloid
leukemia blasts with chimeric antigen receptor expressing T cells
Summary
T cells expressing a chimeric antigen receptor (CAR) can produce dramatic results in
lymphocytic leukemia patients; however, therapeutic strategies for myeloid leukemia remain
limited. Folate receptor beta (FRβ) is a myeloid-lineage antigen expressed on 70% of acute
myeloid leukemia (AML) patient samples. Here, we describe development and evaluation of the
first CARs specific for human FRβ (m909) in vitro and in vivo. m909 CAR T cells exhibited
selective activation and lytic function against engineered C30-FRβ as well as endogenous FRβ+
AML cell lines in vitro. In mouse models of human AML, m909 CAR T cells mediated the
regression of engrafted FRβ+ THP1 AML in vivo. In addition, we demonstrated that treatment of
AML with all-trans retinoic acid (ATRA) enhanced FRβ expression, resulting in improved
immune recognition by m909 CAR T cells. As many cell-surface markers are shared between
AML blasts and healthy hematopoietic stem and progenitor cells (HSCs), we evaluated FRβ
expression and recognition of HSCs by CAR T cells. m909 CAR T cells were not toxic against
healthy human CD34+ HSCs in vitro. Our results indicate that FRβ is a promising target for CAR
T cell therapy of AML, which may be augmented by combination with ATRA.
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Introduction
Acute myeloid leukemia (AML) remains a disease with a dismal clinical prognosis. While
induction chemotherapy generates remission in the vast majority of patients, nearly all of them
relapse and require intense consolidation chemotherapy or hematopoietic stem cell transplant.
The majority of patients will eventually die of their disease, and 5-year survival remains below
50%172. Therefore, development of new, more effective therapies for AML is essential.
Chimeric antigen receptor (CAR) T cell therapy is an innovative, new treatment that has recently
achieved groundbreaking clinical success in treating therapy-refractory lymphocytic leukemia
patients. By linking the single-chain variable fragment (scFv) of a conventional monoclonal
antibody (mAb) to intracellular T cell receptor signaling domains to produce a chimeric T cell
receptor with antibody-like affinity87, a patient’s own T cells are genetically redirected to target
antigen-positive tumor cells. In the case of acute lymphoblastic leukemia (ALL) patients, CD19redirected CAR T cells are generating complete remissions in as high as 90% of patients118,120-123.
One major challenge in translating the astonishing clinical success of CAR T cells in ALL to
other types of cancer including AML is finding an appropriate tumor cell target.
The folate receptor (FR) family is a group of folate-binding protein receptors comprised of four
known members (α, β, γ, and δ). FRα and FRβ are bound to the cell membrane via
glycosylphosphatidylinositol (GPI) linkages136, share ~70% homology, similar affinity for folate,
and a common mechanism of receptor endocytosis-mediated folate uptake. However, these
receptors differ in tissue distribution: FRα is expressed on epithelial tissues, while FRβ is
primarily found on myeloid-lineage hematopoietic cells147. Interestingly, both receptors are
commonly upregulated in the setting of malignancy139,141,148. FRα-specific CAR T cells were
developed more than 20 years93,95,109,110, with ongoing optimization and new clinical trials
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currently being designed to evaluate 4-1BB costimulated CAR T cells in ovarian cancer
patients173. However, CAR therapy has not yet been expanded to target FRβ+ malignancies. FRβ
is expressed on approximately 70% of primary AML patient tumors148,174 thus making it an
attractive target for CAR T cell therapy. In addition, FRβ expression can be enhanced on AML
blasts by treatment with all-trans retinoic acid (ATRA), a drug already FDA-approved for
subclass M3 AML150,151. In preclinical models, the efficacy of folate-conjugated drug therapy for
targeting FRβ+ AML is improved when combined with ATRA treatment174. Given the presence of
FRβ in AML, limited expression in normal tissues, as well as inducibility by clinically-approved
drugs, we sought to develop the first CAR to target FRβ. Here, we generated and characterized
fully human FRβ-specific CAR constructs containing the m909 scFv175, previously validated for
recognition of human FRβ.
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Materials and Methods
CAR construction
The m909 scFv175 was PCR-amplified using the following primers: 5′TATTGATCAGCCGAAGTGCAGCTGGTGCAGTCTGG-3′ (BclI) and 5′TATGCTAGCCTGGCCTAGGACGGTCAGCTTGGTC-3′ (NheI). The PCR product was
digested and ligated into third generation pELNS-GFP-2A lentiviral vectors containing CD3ζ or
CD28-CD3ζ signaling domains (pELNS, previously described110,176). Resulting constructs were
designated pELNS-GFP-2A-m909-Z/28Z. Vectors encoding GFP, MOV19-Z/28Z, specific for
FRα, or CD19-28Z have been previously described110,176.
Lentiviral vector production and T cell transduction
High-titer replication-defective lentiviral vectors were produced in 293T human embryonic
kidney cells. 12x106 293T cells were seeded per T150 tissue culture flask 24 hours before
transfection. All plasmid DNA were purified using Endo-free Maxi prep kits (Qiagen, Valencia,
CA). Cells were transfected with 7µg pMD2.G, 18µg pRSV.REV, 18µg pMDLg/p.RRE, and
15µg pELNS transfer plasmid DNA using Express In (Open Biosytems). 24 and 48h supernatants
were harvested and combined. Viral particles were concentrated by ultracentrifugation for 3h at
28000 rpm with a Beckman SW32TI rotor (Beckman Coulter), titered, and stored at -80°C until
use. Primary human CD4+ and CD8+ T cells were isolated from healthy volunteer donors after
leukapheresis by negative selection and purchased from the Human Immunology Core at
University of Pennsylvania. All specimens were collected under a University Institutional Review
Board-approved protocol, and written informed consent was obtained from each donor in
accordance with the Declaration of Helsinki. CD4+ and CD8+ T cells were mixed at a 1:1 ratio
and activated with anti-CD3/anti-CD28 mAb–coated beads (Invitrogen, Carlsbad, CA) at a 3:1
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bead:T-cell ratio. T-cells were cultured in complete media (CM) (RPMI 1640-GlutaMAX
supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin, 100 μg/mL streptomycin
sulfate). At 20 hours after activation, lentiviral vectors were added at MOI of 5-10. T cells were
expanded in CM in the presence of human recombinant IL2 (Novartis, St Louis, MO) at a final
concentration of 50-100 IU/mL, maintaining a cell density of 0.5-1x106 cells/mL. After 2 weeks,
rested T cells (cell size <300 fL) were then adjusted to equalize the frequency of transgeneexpressing cells before use in functional assays.
Cell lines
293Ts were purchased from ATCC. FR-negative human ovarian cancer cell line C30177 was
kindly provided by Dr. George Coukos178. C30 was transduced with lentiviral vectors encoding
human FRβ cDNA (Origene) to generate C30-FRβ. Human AML cell lines THP1, MV411, and
HL60 were kindly provided by Dr. Gwenn Danet-Desnoyers (University of Pennsylvania). All
cells were grown at 37°C in CM. C30, C30-FRβ, and THP1 were transduced with lentiviral
firefly luciferase (fLuc).
T cell activation and cytokine release assays
1x105 CAR+ T cells were co-cultured with 1x105 targets in triplicate in 200μL CM. After 24h,
supernatants were assayed for the presence of interferon-γ (IFNg) by ELISA (Biolegend). IL-2,
IFNg, TNF-α, and MIP1α were measured by flow cytometry with Cytometric Bead Array (BD).
Cell pellets were labeled for CD3 and CD69 and assessed by flow cytometry. Live, CD3+ gates
were used for analysis. In some cases cell pellets were labeled for FRβ expression.
T cell proliferation
T cells were labeled with 2.5μM PKH26 (Sigma-Aldrich) according to the manufacturer’s
protocol. T cells were co-cultured with targets at 1:1 ratio in the absence of exogenous IL-2. After
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5 days, cells were labeled for CD3 and analyzed for PKH26 dilution. Live, CD3+ gates were used
for analysis.
Degranulation
1x105 CAR+ T cells were co-cultured with 1x105 targets in triplicate in 200µl CM with antiCD107a and anti-CD107b antibodies (or control IgG1) and monensin (BD). After 5-6h cells
were labeled for CD3 and analyzed by flow cytometry. Live, CD3+ gates were used for analysis.
Cytotoxicity
fLuc-transduced targets were plated at 1x104 /well in triplicate. CAR+ T cells were added at the
indicated E:T (effector: target) ratios. Co-cultures were incubated overnight in phenol-free CM.
The Extended-Glow Bioluminescent Reporter Gene Assay (Applied Biosystems) was used to
measure residual luciferase activity from remaining targets, and lysis was calculated as follows:
Percent Lysis = 100 – [(average signal from T cell-treated wells)/(average signal from untreated
target wells) x100]. Monocyte lysis was assessed after 4-hour co-culture at indicated E:T ratios
plated in triplicate wells. Total cells were labeled for CD3, CD14, and 7AAD. Flow cytometry
with CountBright beads (Life Technologies) was used to determine the total number of live CD3-,
CD14+ monocytes per well (N). Lysis was calculated as follows: Percent Lysis = 100 – [(average
N treated wells)/(average N untreated wells) x100].
CFU
Bone marrow CD34+ HSCs were isolated from healthy donors by magnetic bead selection by the
University of Pennsylvania Stem Cell and Xenograft core. 2000 CD34+ cells were cultured with
2000 CAR+ T cells in V-bottom plates. After 4h, wells were diluted in methylcellulose and plated
in duplicate. After 14 days colonies were counted and scored as CFU-GEMM, GM, G, M, or
BFU-E. Untreated CD34+ cells were cultured in the absence of T cells.
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qRT-PCR
Total RNA was extracted from 5x106 viable tumor cells using RNeasy Mini kit (Qiagen). RNA
quantity and quality (A260/280 = 2.0-2.1) were verified using a Nanodrop 2000 spectrophotometer
(Thermo). cDNA was generated from 1μg total RNA using the High-Capacity-RNA-to-cDNA kit
(Applied Biosystems). cDNA quantity (2.05 μg/µl) and quality (A260/280 = 1.82) were verified to
be equal for all samples. Human FRβ mRNA copy number was calculated using the standard
curve method and ViiA7 real time PCR system (Applied Biosystems). 200ng cDNA template was
added to SYBR green PCR master mix (Applied Biosystems) and 200nM PrimeTime qPCR
Primers (IDT) specific for hFOLR2 in 5 replicate wells. Known quantities of plasmid-FRβ cDNA
were used to construct a 6-point standard curve. Amplification was detected in all wells. Relative
mRNA copy numbers are represented as indicated.
ATRA
Pre-treatment: cells were cultured in CM with 10nM ATRA. On day 5, cells were washed then
stained for FRβ surface expression by flow cytometry, processed for RNA extraction, or used in
co-cultures for T cell functional assays. In ATRA co-treatment assays, cells were prepared as
above (for cytokine release), and 10nM ATRA was included fresh in the culture media. 3-day
supernatants were analyzed for IFNg by ELISA.
Flow cytometry
All samples for flow cytometry were labeled in 100µl FACS Buffer (PBS, 2% FBS) at 4°C .
Cells were processed on a BD FACS-Canto flow cytometer, and results were analyzed with
FlowJo 7.6.5. m909-IgG (prepared by Dimiter Dimitrov) was conjugated to biotin using the EZLink Biotinylation Kit (Thermo). For FRβ staining, 3x105 cells were incubated with 10μg
unlabeled human IgG (Jackson ImmunoResearch) to block nonspecific Fc receptor binding. 329

5μg/mL m909-biotin or human-IgG-biotin was added in 100µl and cells were labeled at 4°C for
30min. Cells were washed and secondary labeling with 1:200 Streptavidin-APC (BD) was
conducted for 25min. Cells were washed twice and analyzed by flow cytometry in the presence of
7AAD. For in vivo T cell quantification, 50μL blood was obtained from treated mice via retroorbital bleeding and labeled for human CD45, CD3, and CD8. Cell numbers were quantified with
BD TruCount tubes per manufacturer's instructions. CD4+ subsets were calculated by subtracting
CD8+ from total CD3+. m909 CAR expression was detected by biotin-labeled rabbit-anti-human
IgG (H+L) (Jackson ImmunoResearch), MOV19 CAR by biotin-recombinant FRα (R&D), and
CD19 CAR by biotin-proteinL (GenScript). Secondary labeling with Streptavidin-APC was used
for all CARs. The following marker antibodies were used for phenotypic analysis according to
manufacturer recommendations: PE-Cy7- CD3; APC-Cy7- CD3; PE- CD4; APC- CD8; PECD45; APC- CD34; PE- CD19; PE- CD69; PE-Cy7-CD28; PerCP-Cy5.5-CD27; BV421-PD-1;
PE-CD25; APC-CD86; FITC-CD70; PE-41BBL; APC-HLA-A,B,C (Biolegend) and APC-CD33;
APC- CD107a; APC- CD107b; FITC-HLA-DR,DP,DQ (BD). 7AAD (Biolegend) was used to
assess viability.
Xenograft model of AML
(NOD/SCID)/γ-chain−/− (NSG) mice were obtained from the University of Pennsylvania Stem
Cell and Xenograft core. 6-12 week old female mice were bred, treated, and maintained under
pathogen-free conditions in-house under University of Pennsylvania IACUC-approved protocols.
5x106 THP1-fLuc tumor cells were inoculated subcutaneously or intravenously. 5 mice per group
were injected intraperitoneally or intravenously with 5x106 CAR+ T cells at indicated time points.
Tumor growth was assessed by weekly imaging and/or caliper measurements. Tumor volumes
were calculated using the following formula: V=1/2(length×width2), where length is greatest
longitudinal diameter and width is greatest transverse diameter.
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Bioluminescence imaging
Bioluminescence imaging of fLuc+ tumor cells was performed with the Xenogen IVIS imaging
system and quantified with the Living Image software (Perkin Elmer). Mice were injected
intraperitoneally with D-luciferin (150 mg/kg) and imaged under isoflurane anesthesia. Images
were recorded until 2 consecutive images showed decreasing signal. Peak signal was determined
for each mouse at each indicated time point. Pseudocolor images (scale 1x106-108) representing
light intensity were generated with Living Image.
in vivo combination with ATRA
8-10 week old NSG mice were inoculated with 5x106 THP1 IV via tail vein injection. 5mg/kg
ATRA (or vehicle control) was injected IP daily from days 6-13 and every 2 days from days 1341 post tumor challenge. In indicated groups, 5x106 CAR+ (or GFP+) T cells were injected IV on
day 9. Tumor progression was monitored by weekly bioluminescent imaging. Peripheral blood
sampling was performed on day 26 to measure CAR T cell persistence and phenotype by flow
cytometry.
Statistical analysis
The data are reported as means and standard error (SEM) unless otherwise noted. Statistical
analysis was performed using unpaired 2-tail student t test. GraphPad Prism 6.0 software was
used for statistical calculations. P < .05 was considered significant.
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Results
Generation of anti-FRβ CAR
The m909 scFv175 was cloned into previously validated lentiviral constructs containing CD8α
hinge and transmembrane domains with intracellular CD3ζ alone or with the CD28 signaling
domain in tandem, referred to as m909-Z and m909-28Z, respectively110,176. Both constructs
included green fluorescent protein (GFP) separated by a viral 2A peptide to identify transduced T
cells (Figure 2.1A). MOV19 CAR T cells with specificity for human FRα, CD19 CAR T cells
with specificity for human CD19, or GFP transduced T cells were used as controls (not shown).
Transduction of human T cells with m909 CAR constructs was reproducibly achieved at
efficiencies of 70-80%, as measured by both GFP and surface CAR expression (Figure 2.1B).
Transduction efficiencies of m909-Z and m909-28Z were virtually identical. Following two
weeks expansion, CAR expression was maintained in both CD4+ and CD8+ T cells with a usual
ratio of 30:70 CD4:CD8 (Figure 2.1C).
m909 CAR T cells exhibit antigen-specific reactivity against engineered C30-FRβ
To evaluate FRβ-specific reactivity of m909 CAR T cells, we engineered C30, a FR-negative
human ovarian cancer cell line, to constitutively overexpress human FRβ (C30-FRβ; Figure
2.2A). After overnight co-culture of CAR T cells with C30 or C30-FRβ, supernatants were
assayed for release of proinflammatory cytokines. m909-Z and m909-28Z CAR T cells
selectively secreted IFNg in response to C30-FRβ (Figure 2.2B). m909 CAR T cells also
produced TNFα, IL2, and MIP1α (Figure 2.3). m909 CAR+ (GFP+) T cells specifically
upregulated surface expression of activation marker CD69 in the presence of C30-FRβ but not
C30 (Figure 2.2C). As increased in vivo expansion of CAR T cells110 and persistence of
transferred T cells in melanoma patients69 correlates with anti-tumor efficacy, we tested the
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ability of m909 CAR T cells to proliferate in vitro in response to cell-surface FRβ. T cells were
labeled with PKH26, and dye dilution by proliferating cells was measured by flow cytometry
after 5 days in co-culture with the indicated targets. Both m909-Z and m909-28Z exhibited
specific proliferation in response to C30-FRβ but not C30 (Figure 2.2D). Degranulation, as
quantified by increased cell-surface CD107 expression, is an established surrogate for T cell lytic
function179. After 6 hour co-culture, we observed specific degranulation by m909 CAR+ (GFP+) T
cells only in the presence of C30-FRβ (Figure 2.2F). To evaluate true lytic capability of m909
CAR T cells, we co-cultured C30-FRβ-fLuc with CAR T cells. After overnight incubation, both
m909-Z and m909-28Z CAR T cells showed high, dose-dependent lysis of C30-FRβ (Figure
2.2E).
m909 CAR T cells exhibit specific reactivity against endogenous FRβ on human AML
After establishing antigen-specific reactivity for cell-surface human FRβ, we next evaluated
m909 CAR T cell function against physiologically relevant levels of antigen in myeloid tumor
cells. We acquired three human AML cell lines with high, medium, and low (undetectable)
surface expression of FRβ (THP1, MV411, and HL60, respectively). Surface protein expression
was assessed by labeling with m909-IgG using flow cytometry (Figure 2.4A), and mRNA
expression was confirmed with qRT-PCR (Figure 2.4B). For all AML experiments, CD19-28Z
CAR T cells were used as a control as none of the AML cells expressed CD19 (Figure 2.5). After
overnight co-culture with AML targets, IFNg secretion was measured by ELISA (Figure 2.4C).
Because not all CAR T cell donors respond comparably, we conducted 10 independent
experiments using 10 distinct T cell donors. m909 CAR T cells from most donors produced
significantly higher IFNg in response to FRβ+ AML targets, compared to CD19-28Z control T
cells.
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To evaluate the proliferative potential of m909 CAR T cells in response to FRβ+ AML, T cells
were labeled with PKH26 and dye dilution was measured by flow cytometry following co-culture
with targets (Figure 2.4D). Overlaying histograms represent PKH26 fluorescence of GFP, CD1928Z, or m909-28Z CAR T cells before (Pre) and after 5-day exposure to the indicated targets.
m909-28Z CAR T cells proliferated in response to FRβ+ C30-FRβ, THP1, and MV411 but not
FRβ- C30 or HL60; control T cells did not proliferate under any condition. In 3 of 4 T cell donors
evaluated, response to FRβ-low MV411 was slightly greater than for FRβ-high THP1. To assess
whether this could be due to different levels of non-antigen specific stimulation by target cells,
we evaluated HLA and costimulatory ligand expression on the AML cell lines (Figure 2.6).
Indeed, we found that MV411 expresses more CD86, 41BB-L, and HLA-ClassII compared to
THP1.
The lytic capability of m909 CAR T cells against AML was evaluated using THP1-fLuc (Figure
2.4E). m909 CAR T cells exhibited specific lysis of THP1 but not C30 compared to control
CD19-28Z CAR T cells. Finally, surface FRβ expression was measured on remaining THP1
following overnight co-culture (Figure 2.4F). Cells surviving co-culture with m909-28Z CAR T
cells had significantly reduced expression as measured by both FRβ median fluorescence
intensity (MFI) and percent FRβ positive, suggesting m909 CAR T cell elimination of THP1 was
antigen-dependent.
To validate the applicability of m909 CAR T cells to primary AML, we co-cultured m909 CAR T
cells with peripheral blood cells from 2 patients with validated FRβ expression on blasts. We
observed significantly higher IFNg secretion from m909-28Z CAR T cells compared to control
GFP T cells after overnight co-culture (Figure 2.7), suggesting m909 CAR T cells are capable of
recognizing FRβ+ primary patient tumor cells in addition to FRβ+ AML cell lines.
Antigen upregulation by ATRA enhances m909 CAR T cell recognition of AML
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We hypothesized that the level of FRβ expression by some AML cells represents a possible
limitation to m909 CAR T cell recognition. ATRA has been reported to increase FRβ expression
on AML150 and improve FRβ-targeted liposomal drug delivery in vivo174. Therefore, we sought to
determine whether ATRA-treated AML is more susceptible to targeting with m909 CAR T cells.
First, elevated cell-surface FRβ expression by THP1 and MV411 AML was observed over a 5
day time course in the presence of 10nM ATRA (Figure 2.8A). Increased production of FRβ
mRNA was confirmed after 3 and 5 days of ATRA treatment (Figure 2.8B). Consistent with
previous reports150,152, we observed enhanced expression in FRβ+ THP1 and MV411 but not FRβHL60. To assess whether ATRA-induced FRβ expression on target cells sensitized them to m909
CAR T cell attack, AML cells that had been pre-treated for 5 days with ATRA were washed,
plated in fresh media and co-cultured with m909 CAR or control GFP T cells. m909-Z and
m909-28Z CAR T cells secreted significantly more IFNg when cultured with ATRA pre-treated
THP1 but not MV411 (Figure 2.8C). Cytokine secretion in response to ATRA-treated HL60 was
slightly increased, although receptor levels were not detectably upregulated. To assess whether
ATRA-treated AML is more susceptible to CAR T cell-mediated lysis, we cultured untreated or
ATRA-pretreated THP1-fLuc with m909 CAR T cells. In addition to IFNg secretion, m909 CAR
T cells displayed significantly increased lytic activity against ATRA pre-treated THP1 (Figure
2.8D).
Numerous reports suggest direct modulatory effects of ATRA on T cells. In mice, vitamin A
deficiency leads to excessive Th1 and impaired Th2 responses180, and treatment with vitamin A
ex vivo decreases Th1 cytokine secretion by activated PBMCs181, suggesting a role for retinoids in
negatively regulating Th1 development. Retinoic acid was also shown to impair IFNg production
in human cells182. In contrast, others report ATRA enhancement of IL2-mediated T cell
activation, proliferation, and survival183-185. To address the possible effects of ATRA on CAR T
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cells, we co-cultured (previously untreated) targets and T cells with or without 10nM ATRA
continually present in the media. Because elevated surface FRβ was not measureable until 2-3
days in treatment with ATRA (Figure 2.8A), 3 day co-cultures were performed. IFNg was
significantly elevated in m909 CAR-treated THP1 and MV411 with ATRA compared to cultures
treated without ATRA (Figure 2.8E), indicating maintenance of a Th1 cytokine profile. Since
ATRA acts in target cells at the endogenous FRβ promoter151, C30-FRβ (with FRβ expression
driven from the EF1α promoter) is not susceptible to ATRA-induced upregulation. Accordingly,
the presence of ATRA did not impact IFNg secretion from m909 CAR T cells activated by C30FRβ, suggesting that direct effects of ATRA on CAR T cells are likely not responsible for their
improved reactivity against AML .
m909-28Z CAR T cells reduce AML tumor growth in vivo
After confirming m909 CAR T cell reactivity against human AML in vitro, we investigated their
anti-tumor activity in vivo. In previous studies, inclusion of the CD28 activation domain in CAR
constructs enhanced in vivo performance and persistence of engineered T cells in mice as well as
patients receiving CD19 CAR T cells186,187. Therefore, m909-28Z CAR T cells were tested for in
vivo reactivity against THP1. GFP and CD19-28Z CAR control T cells were tested in parallel.
Immunocompromised NSG mice were inoculated with 5x106 THP1-fLuc subcutaneously.
Bioluminescent imaging was used to confirm engraftment of tumor cells. On days 8 and 10 after
tumor inoculation, mice received 5x106 CAR+ (or GFP+) T cells via intraperitoneal injection.
Tumor progression was evaluated by luminescence (Figure 2.9A-B) and caliper measurements
(Figure 2.9C). Treatment with m909-28Z CAR T cells mediated tumor regression and
significantly inhibited THP1 outgrowth. To investigate in vivo expansion/persistence of m90928Z CAR T cells, we evaluated human CD3+ cells in the peripheral blood of treated mice.
Consistent with a productive anti-tumor response, mice treated with m909-28Z CAR T cells
36

exhibited significantly increased peripheral blood T cells, comprised of both CD8+ and CD4+,
compared to controls at 4 weeks post T cell treatment (Figure 2.9D). In addition, we tracked
CAR expression during treatment and showed that m909-28Z CAR+ T cells persist long term in
THP1 treated mice (Figure 2.10). These data suggest that m909-28Z CAR T cells expanded
peripherally upon specific recognition of FRβ+ tumor in vivo. As AML is a disseminated systemic
disease in humans, we also evaluated m909-28Z CAR T cell activity against disseminated THP1,
delivered by IV injection. m909-28Z CAR T cells also significantly inhibited systemic AML
tumor growth in vivo compared to control T cells (Figure 2.11A-B). To begin to assess the
impact of ATRA on FRβ-directed CAR T cells in vivo we provided ATRA IP during the course
of T cell treatment. In initial results from one study, ATRA did not impact THP1 growth in
untreated or T cell treated mice (Figure 2.11C-F), nor did it affect T cell phenotype when
assessed 17 days post transfer (Figure 2.11H-M).
m909 CAR T cells do not inhibit CD34+ colony formation or eliminate FRβ-low healthy
monocytes
Many surface markers, including others exploited for CAR therapy of AML (e.g. CD123, CD33,
CD38), are shared between AML blasts and normal hematopoietic stem and progenitor cells
(HSCs). One concern in the development of AML-directed CAR therapies is the potential for
depletion of healthy bone marrow progenitors188-191. FRβ has been reported at low levels on
human CD34+ bone marrow HSCs although this receptor was nonfunctional and unable to bind
folate192. To investigate whether m909 CAR T cells recognize healthy HSCs, we first assessed the
binding potential of m909-IgG to normal human bone marrow CD34+ cells. We were unable to
detect surface FRβ protein in any of three healthy donors by flow cytometry (representative
donor, Figure 2.12A). To test for functional reactivity of m909 CAR T cells against
hematopoietic progenitors, we conducted colony forming (CFU) assays following co-culture of
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CD34+ HSCs and CAR T cells. After 4-hour co-incubation, each well was diluted in
methylcellulose and cultured for 14 days. Colonies were counted and scored for CFU-GEMM,
GM, G, M, or BFU-E. Unlike other CARs targeting AML188-191, neither m909-Z nor m909-28Z
CAR T cell pre-treatment inhibited colony formation (Figure 2.12B). There were no significant
differences in the number of total or lineage-specific colonies compared to untreated controls.
Furthermore, 5 day ATRA treatment did not induce FRβ in HSCs (2 pools representing 7 normal
CD34+ donors tested) (Figure 2.13).
We recently published a study highlighting the presence of FRβ on a subset of peripheral blood
monocytes in healthy donors193. This was confirmed in the present study with FRβ expression
from one representative donor shown (Figure 2.12C). 5 day ATRA treatment did not enhance
FRβ expression in healthy monocytes from any of 3 donors evaluated (data not shown). To assess
the potential for myeloid toxicity with FRβ-directed CAR T cells, we co-cultured m909 or control
T cells with CD14+ monocytes isolated from healthy donors. 4hr lysis of CD14+ monocytes was
assessed using flow cytometry. We did not observe any significant lysis of monocytes by m909
CAR T cells compared to controls (Figure 2.12D). Together, our findings suggest that FRβ can
be safely pursued as a target for CAR T cell therapy of AML without harming essential healthy
HSCs or normal monocytes expressing low levels of FRβ.
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Discussion
Here, we describe the first CAR specific for human FRβ for the targeting of AML. m909 CAR
constructs are fully human in composition, addressing the issue of transgene immunogenicity
reported elsewhere with CARs using mouse scFvs95,128,129. Our initial data using C30 and C30FRβ, a cell line engineered for FRβ expression, confirm the feasibility of targeting cell-surface
human FRβ with CAR T cells. This model provides a robust positive control for CAR T cell
specificity by providing high levels of antigen for CAR stimulation in a true negative epithelial
cell line. The m909 CAR platform allows for efficient and specific targeting as demonstrated by
in vitro co-culture assays resulting in cytokine production, activation marker upregulation,
proliferation and target cell lysis when high levels of antigen are present. In the presence of
human AML cells expressing endogenous levels of FRβ, m909 CAR T cells maintained specific
activation in the presence of antigen. However, CAR activity decreased with lower surface levels
of FRβ, as demonstrated by reduced output of IFNg and cytolysis. In addition, it was clear that
m909 CAR T cells specifically eliminated THP1 target cells displaying the highest antigen
expression.
Despite only moderate activity against THP1 in vitro, m909-28Z CAR T cells did significantly
inhibit subcutaneous and disseminated THP1 tumor growth in vivo, suggesting that systemic
delivery of m909-28Z CAR T cells to tumor-bearing mice resulted in efficient trafficking,
activation, and lysis at sites of tumor growth. When m909-28Z CAR T cells were delivered to
mice bearing large established subcutaneous THP1 tumors (~3 weeks post tumor injection), they
were unable to control tumor growth (see chapter 3). These data suggest m909-based CARs may
only be effective at overcoming small tumor burden. However, over 90% of AML patients reach
remission through chemotherapy but eventually relapse due to minimal residual disease (MRD)
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that is often undetectable172. Therefore, m909-28Z CAR T cells could be utilized as an effective
treatment for patients with chemotherapy-induced remission or MRD conditions.
As m909 CAR T cells displayed decreased lysis against targets with lower FRβ expression,
outgrowth of FRβ-low leukemic clones remains a potential concern for m909 CAR-based
therapy. However, we and others have established that ATRA specifically upregulates FRβ
expression in FRβ+ AML. Tumor cells with surface antigen expression under the threshold for
m909 CAR recognition can potentially be induced to levels high enough to stimulate T cell
activation. Indeed, IFNg release and lytic activity from m909 CAR T cells was increased
following co-culture with ATRA pre-treated AML. We also observed small increases in IFNg
secretion of control GFP T cells and m909 CAR T cells against FRβ- HL60, suggesting that other
effects of ATRA on target cells may slightly enhance T cell recognition of AML. Notably, ATRA
is known to induce differentiation of THP1 and HL60194,195 as measured by greater cytokine
production and costimulatory molecule expression196. ATRA-mediated differentiation of AML
cells may have heightened the allogeneic T cell response. However, the largest differences in
reactivity were observed when m909 CAR T cells were incubated with ATRA-treated FRβ+
AML, suggesting greater antigen density played the dominant role in mediating increased m909
CAR T cell reactivity. Although a pilot experiment with the addition of ATRA in vivo did not
provide augmentation of m909 CAR T cell performance, we also did not observe any reduction in
anti-tumor response. While further optimization of dosing and treatment regimen will be
necessary, these preliminary results suggest ATRA can safely be combined without adverse
effects on CAR T cell function in vivo. In addition to ATRA alone, dual treatment with HDAC
inhibitors has been shown to even further stimulate FRβ expression in AML in vitro152.
Optimized combinations of ATRA and other FRβ-inducing agents present an opportunity for
additional augmentation of m909 CAR T cell efficacy. Importantly, ATRA did not impact FRβ
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expression in healthy HSCs or monocytes suggesting ATRA-induction of FRβ in AML could be
applied without increasing the capacity for healthy tissue recognition by m909 CAR T cells.
Of note, neither ATRA, HDAC inhibition, or combination is capable of inducing FRβ in nonexpressing cells of either myeloid origin (like HL60) or epithelial origin (like 293)152 suggesting
their effects are not potent enough to overcome the genetic program responsible for maintaining
tissue specificity. Therefore, de novo induction of FRβ expression in negative tissues is not a
major concern. Similarly, AML patients would need to be pre-screened for FRβ as ATRA will
not induce FRβ without baseline expression present. While previous studies have identified FRβ
on all classes of AML, incidence does increase with myeloid/monocytic distinctions (M4 and
M5)174, and these patients may benefit the most from FRβ-directed CAR therapy. Generally, new
cancer therapeutics are moving towards a more personalized approach and need not necessarily
be applicable to all patients across one broad and complex disease indication in order to be
clinically beneficial.
Beyond pharmacological upregulation of FRβ antigen, the modest activity of m909 CAR T cells
against FRβ-low AML targets may also be overcome by CAR platform optimization. For
example, Hudecek and colleagues were able to greatly increase activity of a ROR1-specific CAR
by modifying the hinge length and improving the scFv affinity197. It remains possible that the
monovalent affinity of the m909 scFv (KD=57 nM) may be suboptimal for interaction with FRβ
expressed at low levels. We anticipate that modifying the FRβ CAR T cell platform by
introducing higher affinity scFvs could improve overall anti-tumor efficacy. However, higher
affinity activity could result in increased toxicity against normal cells expressing low levels of
FRβ. Further toxicology and other preclinical evaluation of m909 and variants could help identify
platforms with optimal affinity for tumor cell destruction while sparing normal tissues.
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In addition to leukemia, FRβ expression is also reported on some normal myeloid lineage cells
and can be induced upon macrophage activation198. Although we did not observe lysis of
peripheral blood monocytes with m909 CAR T cells, healthy myeloid tissues remain a potential
target for off-tumor toxicity by FRβ specific CAR T cells. Recent innovations in the field have
the potential to mitigate these risks by restricting CAR T cell persistence via transient expression
through RNA electroporation199 or combining CAR delivery with an inducible suicide gene200.
CD34+ HSCs continuously give rise to peripheral myeloid lineage immune cells. Despite previous
reports of FRβ expression in HSCs, we did not observe any toxicity against CD34+ bone marrow
progenitors, suggesting m909 CAR T cells may be applied with reduced risk to HSCs. Therefore,
by providing transient expression of the m909 CAR platform, as described above, CAR T cell
elimination following tumor clearance could allow for restoration of affected healthy myeloid
populations from normal HSCs.
A successful FRβ CAR T cell platform has the potential for therapeutic benefit in a wide variety
of diseases beyond AML. FRβ has also been described on chronic myelogenous leukemia
(CML)139,147,148. In addition to leukemia, FRβ is increased on the surface of macrophages
associated with various pathological conditions. Tumor associated macrophages (TAMs) display
high levels of FRβ in solid tumors from diverse tissue origins166. Since TAMs correlate with
worse prognosis across multiple types of cancer20, FRβ CAR T cells could potentially be used to
improve the treatment of solid tumors by eliminating immunosuppressive, pro-tumorigenic
macrophages. FRβ is also highly expressed on macrophages at sites of ongoing inflammation159
and has been effectively exploited for imaging and targeting of pathologic macrophages in
rheumatoid arthritis160 and atherosclerosis201. FRβ-specific immunotoxins have successfully
depleted macrophages in mouse models of glioma171, atherosclerosis202, collagen-induced
arthritis164, and fibrosis203. Given their potent effector function and ability to persist after infusion,
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FRβ-specific CAR T cells have the potential to improve upon antibody-directed toxicity and may
present an exciting new way to expand the use of CAR T cells to inflammatory diseases as well
as cancer.
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Figure 2.1

Figure 2.1 FRβ CAR construction and expression in primary human T cells.
(A) Schematic of lentiviral CAR expression vectors containing the anti-human FRβ scFv
m909 linked to either intracellular signaling domains from CD3-ζ alone (m909-Z) or
CD28 and CD3-ζ in tandem (m909-28Z). Both constructs also encode GFP separated by
a viral T2A (2A) ribosomal skipping peptide. (B) CAR expression in primary human T
cells. Expression of m909 CAR in primary human T cells was confirmed by GFP, and
surface expression was confirmed by labeling with a rabbit anti-human IgG antibody that
binds the human m909 scFv portion of the CAR. (C) After 13 days expansion, m909
CAR transduced T cell populations are comprised of approximately 70% CD8+ and 30%
CD4+. Upper and lower panels show results from two representative donors. VH –
variable heavy chain, VL – variable light chain. L – linker, TM-transmembrane domain.
UN – represents untransduced T cells.
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Figure 2.2

Figure 2.2 m909 CAR T cells are reactive against cell-surface FRβ on engineered
C30-FRβ cell line.
To first test the functionality of m909 CARs, the antigen-negative ovarian cancer cell line
C30 was transduced to stably overexpress human FRβ cDNA. Co-cultures were
performed at a 1:1 E:T ratio unless otherwise noted. Control MOV19-28Z CAR T cells
are specific for FRα and do not express GFP. Control GFP T cells only express GFP.
Error bars represent mean ± SEM. (A) FRβ expression on engineered C30-FRβ was
detected by flow cytometry using biotinylated m909-IgG (black histogram). For
comparison, the unmodified parental C30 cells were used as a control (gray histogram).
(B) Antigen-specific IFNg production by m909 CAR T cells as detected by ELISA from
24hr co-culture supernatants. (C) m909 CAR+ T cells upregulate surface CD69
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expression upon 24hr exposure to C30-FRβ. The m909 CAR+ cells are identified by GFP
expression (y axis). (D) m909-Z and m909-28Z CAR T cells proliferate in response to
C30-FRβ. PKH26 dilution in labeled T cells was measured by flow cytometry after 5
days in co-culture. Percent of CD3+ cells proliferating (diluted PKH26 compared to d0) is
quantified. P values represent significant differences compared to MOV19-28Z CAR T
cells. (E) m909-Z and m909-28Z exhibit specific lysis of C30-FRβ. Target cells were
transduced to express firefly luciferase and co-cultured with CAR T cells at E:T ratios of
10:1, 3:1, or 1:1. Residual luciferase signal was determined after 18hrs. Percent lysis was
determined by luminescence comparison to untreated target wells. (F) m909-Z and
m909-28Z exhibit degranulation upon co-culture with C30-FRβ. CD107a/b surface
expression was measured after 5 hours co-culture. CAR+ cells are identified by GFP
expression (y axis). Percent of CAR+ cells with positive staining for CD107a/b is
quantified to the right. P values represent significant increases compared to MOV19-28Z
control T cells. (* P < .05, ** P < .01, *** P < .001)
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Figure 2.3

Figure 2.3 m909 CAR T cells secrete proinflammatory Th1 cytokines in vitro.
T cells were co-cultured overnight with C30 or C30-FRβ target cells or in media alone.
Co-cultures were set up at 1:1 E:T ratio. Culture supernatants were analyzed for cytokine
secretion by CBA. Levels of (A) IFNg, (B) IL2, (C) TNFα and (D) MIP1α are shown.
E:T –Effector:Target, CBA – cytokine bead array.
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Figure 2.4

Figure 2.4 m909-28Z CAR T cells are reactive against endogenous FRβ on human
AML cell lines in vitro.
To test m909 CAR T cell reactivity against clinically-relevant targets, we acquired three
human AML cell lines with varying levels of FRβ expression. Co-cultures were
performed at a 1:1 E:T ratio unless otherwise noted. Control CD19-28Z CAR T cells are
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specific for human CD19 and do not express GFP. In Media controls, T cells were plated
without target cells. Error bars represent mean ± SEM. (A) Surface expression of FRβ on
AML cell lines THP1, MV411, and HL60 was determined by flow cytometry using
m909-IgG (black) and human IgG isotype control (gray). Percentages represent the
proportion of cells with a positive fluorescent signal compared to isotype. (B) Relative
FRβ mRNA expression was confirmed using qRT-PCR. Indicated mRNA expression is
shown relative to HL60. (C) Antigen-specific IFNg secretion was quantified by ELISA
after overnight co-culture. Each data point represents the mean value of triplicate wells
from independent experiments. n=10 different normal T cell donors are represented. (D)
m909-28Z CAR T cells proliferate in response to THP1 and MV411, but not HL60,
compared to control T cells. PKH26 dilution was measured via flow cytometry after 5
days in co-culture. Overlaying histograms display d5 PKH26 fluorescence in GFP (gray),
CD19-28Z (dotted), and m909-28Z (black solid) T cell co-cultures with the indicated cell
targets. A live, CD3+ gate was used. Percentages represent the proportion of m909-28Z T
cells with diluted PKH26 compared to CD19-28Z CAR T cells. (E) m909 CAR T cells
exhibit specific lysis of THP1. Luciferase-expressing target cells were co-cultured with
CAR T cells at 1:1 E:T ratio. Residual luciferase signal was determined after 24hrs.
Percent lysis was determined by luminescence comparison to untreated target wells. Data
shown are mean and SEM of n=9 independent T cell donors. P values are calculated
compared to CD19-28Z control treated wells. (F) Decreased FRβ expression on THP1
cells surviving overnight co-culture with m909 CAR T cells. FRβ surface expression was
determined by flow cytometry using m909-IgG and human IgG isotype control. A live,
CD3- gate was used to distinguish surviving THP1 cells. The percent of cells showing
positive FRβ staining compared to isotype (left) and the FRβ MFI (right) were
determined for triplicate wells (n=3). P values were determined compared to control GFP
T cell treated wells. (* P < .05, ** P < .01, *** P < .001, ns P > .05). MFI – median
fluorescence intensity.

49

Figure 2.5
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Figure 2.5 AML target cell lines do not express CD19.
Target AML cell lines THP1, MV411 and HL60 were analyzed for surface expression of
human CD19 by flow cytometry. Overlaying histograms represent anti-CD19 (black) or
isotype control (gray) stained cells. K562 cells engineered to overexpress CD19 were
used as a positive control. AML – acute myeloid leukemia.
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Figure 2.6

-



Figure 2.6 HLA and costimulatory ligand expression in human AML cell lines.
Surface expression of HLA class I and class II as well as T cell costimulatory ligands
CD86, CD70, and 41BB-L was assessed on target human AML cell lines THP1, MV411,
and HL60 and is represented by black lines in the above histograms. Respective isotype
staining for each cell line is represented by the gray line. Percentages represent the
percent of cells with a positive shift compared to isotype. (HLA- human leukocyte
antigen).
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Figure 2.7

Figure 2.7 m909-28Z CAR T cells specifically recognize primary human AML.
To validate the applicability of m909 CAR T cells to primary AML, we co-cultured
1x105 m909-28Z CAR+ T cells (or GFP+ control T cells) with 1x105 peripheral blood
cells isolated from 2 different patients with validated FRβ expression on blasts. IFNg
secretion after overnight co-culture was assessed by ELISA. Results incorporate
independent experiments using 5 T cell donors. Error bars represent mean ± SEM. (M4myelomonocytic AML classification, NOS-not otherwise specified AML classification).
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Figure 2.8
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Figure 2.8 ATRA increases FRβ expression and m909 CAR T cell recognition of
AML cell lines.
(A) AML cell lines were treated with (dotted black line) and without (solid black line)
10nM ATRA for 5 days. Surface FRβ expression was determined each day by flow
cytometry with m909-IgG (black) or human IgG isotype control (gray). (B) FRβ mRNA
expression was determined before (untreated) and after 3 days and 5 days of 10nM
ATRA treatment. Relative mRNA is shown compared to untreated HL60. Bars represent
mean ± SEM of n=5 replicate wells. P values were calculated for each cell line compared
to untreated controls. (C) m909 CAR T cells secrete higher IFNg in response to THP1
cells pre-treated for 5 days with 10nM ATRA (gray bars) compared to untreated cells
(black bars) in overnight co-cultures. (D) THP1-fLuc cells were pre-treated with (THP1ATRA) or without (THP1) 10nM ATRA for 5 days before co-culture with m909 CAR or
GFP control T cells at 1:1 E:T ratio. Percent lysis was determined by residual luciferase
activity after overnight co-culture. (E) m909 CAR T cells secrete higher IFNg after 3
days co-culture in the presence of 10nM ATRA (gray bars) and AML target cell lines
compared to cultures without ATRA (black bars). No significant differences in IFNg
secretion were observed for m909 T cells activated in the presence of C30-FRβ with or
without ATRA. In panels C-E, graphs represent mean ± SEM from n=3 independent
experiments using 3 distinct T cell donors. P values were calculated for each T cell subset
to compare between untreated and ATRA-treated cell lines. (* P < .05, ** P < .01, *** P
< .001, ns P > .05).
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Figure 2.9
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Figure 2.9 m909-28Z CAR T cells prevent THP1 AML tumor growth in vivo.
5x106 THP1-fLuc cells were injected into NSG mice subcutaneously on day 0. 5x106
CAR+ T cells were given intraperitoneally on days 8 and 10. Tumor growth was
monitored by luminescence (A-B) and caliper measurement (C). Graphs represent mean
± SEM of n=5 mice per experiment. P values were calculated compared to CD19-28Z
treated control mice Differences between GFP and CD19-28Z groups did not reach
statistical significance at any time point. (D) Preferential expansion and survival of
peripheral human T cells in m909-28Z treated mice compared to control T cells.
Peripheral blood was collected on day 38 (4 weeks post T cell injection) and absolute
numbers of human CD3+ (left), CD8+ (middle), and CD4+ (right) T cells were quantified
by flow cytometry and are reported in total cells/µl blood. . (* P < .05, ** P < .01, *** P
< .001, ns P > .05). NSG- NOD/SCID/γ-chain−/−.
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Figure 2.10
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Figure 2.10 Long-term persistence of CAR+ m909-28Z T cells in NSG mice bearing
THP1 tumor.
NSG mice were inoculated subcutaneously with 5x106 THP1-fLuc on day 0. On days 8
and 10 following tumor injection, 5x106 CD19-28Z or m909-28Z CAR+ T cells were
injected IP. Tumor growth was monitored by caliper measurement (A) and
bioluminescence (B). (This is a repeat of the experiment outlined in Figure 2.9 using a
different donor for CAR T cell production). Peripheral blood sampling was conducted on
days 23 (C), 62 (D), and 104 (E) following tumor injection, and 50µl blood was used to
quantify total CD3+ T cells/μL peripheral blood at each time point (left). Remaining
blood was pooled for each group, red blood cells lysed, and stained for CAR expression
by flow cytometry (right). m909-28Z CAR T cells are GFP/CAR double positive. CD1928Z CAR T cells do not express GFP. It should be noted that the injected T cells were
54% CAR+. Error bars represent mean ± SEM of n=5 mice per group. (* P < .05, ** P<
.01, *** P < .001, ns P > .05). NSG- NOD/SCID/γ-chain−/−.
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Figure 2.11
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Figure 2.11 m909-28Z CAR T cells significantly delay growth of disseminated
human AML.
NSG mice were inoculated with 5x106 THP1-fLuc via IV injection on day 0. On day 9
following tumor injection, 5x106 GFP, CD19-28Z, or m909-28Z CAR+ T cells were
injected IV. Untreated mice did not receive T cells. Tumor growth was monitored by
bioluminescence (A-B). To measure the impact of ATRA co-treatment on CAR T cell
function in vivo, 5mg/kg ATRA or vehicle control was provided IP daily from d6-d13
and every other day d13-d41 following tumor inoculation. The provision of ATRA did
not impact tumor growth in (C) Untreated, (D) GFP T cell, (E) CD19-28Z CAR T cell, or
(F) m909-28Z CAR T cell treated mice. To measure the impact of ATRA on T cell
phenotype in vivo, peripheral blood sampling was performed on day 26 following tumor
inoculation. (G) Total CD3+ cells/µl blood was quantified by flow cytometry using
Trucount assay. CD3+ T cells were also labeled with antibodies to detect (H) CAR, (I)
CD8, (J) PD-1, (K) CD28, (L) CD27, and (M) CD25. In panels H-M, marker prevalence
as a percentage of total CD3+ cells is displayed. Error bars represent mean ± SEM for
n=5 mice per group. (* P < .05). Although m909-28Z CAR T cells display elevated PD-1,
CD28, and CD27 compared to CD19-28Z CAR T cells, there were no significant
phenotypic differences between vehicle and ATRA treated groups.
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Figure 2.12

Figure 2.12 m909 CAR T cells do not inhibit CD34+ HSC colony formation or
eliminate FRβ-low healthy monocytes in vitro.
Healthy adult human bone marrow CD34+ HSCs were isolated and (A) stained for FRβ
expression using m909-IgG (black line) or human IgG isotype control (gray line). One
representative donor shown. (B) CD34+ HSCs were co-cultured with CAR T cells at 1:1
E:T ratio for 4 hours. Wells were diluted in methylcellulose and cultured for 14 days.
Total colonies were counted and scored for CFU-GEMM, CFU-GM, CFU-G, CFU-M,
and BFU-E. There were no significant differences between total or lineage-specific
colonies for any of the treated groups compared to untreated CD34+ HSCs. Bar graphs
represent mean ± SD for n=2 wells per condition. Results are representative of 4
independent experiments and 3 normal bone marrow donors. CFU- colony forming unit,
GEMM-granulocyte/erythrocyte/monocyte/megakaryocyte, GM-granulocyte/monocyte,
G-granulocyte, M-monocyte, BFU-E – erythroid blast forming unit. (C) Low surface
expression of FRβ on normal human monocytes detected by flow cytometry using m909IgG (black line) or human IgG isotype control (gray line). One representative of 7 normal
donors shown. (D) CD14+ human monocytes were co-cultured with indicated engineered
T cells at a 3:1 and 1:3 effector to target cell ratio for 4 hours, after which total number of
live CD3-, CD14+ monocytes per well was quantified by bead-based flow cytometry.
Percent Lysis was calculated as (average counts for treated wells)/(average counts for
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untreated wells) x100. Data incorporates results using 3 different CAR T cell donors and
4 different monocyte donors as target cells.
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Figure 2.13

Figure 2.13 ATRA does not induce FRβ in normal HSCs.
Healthy CD34+ cells isolated from normal donor bone marrow were cultured for 5 days
in IMDM with 20% BIT9500 serum substitute with or without 10nM ATRA. (A) FRβ
expression was assessed after 5 days by flow cytometry using m909 IgG (black lines) and
human IgG isotype (gray lines). Live, CD34+ gates were used for FRβ analysis. In
contrast to THP1, we were still unable to detect FRβ expression on CD34+ HSCs
following 5 days ATRA treatment. Two independent samples containing pooled CD34+
cells from 7 total normal donors were tested.
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CHAPTER 3: High affinity FRβ-specific CAR T cells eradicate AML
and normal myeloid lineage without HSC toxicity.
Summary
On-target, off-tumor recognition of antigen in healthy tissues is a major concern in developing
new chimeric antigen receptor (CAR) T-cell therapies for cancer. Careful assessment of protein
expression by flow cytometry or IHC can provide helpful data for prediction of potential toxicity.
However, high affinity reagents should be carefully chosen in order to assure the most accurate
detection of target antigen levels, which may be low in normal tissues. In optimizing our FRβdirected CAR T-cell platform for targeting acute myeloid leukemia (AML), we isolated a high
affinity scFv (m923, 2.48nM KD) for production of CAR. m923 CAR T-cells exhibited greatly
enhanced reactivity against FRβ+ AML in vitro and in vivo compared to low affinity CAR
(m909, 54.3nM KD). To most accurately predict m923 CAR T-cell toxicity, high affinity m923IgG was used for analysis of FRβ expression in normal hematopoietic tissues by flow cytometry.
We were able to detect previously unrecognized levels of antigen compared to analyses with
lower affinity m909. CD34+ bone marrow (BM) hematopoietic stem cells (HSCs) displayed very
low expression of FRβ and m923 CAR T-cells did not inhibit HSC colony formation. Upon coculture, m923 CAR T-cells eliminated FRβ+ BM myeloid cells while sparing neighboring FRβnegative cells. Due to the potential for myeloid toxicity, we investigated transient CAR
expression via mRNA electroporation. mRNA-m923 CAR T-cells retained effective anti-tumor
activity in vitro and in vivo. Our results highlight the importance of antibody affinity for
assessment of target protein during CAR development. In addition, we report a highly potent
FRβ-specific CAR T-cell platform that, when delivered transiently, retains anti-tumor activity
while providing a decreased risk for long-term myeloid toxicity.
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Introduction
Acute myeloid leukemia (AML) remains a disease with poor prognosis131,132. Currently, the most
effective therapy, allogeneic bone marrow transplant, is not feasible in all patients, may not fully
eliminate tumor cells, and carries a substantial risk of GVHD-associated toxicity204-206. Therefore,
newer more potent therapy is needed for AML. Chimeric antigen receptor (CAR) T-cell therapy
has recently produced dramatic clinical success in CD19+ acute and chronic
lymphoblastic/lymphocytic leukemia (ALL and CLL) with reports of up to 90% complete
response rates122-124. CAR T-cells are genetically modified to eliminate tumor cells by linking an
extracellular tumor antigen-recognition domain (most commonly antibody-derived single-chain
variable fragments (scFvs)) to intracellular T-cell receptor signaling moieties87 (usually CD3ζ
with or without additional T-cell costimulatory signaling domains). Numerous target antigens are
currently being explored in hopes of expanding the clinical efficacy of CD19-directed CAR
therapy to many additional types of cancer. The success of CAR therapy in other malignancies
depends foremost on the identification of appropriate cell-surface tumor antigens. Due to the
potency of cytolytic CAR T-cells, the largest concern for development of new targets must be offtumor expression of the target protein in healthy tissues.
The high expression of many AML surface antigens on healthy hematopoietic stem cells (HSCs)
remains a prominent challenge for developing safe and effective CAR targets for AML189191,207,208

. We have previously established that folate receptor beta (FRβ)-specific CAR T-cells can

target AML without HSC toxicity209. However, these CAR T-cells were functionally limited.
Modifying CAR platforms with high affinity scFvs can result in improved anti-tumor
activity197,210. However, higher affinity CARs could result in heightened activity against normal
tissues with low levels of antigen and may present a greater risk for off-tumor toxicity in patients.
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Indeed, toxicity related to off-tumor recognition has led to patient morbidity in clinical trials
using Her2126 and CAIX211 CAR T-cells.
Awareness of target tumor antigen expression in normal tissues is exceedingly important for
prediction of possible off-tumor toxicity. Because many target antigens for T-cell therapy are
self-antigens, with overexpression on tumor cells, low levels of antigen are often expressed on
normal tissues212. Antibodies are commonly used to assess protein expression in target cells by
flow cytometry or IHC. The detection method should be carefully considered as antibodies with
lower affinity for the target protein could be unable to bind low levels of antigen and produce
false-negative results.
We hypothesized that our previously described FRβ-specific scFv, m909, may not be the ideal
reagent for optimal interaction with FRβ, either in a CAR platform or as a labeling reagent.
Therefore, in this study, we sought to develop high affinity reagents for CAR platform
optimization as well as sensitive protein detection in normal bone marrow to best characterize
potential toxicity related to targeting FRβ in AML.
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Materials and Methods
Antibody selection by phage display
Purified recombinant human folate receptor beta protein (rFRβ) was used for panning of a human
naïve Fab phage library according to the protocol described213. Three hundred colonies were
picked from the last two rounds of panning and rescued with helper phage for screening. The best
clone was selected for further affinity improvement by light chain shuffling. Briefly, the heavy
chain sequence (NcoI and SpeI fragment) of the clone was gel purified and ligated with the light
chain repertoire of the Fab library. The sub-library was then further screened with rFRβ for three
rounds. The clone with the best affinity, m909, and m923, were converted into scFv and IgG1.
The scFv fragment and IgG1 were prepared from E. coli HB2151 cells and 293Free Style cells,
respectively. The recombinant scFvs have Flag tag on the C-terminus.
Surface plasmon resonance analysis
Binding of m909 Fab to human rFRβ was assayed using BiacoreX100 instrument. Purified rFRβ
was diluted in 10 mM sodium acetate buffer, pH 5.0, and immobilized on a CM5 sensor chip with
an amine coupling kit. The reference flow cell was treated with the amine coupling reagent
without exposure to rFRβ. The running buffer was HBS-EP (10 mM HEPES, pH 7.4, 150 mM
NaCl, 3 mM EDTA, 0.05% surfactant P20). m909 or m923 scFv, diluted with the running buffer
to 0.04, 0.4, 4, 40, and 400 nM, was allowed to flow through the cells. The chip was regenerated
with 10 mM glycine pH 2.5, 1 M NaCl. The sensorgram was analyzed with BiaEvaluation
software, and data were fitted to a 1:1 binding model.
ELISA binding assay
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rFRβ diluted in PBS (2 μg/ml) was coated on a 96 well plate at 100 ng/well overnight at 4°C.
Wells were blocked with 100 µl of 4% nonfat dry milk/PBS (MPBS) for 1 hour at 37°C.
Antibodies were diluted at indicated concentrations, and each concentration was tested with
duplicates wells at 50 µl/well. After 2 hour incubation at 37°C, the wells were washed four times
with PBST (0.05% Tween 20 in PBS). For direct ELISA with IgG1, a goat anti-human Fc IgG
(Jackson Immunoresearch) conjugated with HRP was used at 1:1000 (1 hour x 37°C). Wells were
washed again with PBST, the substrate ABTS is added (50 µl/well), and the absorbance was read
at 405 nm. For competition ELISA of m909-IgG1 with m923 scFv, 20 nM of m909 IgG was
constantly present in the dilutions of m923 scFv. Binding of m923 scFv was detected with antiFlag-mAb-HRP (Sigma). For competition of m923 IgG with m909 scFv, the two antibodies
switched places.
Construction of m923 and CL10-28Z CAR
The m923 scFv was amplified by PCR using the primers Fwd 5’TATTGATCAGCCGAAGTGCAGCTGGTGCAGTCTGG-3’ (BclI underlined) and Rev 5’TATGCTAGCCTGGCCTAGGACGGTCAGCTTGGTC-3’ (NheI underlined), digested with the
relevant enzymes (NEB) and ligated into previously described pELNS lentiviral vectors
containing CD3ζ or CD28-CD3ζ to create m923Z and m923-28Z CAR constructs. pELNs
lentiviral constructs encoding GFP, CD19Z, CD19-28Z, m909Z, and m909-28Z CAR have been
previously described106,209. The CL10 scFv specific for mouse FRβ was kindly provided by
Takami Matsuyama. The CL10 scFv was PCR amplified using the following primers Fwd 5’TAT GGA TCC GAC ATT GTG ATG ACC CAA TCT CCA TCC TCT CTG-3’ (BamHI) and
Rev 5’- TAT GCT AGC TGA GGA GAC AGT GAC TGA AGC TCC TTG AC-3’ (NheI). The
PCR product was digested with BamHI and NheI and ligated into previously described lentiviral
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pELNS CAR vectors containing intracellular CD28 and CD3ζ signaling domains to produce the
CL10-28Z CAR construct.
Lentiviral CAR Production
Third generation lentiviral vector was produced in 293T (ATCC) as previously described 176,209.
10-15x106 293Ts were plated in T150 tissue culture flasks and transfected 24hr later with 18μg
pRSV-Rev, 18μg pMDLg/pRRE, 7μg pMD2.G and 15μg pELNS CAR plasmid DNA. 24hr and
48hr supernatants were collected, filtered through .45um syringe filters, combined, and
concentrated using high-speed ultracentrifugation (Beckman Coulter SW32-TI rotor). Lentiviral
vectors were titered in 293Ts and stored at -80°C in individual use aliquots until use.
Cells
All cells were cultured in complete media (CM, RPMI-1640-GlutaMAX, 10% FBS, 100U/mL
penicillin, 100μg/mL streptomycin) at 37°C. C30177 was provided by George Coukos. C30-FRβ
was created as described209. Human AML cell lines THP1, MV411, and HL60 were provided by
Gwenn Danet-Desnoyers. Healthy adult bone marrow (BM), CD34+ HSCs and primary human
AML were purchased from the University of Pennsylvania Stem Cell and Xenograft Core
(SCXC). Peripheral blood was collected by apheresis from volunteer donors by the University of
Pennsylvania Human Immunology Core (HIC) with informed consent according to the
Declaration of Helsinki. Whole blood, CD14+ monocytes, CD4+ and CD8+ T-cells were
purchased from HIC. T-cells were activated, transduced, and expanded as previously
described176,209. Briefly, 1:1 CD4:CD8 were activated with αCD3/αCD28 beads (Life
Technologies) and transduced with lentiviral vectors at MOI=10 20hr later. T-cells were
expanded in CM with 50IU/mL IL2 (Novartis) for 10-14 days. Rested T-cells (<300fL volume)
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were used for functional assays in vitro or in vivo. Transduction frequencies were normalized
using untransduced T-cells before each experiment.
Flow Cytometry
Up to 1x106 total cells were labeled in 100μL staining buffer (2% FBS in PBS) for 30min at 4°C
containing relevant antibodies. For assessment of FRβ expression, m909 and m923 scFv and IgG
were prepared as described and biotinylated (Sulfo-NHS-LC-biotin, Thermo) in vitro. 0.5μg IgG
or 1μg scFv was used for primary labeling, and 1:200 Streptavidin (SA)-APC (BD) for secondary
detection. Washed samples were assessed by flow cytometry using a BD FACSCantoII flow
cytometer in the presence of 7AAD. Surface CAR expression was labeled using 0.3μg rabbitanti-human IgG(H+L)-biotin (m909, m923, or CL10) or 0.3μg goat-anti-mouse IgG (H+L)-biotin
(CD19) (Jackson Immunoresearch) and secondary SA-APC or PE. The following antibodies were
used in this study: CD3-PECy7, CD8-APC, CD45-PE, CD4-PE, CD69-PE, CD107a-APC,
CD107b-APC, CD34-APC, CD123-BV421, CD14-FITC, CD19-APCCy7, CD11b-PacBlue,
CD38-PECy7 (Biolegend) and CD33-APC (BD Biosciences) at the manufacturer’s recommended
concentrations.
CAR binding to rFRβ
GFP-2A-CAR constructs were used to evaluate binding to rFRβ by flow cytometry. rFRβ (R&D)
was biotinylated (Sulfo-NHS-LC-biotin). 2x105 T-cells were incubated with 200ng, 500ng, or 1μg
rFRβ-biotin and secondary SA-APC. For CAR T-cell reactivity against rFRβ, 250 or 500ng rFRβ
was coated on 96-well plates overnight at 4°C. 1x105 CAR+ T-cells/well were cultured overnight
in 200μL CM. IFNγ secretion was assessed by ELISA (Biolegend).
Cytokine Release and CD69

70

1x105 targets and 1x105 CAR+ T-cells were plated in 200 μL CM. After overnight (18-24hr) coculture, supernatants were analyzed for IFNγ release by ELISA. In addition, IFNγ, IL2, MIP1α,
TNFα, IL4, and IL10 were assessed using cytokine bead array (BD). In some cases, cell pellets
were washed and labeled for CD3, CAR, and CD69 by flow cytometry following co-culture.
m923 and m909 IgG blocking CAR co-culture
For IgG blocking of m909 and m923 CAR activity (Figure 3.7), 1x105 C30-FRβ target cells were
pre-incubated with control human IgG, m909-IgG, or m923-IgG at 5000, 1000, 200, 40, 8, 1.6, or
0 ng IgG/well in 100µl CM in 96-well tissue culture plates. After 40 min pre-incubation at 37°C,
1x105 CAR+ T cells were added in 100µl CM to each well. m909-28Z, m923-28Z, or CD19-28Z
control CAR T cells were used. Each condition was plated in triplicate wells. After overnight
(18hr) co-culture at 37°C, supernatants were collected and IFNγ was assessed by ELISA.
Cell Lysis
Target cell lines C30, C30-FRβ, THP1, MV411, and HL60 were stably transduced with GFP-2Afirefly luciferase (fLuc) lentiviral vector. GFP was used to sort 100% positive lines if necessary.
2x104 fLuc+ target cells were plated in white 96-well plates (Gibco) and CAR+ T-cells were added
at 5:1, 1:1, or 1:5 E:T ratios in triplicate. After overnight co-culture, residual luciferase activity
was measured using the Extended-Glow Luciferase Reporter Gene Assay System (Life
Technologies). Percent lysis was calculated as follows [100- ((Average Signal T-cell Treated
Wells)/(Average Signal Untreated Target Wells)x100)].
Degranulation
1x105 targets and 1x105 CAR+ T-cells were plated together in 200μL CM with monensin (BD)
and 5μL /well CD107a-APC and CD107b-APC (BD) in triplicate. After 6hr co-culture, total cells
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were labeled for CD3, CAR and 7AAD by flow cytometry. Live, CD3+ CAR+ gates were used to
assess CD107 expression.
CFU Assay
2000 healthy adult BM CD34+ HSCs were cultured with 2000 CAR+ T-cells in V-bottom plates.
After 4hr, wells were diluted in methylcellulose and plated in duplicate. After 14 days colonies
were counted and scored as CFU-GEMM, GM, G, M, or BFU-E.
BM Lysis Assay
1x105 CD34- BM cells and 1x105 CAR+ T-cells were plated in 200μL CM. After 5hr, cells were
washed and labeled for CD3, CD33, CD19, FRβ and 7AAD. The phenotype of cells surviving coculture is indicated in represented flow cytometry plots.
Monocyte Lysis
2x105 normal donor CD14+ monocytes were labeled with Cr51, washed, and plated with CAR+ Tcells at 25:1, 5:1, or 1:1 E:T ratios in 6 replicate wells per condition. Monocyte lysis was assessed
after 4hr by Cr51 release. Spontaneous Release was assessed in untreated target wells. Lysis was
induced with 10% SDS to determine Max Release. Percent Lysis = [(Release in T-cell-treated
wells) – (Spontaneous Release))/((Max Release) – (Spontaneous Release))x100].
Mice
Nod/SCID/γchain-/- (NSG) and NSGs mice were purchased from, treated and maintained under
pathogen-free conditions by the SCXC under protocols approved by the University of
Pennsylvania IACUC. We injected 5x106 fLuc-THP1 tumor cells subcutaneously (sc) or
intravenously (IV) and T-cells intraperitoneally (IP) or IV as indicated in the figure legends.
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Tumor growth was monitored by caliper measurement (sc models) and bioluminescent imaging
as described209. Peak luminescence is displayed as p/s (IV tumor) or p/s/cm2 (sc tumor).
Peripheral blood sampling was conducted via retro-orbital blood collection under isoflurane
anesthesia. 50µl blood was labeled for indicated cell markers and quantified by TRUCount (BD)
per manufacturer’s instruction.
Humanized (NSGs-HIS) Mice
NSGs mice (Nod/SCID/γchain-/- with transgenic human SF, GM-CSF, and IL3) were
reconstituted with 1x105 adult BM CD34+ HSCs via intra-femur injection following sublethal
irradiation by the SCXC. Engraftment was confirmed by peripheral human CD45+ presence at 2
weeks post-inoculation. Mice were treated with 5x106 CD19Z or m923Z CAR+ T-cells via IV
injection. Peripheral blood collection was performed on day 8 and mice were euthanized on day
15 post T-cell treatment. BM from the injected femur was collected for further analysis.
mRNA CAR
pELNS lentiviral CAR plasmids were digested and ligated into PDA mRNA expression plasmids.
mRNA was produced as described. Briefly, PDA-CAR plasmid DNA was linearized and mRNA
was transcribed in vitro using the T7 mScript Standard mRNA kit (Cellscript). T-cells were
electroporated with 10μg mRNA/10x106 cells using an ECM 830 BTX electroporator (Harvard
Apparatus) using the following settings: unipulse, 500V, 700μs. “Mock” T-cells were
electroporated without mRNA. mRNA-CAR expression and functional activity were assessed at
the indicated time points following electroporation.
Statistical Analysis
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Data was analyzed for significance using student’s T test (GraphPad Prism 6). P < .05 was
considered significant. All error bars represent mean and standard error (SEM) unless otherwise
noted in figure legends.
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Results
m923 exhibits superior affinity for FRβ compared to m909.
The m923-scFv was isolated from our phage-display library as previously described for m909.
We utilized Biacore X100 (Figure 3.1A) to define monovalent affinities of 54nM and 2.1nM for
m909 and m923, respectively. Consistent with higher affinity, m923-IgG bound better to rFRβ by
ELISA (Figure 3.1B) and cell-surface FRβ by flow cytometry (Figure 3.1C). FRβ+ engineered
cell line C30-FRβ and FRβ+ AML lines THP1 and MV411 all displayed higher MFI with m923IgG than m909-IgG. m923-scFv also bound THP1 and MV411, albeit at lower levels compared to
the full bivalent IgG. m909-scFv could not be visualized by flow cytometry (Figure 3.2).
Although the epitopes recognized by m909 and m923 are unknown, blocking ELISAs
demonstrated the ability of m909 and m923 to inhibit association of the other to rFRβ (Figure
3.3), suggesting binding at nearby locations.
High affinity m923 CAR T-cells bind rFRβ with greater affinity than m909.
m923-scFv was cloned into previously validated lentiviral vectors containing CD3ζ alone or
CD28-CD3ζ intracellular signaling domains to create m923Z and m923-28Z CAR constructs
(Figure 3.1D and 3.4A). Human T-cells were transduced with lentiviral CAR constructs, and
transduction efficiency was determined by labeling for surface CAR expression. Control T-cells
were transduced with GFP, CD19-28Z CAR, or CL10-28Z CAR (specific for mouse FRβ). High
transduction efficiencies were reproducibly achieved at 70-80% (Figure 3.4B). GFP-2A-m909
and m923 CAR T-cells were labeled with rFRβ, and binding of cell-surface CAR to recombinant
antigen was determined by flow cytometry. m923 CAR T-cells highly associated with rFRβ,
whereas this interaction could barely be visualized with m909 CAR (Figure 3.1E). Accordingly,

75

high affinity m923 CAR T-cells also produced more IFNγ in response to immobilized rFRβ
(Figure 3.1F).
High affinity m923 CAR T-cells are highly reactive against cell-surface FRβ.
Next we assessed the relative functional reactivity of m909 and m923 CAR T-cells against cellsurface FRβ by measuring T-cell cytokine secretion, CD69 expression, and lytic activity against
FRβ+ cell lines. Compared to m909, m923 CAR T-cells secreted dramatically increased IFNγ in
the presence of FRβ+ C30-FRβ, THP1 and MV411 without activity against negative lines C30
and HL60 (Figure 3.5A). m923 CAR T-cells also produced high levels of IL2 and MIP1α, and
moderate to low TNFα, IL4, and IL10 (Figure 3.6). >90% of m909 and m923 CAR+ T-cells
upregulated CD69 in the presence of high density FRβ (C30-FRβ). However, when encountering
endogenous FRβ on AML cell lines THP1 and MV411, only ~40% of m909 CAR+ T-cells
expressed CD69, whereas nearly all m923 CAR+ T-cells expressed CD69 (Figure 3.5B). Like
CD69, both m909 and m923 were highly lytic against C30-FRβ (Figure 3.5C). However, only
m923 CAR T-cells efficiently lysed THP1 and MV411 AML with endogenous FRβ.
To determine whether soluble m909 or m923-IgG could block CAR T-cell activity, we measured
IFNγ secretion in response to C30-FRβ in the presence of m909 or m923-IgG. High
concentrations (>40ng/1x105 target cells) of m923-IgG completely blocked m909 CAR T-cell
IFNγ secretion (Figure 3.7). Interestingly, neither m909 nor m923-IgG was able to block activity
from m923 CAR T-cells.
m923 CAR T-cells demonstrate dramatic anti-tumor activity against FRβ+ AML in vivo.
To determine whether high activity of m923 CAR T-cells against AML could be recapitulated in
a mouse model of human disease, we inoculated immunocompromised NSG mice with FRβ+
fLuc-THP1 human AML. Previously, in mice treated with T-cells at days 8 and 10 of tumor
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growth, both m909 and m923 CAR T-cells led to long-term tumor-free survival209 (and Figure
3E). Here we evaluated FRβ CAR T-cells in mice with large, palpable AML tumors. m923Z and
m923-28Z CAR T-cells produced rapid and enduring complete tumor destruction (Figure 3.8AC). Low affinity m909-28Z CAR T-cells were ineffective. Consistent with robust in vivo
activation, m923 CAR T-cells were significantly elevated in peripheral blood 2 weeks post
treatment whereas m909-28Z CAR T-cell numbers were not different from controls (Figure
3.8D). However, when analyzed at day 42, m909-28Z CAR T-cells were >5000 cells/μL (Figure
3.8D) suggesting activation in the presence of FRβ+ tumor in vivo led to robust expansion,
however, likely due to low affinity, could not effectively control large tumor burden.
High affinity m923 CAR T-cell treatment resulted in expansion then contraction of peripheral Tcell numbers following tumor clearance. m923Z and m923-28Z CAR T-cells were still detectable
at day 92 (Figure 3.9), suggesting the potential for long-lasting tumor protection. To directly
assess this hypothesis, we re-challenged mice that had previously eradicated a primary tumor
(m923-28Z) or previously untreated (naïve) mice with 5x106 THP1 on the opposite flank.
Previous treatment led to complete protection against tumor re-challenge (Figure 3.8E). In
addition to subcutaneous tumor, m923 CAR T-cells also efficiently eliminated disseminated
THP1, which more closely resembles clinical disease (Figure 3.14C-D).
High affinity m923 CAR T-cells are reactive against primary human AML.
Importantly, m923 CAR T-cells also recognized primary human AML. Previous reports found
that 70% of AML patients express FRβ148,149. Using m923-IgG we confirmed expression in 15/16
specimens by flow cytometry. Four samples with varying FRβ expression (Figure 3.10A) were
used to assess CAR function. For these experiments CL10-28Z control CAR T-cells were used
because of CD19 presence in patient blood samples. Both m923Z and m923-28Z CAR T-cells
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secreted significantly more IFNγ compared to control T-cells in response to all four patient
samples (Figure 3.10B). For 3/4 primary AML, m923 IFNγ secretion was comparable to THP1,
suggesting robust activity against patient tumor. The viability of cryopreserved patient samples
was low, and standard lysis assays were not possible. Instead we evaluated CD107 expression on
CAR+ T-cells as a well-accepted surrogate for lytic function179. Significantly larger frequencies of
m923-28Z CAR+ T-cells expressed CD107 following 6hr culture with primary AML (Figure
3.10C) compared to control T-cells. These data confirm the potential for clinical responses in
AML patients using high affinity m923 CAR T-cells.
m923-IgG reveals increasing expression of FRβ along myeloid differentiation in healthy
hematopoietic cells.
We next evaluated the potential for off-tumor recognition of FRβ in healthy tissues. Although
previously reported192 we did not detect FRβ in HSCs with m909-IgG. The affinity of m909 may
not be sensitive enough to detect low levels of FRβ described elsewhere. Therefore, we used
m923-IgG to investigate FRβ expression in CD34+ BM HSCs isolated from 5 healthy adults. In
contrast to m909-IgG, we were able to detect FRβ on the surface of HSCs from most donors,
albeit at very low levels (Figure 3.11A). FRβ expression has been previously described in mature
myeloid cells147,159,193, however, expression in BM progenitors has not been well characterized.
Using myeloid markers (CD123, CD33, CD14), we found increasing FRβ expression during
myeloid differentiation, with highest levels in mature CD14+ monocytes (Figure 3.11B). Other
BM lineages were FRβ-negative (data not shown). Analysis of FRβ in peripheral blood using
m909-IgG has revealed expression in monocytes193,209. To more carefully assess possible toxicity
of m923-based CAR T-cells, we repeated peripheral blood analysis of FRβ using m923-IgG. In
agreement with previous results, we confirmed lack of expression in peripheral blood T-cells, B
cells, NK cells, and granulocytes (Figure 3.11C). Peripheral blood FRβ expression was limited to
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CD14+ monocytes, however, m923-IgG revealed >70% of peripheral blood monocytes express
FRβ, whereas m909-IgG detection suggested <40% (Figure 3.11D).
m923 CAR T-cells specifically eliminate FRβ+ myeloid lineage cells without toxicity against
HSCs.
To assess HSC toxicity we conducted colony-forming (CFU) assays following co-culture with
CAR T-cells. We did not observe inhibition in total or lineage-specific colonies formed by HSCs
under any condition (Figure 3.12A) suggesting the very low levels of FRβ observed in some
CD34+ donors were insufficient to activate m923 CAR T-cells. However, surface FRβ expression
increases along BM myeloid differentiation which could activate m923 CAR T-cells. We cocultured whole CD34- BM cells with CAR T-cells and assessed the phenotype of surviving cells
after 5hr (Figure 3.12B). Encouragingly, we did not observe extensive loss of viable myeloidlineage (CD33+) target cells, however, m923 CAR T-cells clearly eliminated FRβ+ CD33+
myeloid cells (Figure 3.12C). These results suggest that toxicity may be limited to FRβ+ BM
resident cells, while sparing neighboring FRβ- myeloid and alternative lineage cells. m923-28Z
CAR T-cells also exhibited specific lysis of peripheral CD14+ monocytes compared to control
CD19-28Z T-cells in vitro whereas m909-28Z CAR T-cells again did not lyse this population
(Figure 3.12D).
To assess the impact of targeting FRβ in the native BM microenvironment we treated NSGs mice
reconstituted with human adult BM CD34+ HSCs with m923 or CD19 control CAR T cells
derived from autologous BM T-cells (Figure 3.13A-B). Similar to our in vitro experiments, we
did not see targeting of BM HSCs or myeloid progenitor cells after treatment with m923,
however, CD19 CAR T-cell treated mice had decreased CD19+ lymphoid progenitor and mature
CD19+ BM cells (Figure 3.13D-G). Total CD14+ monocytes were not depleted by m923 CAR T79

cells in this model (Figure 3.13C and H), however it was noted that FRβ expression in CD14+
cells was lower than usually observed in fresh PB monocytes (Figure 3.13I). Despite lower
overall expression, m923 CAR T-cells still depleted FRβhi monocytes compared to control CD19
CAR T-cell treated mice (Figure 3.13I).
Transient mRNA-m923 CAR T-cells retain effective anti-tumor activity in vitro and in vivo.
High affinity m923 CAR T-cells exhibit the potential to eliminate both FRβ+ tumor and healthy
myeloid cells. Importantly, CD34+ BM HSCs are not targets for m923 CAR T-cell recognition.
We reasoned that transient CAR expression could allow for tumor cell destruction in the short
term, following which healthy myeloid cells could be repopulated from normal HSCs. Thus, we
developed transient expression of the m923 CAR platform via mRNA electroporation of T-cells.
24hr (d1) post-electroporation, both m923Z and m923-28Z CAR was highly expressed on the Tcell surface. Expression gradually decreased over time (Figure 3.14A), coinciding with a similar
reduction in THP1 lysis (Figure 3.14B). mRNA and lentiviral m923 CAR T-cells displayed
similar in vitro functional reactivity (Figure 3.15). We chose m923Z mRNA for in vivo T-cell
evaluation as we reproducibility observed greater stability of m923Z mRNA expression and never
discerned additional benefits with CD28 in lentiviral m932 CAR. The activity of m923Z and
CD19Z lentiviral and mRNA CAR T-cells was assessed against disseminated THP1 delivered IV.
Although not as robust as lentiviral CAR, m923Z mRNA CAR T-cells significantly delayed
disseminated THP1 tumor growth compared to CD19Z mRNA T-cells (Figure 3.14C). These
results suggest that mRNA delivery of the m923 CAR platform could be used transiently to
eliminate FRβ+ tumor cells.
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Discussion
Introducing a higher affinity scFv significantly enhanced our platform for targeting FRβ+ AML in
vitro and in vivo. m923 CAR T-cells reproducibly out-performed lower affinity m909 CAR Tcells as demonstrated by improved in vitro cytokine secretion, CD69 expression, cell lysis, and in
vivo anti-tumor activity. m923 CAR T-cells demonstrated recognition of primary AML patient
samples in addition to AML cell lines.
Utilizing m923-IgG allowed sensitive detection of even very low levels of FRβ in hematopoietic
cells not detectable by m909. Our results highlight the importance of antibody affinity when
evaluating normal tissue expression for preclinical evaluation of new CAR targets. In addition,
the field may find it useful to employ the scFv of the CAR for antibody-based analysis of tissue
expression as this may best correlate with CAR recognition. For example, we found cells that did
not bind m909-IgG (like MV411 or BM progenitors) were not substantially targeted by m909
CAR T-cells.
The scFv affinity is considered critically important to CAR T-cell function, with a general
consensus that higher affinity leads to increased CAR T-cell activation at lower levels of antigen
present. However, this aspect of CAR T-cell design is historically under-studied, especially
compared to the plethora of literature comparing intracellular signaling domains. Chmielewski
and colleagues developed CARs targeting hErbb2 with scFv affinities ranging from 10-7 to 10-11
KD, and established a threshold of 10-8 below which CAR T-cells responded similarly to all levels
of antigen, and above which CAR T-cells only responded to high levels of antigen210. In addition,
Hudecek and colleagues observed increased anti-tumor efficacy from ROR1-directed CAR Tcells with 5.6x10-10 KD compared to 6.5x10-8 KD scFvs197. Our experience with m909 and m923 is
in agreement with these findings. m909 (KD=5.4x10-8) CAR T-cells show strong in vitro function
only in response to high levels of antigen in C30-FRβ with reduced in vitro reactivity for lower
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FRβ expression in THP1 and MV411. m923 (KD=2.1x10-9) CAR T-cells displayed strong
reactivity against C30-FRβ, THP1, and MV411 without large differences in cytokine secretion in
response to different levels of FRβ. It has been hypothesized that “too high” scFv affinity could
result in prolonged T-cell activation and antigen-induced cell death (AICD). Of note, we do see
evidence for either AICD or antigen-induced CAR internalization in co-cultures with m923 CAR
T-cells and C30-FRβ, especially for m923Z (data not shown). However, we only observed this
effect in the context of supraphysiological antigen density in C30-FRβ and not with endogenous
high expression in THP1, suggesting this effect would not be clinically relevant.
We hypothesize that the remarkable difference in m909 and m923 CAR T-cell function is related
to affinity, however, it is formally possible that they recognize different epitopes of FRβ. For
other CAR platforms, recognition of epitopes more distal or more proximal to the cell surface can
drastically alter CAR performance214,215. Blocking studies with m909 and m923 partially
addressed this possibility. m909 and m923 can inhibit the binding capability and/or CAR
function of the other platform suggesting a nearby region is recognized. In addition, m909 and
m923 share the same variable heavy chain, and only13 amino acids are different in the light
chain. This represents an overall 95% scFv sequence homology. The highly similar sequence
further suggests these two scFvs do not recognize dissimilar epitopes. Therefore, we believe
affinity is the major difference driving CAR function although the precise epitopes remain to be
determined.
It is generally believed that the addition of costimulatory domains provides functional
improvement beyond first generation CAR platforms. Notably, the only instance where we
observed functional differences in m923Z and m923-28Z was increased cytokine secretion with
28Z in the context of C30-FRβ. Because there were no significant differences in in vitro activity
of m923Z vs m923-28Z in response to AML, we used both constructs in vivo to determine
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whether second generation CARs displayed increased persistence and anti-tumor activity (as
reported for many other CARs107,109,176,186,187). Both m923Z and m923-28Z resulted in complete
tumor regression. There were also no significant differences in CAR T-cell persistence in treated
mice. It is possible that costimulation through TNFR family members (4-1BB, CD27, or OX40)
could further increase the persistence of m923 CAR T-cells beyond Z or 28Z (as reported
elsewhere106,107,110). However, as discussed below, long term persistence is likely not desirable for
high affinity FRβ-specific CAR T-cells, and robust anti-tumor activity was already evident even
with first generation m923Z CAR T-cells.
Encouragingly, even with high affinity m923 CAR, we failed to see evidence of CD34+ HSC
destruction even though very low levels of FRβ were detectable with m923-IgG. We hypothesize
that the very low surface expression on a minority of CD34+ HSCs was not substantial enough to
cause robust activation of m923 CAR T-cells. We also evaluated FRβ in normal adult BM
hematopoietic cells and have demonstrated increasing expression along myeloid lineage
differentiation with a distinctly later phase of expression in hematopoietic differentiation
compared to other AML tumor antigens like CD123 and CD33. This could be important as
reports of gross BM toxicity have been described using CD123 and CD33 CAR T-cells191,208. Our
in vitro assays targeting whole BM and in vivo experiments with humanized NSG mice indicate
m923 CAR T-cells specifically eliminate FRβ+ cells while sparing neighboring FRβ- myeloid
lineage cells. We also observed high expression of FRβ in mature monocytes from PB, and
accordingly observed depletion of CD14+ monocytes in vitro.
Our in vivo model targeting autologous human BM implanted into NSGs mice resulted in
decreased expression of FRβ in CD14+ monocytes after m923 CAR treatment, but not decreased
frequency of total CD14+ monocytes. We believe this is due to the lower levels of FRβ expressed
by the monocytes in this model (Figure 3.13) compared to normal donors (Figure 3.11). It has
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been reported that FRβ expression is promoted by MCSF and inhibited by GMCSF during
myeloid differentiation166. It is possible that the cytokine milieu (particularly the high levels of
human GMCSF in the NSGs mice) may have contributed to the lower FRβ expression observed.
However, m923 CAR T cells were still able to deplete FRβHI monocytes in vivo without affecting
FRβ- cells.
While ongoing depletion of healthy B cells in patients treated with lentiviral CD19 CAR is
managed through IgG replacement therapy, an analogous therapy regimen to cope with lifelong
myeloid depletion is not available. As such, long-term persistence of m923 CAR T-cells is highly
undesirable. Therefore, we translated m923 CAR constructs to mRNA expression vectors for
transient expression in T-cells. Multiple doses of transient mRNA CAR T-cells significantly
delayed THP1 growth in vivo. The m923 CAR sequence is fully human derived, which decreases
the propensity for transgene immunogenicity which has led to anaphylaxis after repeated
administration of murine-derived CAR T-cells129. While m923 mRNA CAR T cells did not
produce complete tumor destruction of disseminated THP1 like was observed when for lentiviral
m923 CAR T cells, it is possible that a suicide gene or inducible CAR approach could be used in
combination with lentiviral m923 CAR to obtain complete tumor destruction before CAR T cell
depletion. Our results suggest transient treatment with m923 CAR T-cells could be a promising
therapy for FRβ+ AML while decreasing the risk for long-term myeloid toxicity.
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Figure 3.1
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Figure 3.1 m923 exhibits superior affinity for FRβ compared to m909.
(A) Increasing concentrations (0.04, 0.4, 4, 40, and 400 nM) of soluble m909 or m923
scFv were applied to human FRβ-coated chip and affinity was measured by plasmon
resonance with BiacoreX100. Binding of m909 and m923 IgG to (B) immobilized rFRβ
measured by ELISA or (C) cell-surface FRβ measured by flow cytometry in the indicated
cell lines. (D) Representative schematics of lentiviral CAR constructs (full list in Figure
S3A). (E) Binding of m909 and m923 CAR+ (GFP+) T cells to soluble rFRβ. (F) IFNγ
secretion following 24hr culture of m909 and m923-28Z CAR T cells on rFRβ-coated
tissue culture plates. CD19-28Z CAR T cells were used as negative control. Error bars
represent mean ± SD of triplicate wells. scFv – single chain variable fragment, VH –
variable heavy chain, L – linker, VL – variable light chain, TM – transmembrane domain.
(* P < .05, ** P < .01, *** P < .001)
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Figure 3.2
THP1

Isotype

MV411

m909 scFv

HL60

m923 scFv

Figure 3.2 Labeling of human AML cell lines with m909 and m923 scFv.
Human AML cell lines THP1, MV411, and HL60 were labeled with 1μg biotinconjugated scFv/3x105 cells for 30 minutes at 4°C, washed, and subsequently labeled
with streptavidin-APC. High affinity m923 scFv can be visualized by flow cytometry
whereas m909 binding is not discernable by flow.
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Figure 3.3

Figure 3.3 m909 and m923 IgG block binding of m923 and m909 scFv to
immobilized rFRβ.
Plates were coated with recombinant human FRβ. Binding of increasing concentrations of
m923 (A) or m909 (B) scFv was measured by ELISA with (red) or without (blue) the
presence of 20nM respective blocking IgG.
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Figure 3.4
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Figure 3.4 Lentiviral CAR constructs and expression in primary human T cells.
(A) Schematic representation of lentiviral CAR constructs used in this study. (B)
Representative transduction efficiencies and surface CAR expression in primary human T
cells. One representative donor shown. CAR expression is visualized with rabbit antihuman IgG(H+L)-biotin for m909, m923, or CL10 CAR and goat anti-mouse IgG (H+L)biotin for CD19. GFP fluorescence was used to indicate transduction in GFP control T
cells. Gray histograms represent labeling of untransduced T cells. scFv – single chain
variable fragment, VH – variable heavy chain, L – linker, VL – variable light chain, TM
– transmembrane domain.
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Figure 3.5

Figure 3.5 High affinity m923 CAR T cells demonstrate greater in vitro reactivity
against FRβ+ cell lines compared to m909 CAR T cells.
(A) IFNγ secretion following overnight co-culture of m909 or m923 CAR T cells with
the indicated cell lines. Error bars represent mean ± SEM of n ≥5 independent
experiments. (B) CD69 expression on CAR T cells following overnight co-culture with
the indicated target cells. Live, CD3+ CAR+ flow cytometry gates were used to assess
percent CD69+ CAR T cells. Error bars represent mean ± SEM of n=4 independent
experiments. (Note: unstimulated CAR+ T-cells have 20% CD69+ cells at baseline as
revealed in the Media control). (C) High lytic activity from m923 CAR T cells against
FRβ+ cell lines compared to m909. T cells and fLuc+ target cells were co-cultured at the
indicated E:T ratios. Percent lysis was assessed by residual target cell luminescence
following overnight culture. Error bars represent mean ± SEM of n ≥5 independent
experiments. Media indicates T cells cultured without target cells. GFP and/or CD19-28Z
CAR T cells were used as controls. SEM – standard error, fLuc – firefly luciferase. (* P <
.05, ** P < .01, *** P < .001)
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Figure 3.6

Figure 3.6 m923 CAR T cells secrete numerous proinflammatory cytokines in
response to FRβ+ cell lines.
Supernatant was collected after overnight co-culture of 1x105 CAR+ T cells and 1x105
tumor target cells. Concentrations of (A) IFNγ, (B) IL2, (C) MIP1α, (D) TNFα, (E) IL4,
and (F) IL10 were quantified by CBA. Error bars represent mean ± SEM for n=3
independent experiments using 3 distinct T cell donors.
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Figure 3.7
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Figure 3.7 Soluble m923 IgG blocks activity of m909-28Z CAR T cells.
1x105 C30-FRβ target cells and 1x105 CAR+ T cells (CD19-28Z (A, D, and G), m90928Z (B, E, and H), or m923-28Z (C, F, and I) were co-cultured overnight at 37°C in
200µl CM containing the indicated concentrations of control human IgG (A-C), m909
IgG (D-F), or m923 IgG (G-I). IFNγ secretion was assessed by ELISA. Error bars
represent mean ± SD of triplicate wells.
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Figure 3.8

Figure 3.8 High affinity m923 CAR T cells display exceptional anti-tumor activity in
vivo.
In panels A-D, 5x106 fLuc-THP1 cells were injected sc into flanks of NSG mice. 5x106
CAR+ (or GFP+) T cells were injected IP on days 19 and 22 post tumor inoculation.
Tumor growth was monitored by tumor luminescence (A-B) and tumor volume (C). (D)
Peripheral blood T cell quantification on days 29 and 42 post tumor inoculation. Error
bars represent mean ± SEM of n=4 mice per group. Differences in tumor growth between
CD19-28Z and m909-28Z were not significant at any time point. In panel E, mice were
injected with 5x106 m923-28Z CAR T cells on days 8 and 10. Following tumor clearance
on day 30, m923-28Z mice were re-challenged and previously untreated (naïve) mice
were challenged with 5x106 fLuc-THP1. Tumor growth was monitored by
bioluminescence (E). Error bars represent mean ± SEM of n=5 mice per group. fLuc –
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firefly luciferase, NSG – Nod/SCID/γchain-/- , sc– subcutaneous, IP – intraperitoneal,
SEM – standard error. (ns – P >.05, * P < .05, ** P < .01, *** P < .001)

95

Figure 3.9
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Figure 3.9. Long term persistence of m923 CAR T cells following THP1 tumor
clearance.
Peripheral blood human T cell (CD45+, CD3+) counts from m923Z and m923-28Z CAR
T cell treated mice from the experiment outlined in Figure 3.8A-D on days 29, 42, and 92
post tumor injection. Error bars represent mean ± SEM of n=4 or 5 mice per group.
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Figure 3.10

Figure 3.10 High affinity m923 CAR T cells are reactive against primary human
AML.
(A) FRβ expression in primary human peripheral blood cells isolated from AML patients.
Live, CD33+ gates were used to assess FRβ expression by flow cytometry. (gray
histogram– isotype, black histogram – m923 IgG). (B) IFNγ secretion after overnight coculture of indicated primary AML samples with CAR T cells. Error bars represent mean
± SD of triplicate wells. One representative experiment shown. (C) CD107 upregulation
on CAR+ T cells following 6hr co-culture with primary AML patient cells. Live, CD3+,
CAR+ gates were used to assess percent CD107+. Error bars represent mean ± SD of
triplicate wells. One representative experiment shown. SD– standard deviation. (* P <
.05, ** P < .01, *** P < .001)
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Figure 3.11

Figure 3.11 m923-IgG reveals increasing expression of FRβ along myeloid
differentiation in healthy hematopoietic cells.
(A) FRβ expression in healthy adult BM CD34+ HSCs. (gray histogram– isotype, black
solid histogram – m909 IgG, black dashed histogram – m923 IgG). One representative
donor shown. (Mean 6.3% FRβ+ using m923 IgG and n=5 donors). (B) FRβ expression in
healthy adult BM myeloid lineage cells. Myeloid progenitors–CD123HICD33(-)CD14(-),
Monocyte precursors – (CD123low, CD33+, CD14low), Mature monocytes (CD123(-),
CD33+, CD14HI). (gray histogram– isotype, black histogram – m923 IgG). One
representative donor shown. (C) FRβ expression in peripheral blood cells. Upper panels –
gating strategy to identify subsets. Lower panels – FRβ expression in indicated subsets.
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(gray histogram– isotype, color histograms – m923 IgG) Red – T cells, Green – B cells,
Orange – monocytes, Blue – granulocytes, Purple – NK cells. One representative donor
shown. (D) Percent FRβ expression detected in peripheral blood monocytes (n=10) using
m923 IgG (mean=66.6%) or m909 IgG (15.2%) for flow cytometry. Error bars represent
mean ± SEM. BM – bone marrow, HSCs – hematopoietic stem cells, SSC – side scatter,
FSC – forward scatter. (* P < .05, ** P < .01, *** P < .001)
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Figure 3.12
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Figure 3.12 m923 CAR T-cells specifically eliminate FRβ+ myeloid lineage cells
without toxicity against HSCs.
(A) Number of total and lineage specific colonies from CFU assay following 4hr coculture of 2000 CD34+ and 2000 CAR+ T cells. Error bars represent mean ± SD of
duplicate wells. Representative experiment shown of 4 independent assays. (B-C)
Phenotype of CD34(-) adult BM following 5hr co-culture with CAR T cells. Untreated
samples were cultured in the absence of T cells. (B) Frequency of CD33 and CD19
expression in total live, CD3(-) cells surviving co-culture with indicated T cells. (C) FRβ
expression in total live, CD3(-)CD33+ myeloid lineage BM cells following co-culture with
indicated T cells. (gray histogram– isotype, black histogram – m923 IgG). One
representative of 3 experiments is shown. (D) Percent lysis of CD14+ peripheral blood
monocytes isolated from healthy donors following 4hr co-culture with CAR T cells at
25:1, 5:1, or 1:1 E:T ratios. Error bars represent mean ± SD of six replicate wells. 5
different monocyte donors were assessed. CFU– colony forming unit, GEMM–
granulocyte/erythrocyte/monocyte/megakaryocyte,
GM–granulocyte/monocyte,
G–
granulocyte, M–monocyte, BFU-E– erythroid blast forming unit, BM– bone marrow,
NSG-HIS– Nod/SCID/γchain-/--human immune system , IV– intravenous, SD– standard
deviation, SEM– standard error. (* P < .05, ** P < .01, *** P < .001)
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Figure 3.13
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Figure 3.13 m923 CAR T cells deplete FRβ+ monocytes in vivo without HSC toxicity.
NSGs mice (Nod/SCID/γchain-/- with transgenic human SF, GM-CSF, and IL3) were
reconstituted with 1x105 adult BM CD34+ HSCs via intra-femur injection. (A)
Engraftment was confirmed by measuring the frequency of human CD45+ in peripheral
blood at 2 weeks post-inoculation. 5 mice per group were treated with 5x106 autologous
CD19Z or m923Z CAR+ T-cells via IV injection. Peripheral blood collection was
performed on day 8 to evaluate T cell engraftment (B) and peripheral human monocytes
(C) by TRUcount assay. Mice were euthanized on day 15 post T-cell treatment. BM
from the injected femur was collected and assessed for frequency of (D) CD34+CD38+
HSCs, (E) CD45(-), CD38+, CD19+ CLPs, (F) CD45(-)CD38+CD123+ CMPs, (G)
CD45+CD19+ B cells, and (H) CD45+CD14+ monocytes. In D-H, frequencies represent
the percentage of total, live, BM cells. In G-H representative flow cytometry plots are
shown for one mouse per group and the frequencies indicate percentage of live, human
CD45+ cells. (I) FRβ expression in BM CD14+ monocytes. Left – frequency of FRβ+
monocytes and Right – MFI of FRβ in FRβ+ monocytes. Representative flow cytometry
plots show FRβ in live, CD45+, CD14+ BM monocytes. Error bars represent mean ± SEM
for n=5 mice per group. (* P < .05). P values coming close to significance are indicated.
It should be noted that CD19 expression is very low in NSGs mice as the transgenic
factors promote differentiation of myeloid lineage. As such, mice with low total
engraftment did not have any CD19 expression. If low engrafters (<0.5% initial
engraftment) are removed from analysis (2 mice removed per group), the depletion of
CD19+ CLP and B cells in E and G becomes statistically significant. CAR – chimeric
antigen receptor, HSC – hematopoietic stem cell, BM – bone marrow, CLP – common
lymphoid progenitor, CMP – common myeloid progenitor, MFI – median fluorescence
intensity, SEM – standard error, SSC – side scatter.
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Figure 3.14
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Figure 3.14 Transient m923 mRNA CAR T cells retain anti-tumor activity against
disseminated AML.
m923Z and m923-28Z CAR mRNA was introduced into resting T cells by
electroporation. CAR expression (A) and THP1 lysis (B) was measured on day 1 (left
panels), day 5 (middle panels), and day 8 (right panels) following electroporation. “No
RNA” (black) represents T cells electroporated in the absence of mRNA. (C-D)
Bioluminescence of disseminated THP1 tumor growth in mice treated with mRNA or
lentiviral (Lenti) CAR T cells. Mice were inoculated with 5x106 fLuc-THP1 via IV
injection. Mice received 5x106 m923Z or CD19Z Lenti CAR T cells on days 6 and 11, or
10x10e6 m923Z or CD19Z mRNA CAR T cells on days 6, 11, and 18 post tumor
injection via IV delivery. mRNA CAR T cells were injected 18hr post-electroporation.
Mice receiving mRNA CAR T cells also received 60mg/kg Cyclophosphamide (Cy) IP
between T cell doses (days 10 and 17) to eliminate CAR-negative T cells between doses.
Error bars represent mean ± SEM of n=5 mice per group. IV– intravenous, IP–
intraperitoneal, SEM– standard error. (* P < .05, ** P < .01, *** P < .001)
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Figure 3.15

Figure 3.15 m923 mRNA CAR T cells have comparable in vitro function to lentiviral
m923 CAR T cells.
On day 14 post activation mRNA was introduced into untransduced T cells via
electroporation. On day 15, 1x105 lentiviral CAR+ T cells (Lenti) or mRNA CAR+ T cells
(RNA) were co-cultured overnight with THP1 and MV411 for assessment of IFNγ
secretion (A) or with fLuc-THP1 at indicated E:T ratios for assessment of lytic activity
(B). Error bars represent mean ± SD of triplicate wells. “No RNA” T cells were
electroporated in the absence of mRNA.
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CHAPTER 4: Safety and efficacy of FRβ CAR T cells targeting TAMs
in a mouse model of ovarian cancer.
Summary
Tumor associated macrophages (TAMs) have been identified as key pro-tumor players in the
microenvironment. Reported functions of TAMs include improving tumor vascularization, matrix
remodeling, and immunosuppression. Clinically, TAM density generally correlates with worse
overall prognosis in most types of solid cancer. We have previously developed high affinity
chimeric antigen receptor (CAR) T cells to target human FRβ for the treatment of acute myeloid
leukemia (AML). FRβ is also expressed on mature macrophages and is significantly upregulated
at sites of inflammation, including in the tumor microenvironment. The goals of the following
studies were: 1) To test the hypothesis that elimination of TAMs with CAR T cells may be a
novel mechanism to disrupt the tumor microenvironment and inhibit tumor progression and 2) To
evaluate safety in a preclinical mouse model of FRβ-directed CAR T cell therapy.
We established the feasibility of targeting FRβ on human TAMs using human FRβ-specific
(m923) CAR T cells in vitro. To model the effect of targeting TAMs in a dynamic tumor
microenvironment, we developed a mouse FRβ-specific CAR platform (CL10) for use in a fully
immunocompetent, syngeneic mouse tumor model. Due to the poor persistence of mouse CAR T
cells compared to human T cells, in vivo models required some initial optimization to achieve
TAM elimination. Using a single dose strategy of CAR T cells at day 5 of ex vivo expansion, we
were able to discern a phenotype attributed to FRβ targeting. Encouragingly, CL10 CAR T cells
produced a mild anti-tumor effect that required lymphodepleting preconditioning and IL2.
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Interestingly, we learned that targeting FRβ with CAR T cells in vivo resulted in mild to severe
transient toxicity in treated mice, concomitant with marked systemic monocytosis, granulocytosis
and elevated serum cytokines and chemokines associated with myeloid activation. These effects
were most extensive when lymphodepletion and IL2 were provided. This phenotype was specific
to FRβ-directed CAR T cell therapy since preconditioning and IL2 with either control CAR T
cells or tumor antigen-specific CAR T cells did not reproduce the phenotype observed with
CL10.
The observed signs of toxicity (rapid weight loss, ruffled fur, distended abdomens, and lethargic
behavior) after pre-conditioning and CL10 CAR T cell treatment were not dependent on the
presence of tumor, suggesting an on-target, off-TAM effect. We investigated FRβ protein
expression in healthy mice and noted high surface levels in liver Kupffer cells and cardiac
macrophages. Preliminary histological evaluation in the liver revealed depletion of F4/80+
macrophages in pre-conditioned CL10 CAR T cell treated mice and areas of hepatocyte necrosis.
The most obvious and severe pathological finding was the presence of marked, coalescing
extramedullary myelopoiesis (EMM) throughout the livers from this treatment group, which was
consistent with the peripheral increases in myeloid cell numbers.
These data provide the first description of CAR T cell targeting of macrophages. Although
encouraging, the small anti-tumor effects highlight several potential challenges that must be
addressed for successful evaluation and application of this strategy. The transient nature of mouse
CAR T cell persistence paired with ongoing repopulation of TAMs from peripheral blood
monocytes made the ultimate goal of eliminating TAMs throughout tumor progression largely
unfeasible. All mice showed tumor outgrowth with poor persistence of CAR T cells and
resolution of early inflammation at late stages of tumor growth. Future work in this area will need
to address at least one of these two confounding factors to model long term CAR-mediated
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elimination of TAMs in mouse models.
We have developed a model with a reproducible phenotype in which many questions could be
applied to further understand the mechanisms driving myeloid activation following CAR T cellmacrophage interactions. It may be that proinflammatory macrophage destruction activates
signaling pathways to promote increased myeloid output. While we have some preliminary
indication of soluble factors that may be involved, it will be of great importance to fully dissect
these pathways and the players involved. Finally, this work improves our understanding of
potential complications that could result when translating FRβ CAR therapy into the clinic.
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Introduction
Chimeric antigen receptor (CAR) T cell therapy has shown dramatic clinical success in CD19+
leukemia and lymphoma patients. However, CAR T cell therapy for solid tumors has been less
successful. Developing effective CAR T cell therapies for other types of cancer may involve
overcoming several obstacles associated with solid tumors. Poor blood supply and dense stromal
components can hinder access of CAR T cells to tumor cells. In addition, immunosuppressive
elements in the tumor microenvironment may suppress T cell functional activity. Engineering
CAR T cells to combat various components of the tumor microenvironment has shown potential
in preclinical models. CAR T cells engineered to recognize VEGFR2 overexpressed in tumor
vasculature inhibited the growth of 5 different types of tumors in mice216. Multiple groups
developing CARs directed against FAP on cancer associated fibroblasts observed beneficial
effects in xenograft217 and syngeneic218 tumor models. Importantly both of these stromal targets
synergized with tumor-specific CAR T cells217,219. Recently Caruana and colleagues showed that
CAR T cells engineered to express heparanase efficiently degraded components of the
extracellular matrix and exhibited increased tumor infiltration and antitumor activity220.
Therefore, engineered CAR T cells designed to interfere with non-tumor cell components of the
tumor microenvironment show great promise for enhancing CAR T cell therapy in solid tumors.
Tumor associated macrophages (TAMs) are one of the most well-described components of a
tumor promoting microenvironment. Tumors co-opt macrophage function by promoting “M2”
functions of macrophages associated with wound healing. M2 polarized macrophages can secrete
soluble factors to enhance tumor growth, promote angiogenesis, degrade the matrix to promote
metastasis, and aid in fostering an immunosuppressive environment19. Indeed, the presence of
TAMs correlates with worse overall prognosis in many types of cancer20. Ovarian cancer has a
particularly poor prognosis. The majority of patients are not diagnosed until the cancer has
110

metastasized, and 5-year survival remains below 50%131. Like other malignancies, the presence of
TAMs has been reported to correlate with higher stage221, higher grade221,222, and shorter
survival223 in ovarian cancer patients. In particular, an M2 macrophage phenotype denotes worse
prognosis. One report found that a high M1/M2 macrophage ratio224 is associated with improved
5-year survival. Another identified an M2-associated gene signature225 that was predictive of
worse progression-free survival. Lan et al found that high expression of M2 marker CD163
predicted poor survival while pan-macrophage marker CD68 was not predictive226. These
findings suggest that both TAM presence and TAM polarization could be important targets in
treating ovarian cancer.
Different strategies for inhibiting TAM function have proven effective in various preclinical
tumor models and include blocking recruitment of new myeloid cells21-23, direct depletion of
TAMs25-27, and repolarization of TAMs to an anti-tumor (M1) phenotype28-31. We hypothesized
that utilizing the power of CAR T cells to target TAMs could be an effective way to improve
CAR T cell therapy in epithelial cancer.
Folate receptor-beta (FRβ) has been described as a marker of M2 macrophages166 and is
expressed on TAMs from tumors of various tissue origins166-169. FRβ+ TAMs is correlated with
higher vessel density, incidence of metastasis, and worse prognosis in pancreatic cancer167. Turk
and colleagues demonstrated that TAMs from murine ovarian cancer ascites could be
preferentially targeted with labeled folate-conjugated liposomes170, presumably through uptake by
surface FRβ. Furthermore, elimination of FRβ+ TAMs with an immunotoxin reduced vessel
density and inhibited tumor growth in a rat glioma model171. The results of these studies led us to
hypothesize that CAR T cells directed against FRβ could represent a novel mechanism to deplete
TAMs and delay tumor growth.
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FRβ CAR T cells targeting human AML have proven efficacious in preclinical models. While in
vitro safety studies can be done to assess the potential impact on cells isolated from healthy
human donors, the real impact of targeting many tumor antigens is only clarified once patients
have been treated. Researchers have developed CARs targeting the mouse homologs of some
CAR targets including VEGFRII216, FAP217,218,227, CD19228-231, NKG2DL232-234, EGFRVIII235 or
evaluated CAR T cells in transgenic mice expressing the human homolog like Her2236,237 and
CEA238. These models can provide important preclinical safety data before moving into the
clinical setting. Therefore, a second aim of this study was to assess safety in mouse models of
FRβ-directed CAR T cell therapy.
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Materials and Methods
Cells
All cells were grown in complete media (CM, RPMI1640-GlutaMAX with 100μg/mL
streptomycin, 10μg/mL penicillin, and 10% FBS) unless otherwise noted. Human AML cell lines
THP1 and HL60 were cultured in CM as described in Chapter 3. The SKOV3 human ovarian
cancer cell line was obtained from ATCC and transduced with lentiviral firefly luciferase (fLuc).
The ID8 murine ovarian carcinoma cell line was kindly provided by George Coukos. The ID8
line was stably transduced with a lentiviral construct containing mCherry (RFP) and fLuc
separated by a viral T2A ribosomal skipping element (RFP-2A-fLuc) to create ID8-RFP-fLuc.
ID8-RFP-fLuc cell line was then stably transduced with lentiviral constructs encoding murine
FRβ cDNA (Origene) or human mesothelin cDNA (kindly provided by Steven Albelda) to
produce ID8-mFRβ and ID8-Meso, respectively.
Human Monocyte-Derived Macrophages
Healthy donor peripheral blood monocytes were obtained from the University of Pennsylvania
Human Immunology Core and differentiated in CM with 10ng/mL human MCSF (Peprotech) for
7 days. Macrophages were further cultured with MCSF only (M0), 10ng/mL LPS and IFNg (M1
polarized), or 10ng/mL IL4 and IL10 (M2 polarized).
Human T cells
Human T cells were activated, lentivirally transduced, and expanded as described in Chapter 3.
Untransduced, GFP, CD19-28Z, P4Z, P4-28Z, m923-28Z, and CL10-28Z CAR+ T cells were
used for in vitro or in vivo assays on days 12-15 post activation when cells had rested to ~300fL
size.
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Macrophage Lysis
Human M2 polarized macrophages were plated together in CM with human CAR+ T cells at 3:1,
1:1, or 1:3 E:T ratios. After overnight co-culture, total cells were collected and labeled for
expression of CD3 and CD14 and 7AAD. Total number of live, CD3-CD14+ cells (N) was
determined using count-bright beads (Invitrogen) by flow cytometry and lysis was calculated as
follows: Percent Lysis = 100 – [(average N treated wells)/(average N untreated wells) x100].
SKOV3 Bystander Lysis
fLuc+SKOV3 tumor cells were plated at a 1:1 ratio with human M2 polarized macrophages
(SKOV3/MACS) or C30 ovarian tumor cells (SKOV3/Control). C30 is a slow growing antigennegative cell line that serves as a negative control for macrophages. Human CAR+ T cells were
provided at 10:1, 3:1, or 1:1 E:T ratio of CAR+ T cells: SKOV3 tumor cells. After overnight coculture, SKOV3 lysis was determined using the Extended-GLO luciferase reporter assay (Life
Technologies) and calculated as follows: Percent Lysis = 100 – [(average fLuc signal from T cell
treated wells)/(average fLuc signal from untreated wells) x100].
Primary Ovarian Cancer Patient Samples
Ascites and solid tumor samples from ovarian cancer patients were obtained from the University
of Pennsylvania Ovarian Cancer Research Center tumor bank. Written informed consent was
obtained from each patient. Single cell suspensions from either liquid tumor ascites or digested
solid tumor were labeled with antibodies and analyzed by flow cytometry, co-cultured with
human CAR T cells for cytokine release, or labeled with anti-CD11b microbeads for magnetic
isolation of tumor associated myeloid cells.
CD11b Magnetic Bead Isolation
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Total cells from human ovarian cancer patient or mouse ID8 tumor ascites were labeled with
CD11b MicroBeads (mouse/ human) (Miltenyi Biotec) and isolated with LS MACS separation
columns according to the manufacturer’s instructions. CD11b+ and CD11b- fractions were
analyzed by flow cytometry or co-cultured with CAR T cells for cytokine release and/or lytic
assays as described below.
Ovarian Cancer TAM Lysis
Human ovarian cancer patient CD11b-isolated cells were plated together in CM with human
CAR+ T cells at a 1:1 E:T ratio in 6 replicate wells. After overnight co-culture, total cells were
collected and labeled with α-CD14 antibody and 7AAD. Total number of live, CD14+ cells (N)
was determined by flow cytometry using count-bright beads (Invitrogen) and lysis was calculated
as follows: Percent Lysis = 100 – [(average N treated wells)/(average N untreated wells) x100].
Mouse CAR Construction
MSGV1 retroviral plasmid DNA encoding the DC101 CAR with murine CD8α hinge and CD28
transmembrane followed by murine CD28, 41BB, and CD3ζ intracellular signaling domains was
provided by Steve Rosenberg216. eGFP-T2A sequence and P4 scFv (specific for human
mesothelin176) was added by Steve Santoro to create MSGV-GFP-2A-P4-m28BBZ. Plasmid
DNA containing the CL10 scFv, specific for mouse FRβ, was kindly provided by Takami
Matsuyama. The CL10 scFv was amplified using 2-step PCR first with primers A-Fwd and BRev, and second with primers C-Fwd and B-Rev to add on sequence encoding the DC101 leader
sequence from the DC101 vector and restriction sites for NcoI and NotI. The purified PCR
product and MSGV-GFP-2A-P4-m28BBZ plasmid DNA (Steve Santoro) were digested with the
relevant enzymes (NEB), gel purified, and ligated at a 3:1 insert:vector ratio using the Rapid
DNA Ligation kit (Roche) to create MSGV-GFP-2A-CL10-m28BBZ. MSGV-GFP-2A-CD19115

m28BBZ was created using an analogous strategy and primers D-Fwd, E-Rev, and F-Fwd to
amplify the FMC26 scFv specific for human CD19. DNA sequencing was used to confirm the
expected sequence. Hi-Speed MIDI or MAXI DNA prep kits (Qiagen) were used to produce high
quality DNA.
A-Fwd 5’-agcaactgcaactggagtacattcagacattgtgatgacccaatctccatcctctctgg-3’
B-Rev 5’-tatgcggccgctgaggagacagtgactgaagctccttgaccccaggcatccataatatcg-3’
C-Fwd 5’-tatccatgggatggtcatgtatcatcctttttctggtagcaactgcaactggagtacattc-3’
D-Fwd 5’-agcaactgcaactggagtacattca gacatccagatgacacagactacatcctccctgtctg -3’
E-Rev 5’-tatgcggccgc tgaggagacggtgactgaggttccttggccccagtagtccatagcatag -3’
F-Fwd 5’-tatccatgggatggtcatgtatcatcctttttctggtagcaactgcaactggagtacattc-3’
Retroviral Production
The retroviral packaging cell line PlatE with ecotropic envelope was kindly provided by George
Coukos. 6x106 PlatE cells in log phase growth were plated in T150 tissue culture flasks in 27mL
CM. 24hr later, each flask was transduced with 20μg MSGV1 retroviral transfer plasmid DNA
using 3mL Optimem (Gibco) and Lipfectamine2000 (Invitrogen) at a 3:1 Lipofectamine:DNA
ratio. 30mL CM was replaced at 24hr and 48hr. Supernatants from 48hr and 72hr post
transfection were collected, .45um filtered, and frozen at -80C until use.
Mouse T cell Expansion
Mouse T cells were activated, transduced, and expanded in mouse T cell media (CM with 50uM
beta-mercaptoethanol, 100mM sodium pyruvate, 1X GlutaMAX, and 50IU/mL murine IL2
(Peprotech)). Spleens were isolated from C57BL/6 mice after humane euthanasia according to
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protocols approved by the University of Pennsylvania IACUC. Splenocytes were dissociated and
pushed through a 70um cell strainer. Red blood cells were lysed using ACK lysis buffer (Gibco)
and cell number was determined. 3x106 total splenocytes/mL/well were activated with anti-mouse
CD3/CD28 antibody coated beads (Dynabeads, Invitrogen) at a 1.33:1 bead:cell ratio in 24well
plates. Splenocytes were transduced with retroviral vectors on day 1 and day 2 post activation. T
cell media was added daily to maintain ~1x106 cells/mL. Beads were removed on day 4. By day 4
post activation, >97% of live cells were CD3+ T cells, with a usual ratio of about 85:15
CD8+:CD4+. T cells were used for in vitro or in vivo assays on day 5-7 as indicated.
Retroviral Transduction
0.5mL RetroNectin (Takara) diluted to 25μg/mL in sterile PBS was immobilized overnight at 4°C
in 24well non-tissue-culture-treated plates. After overnight incubation, wells were washed with
PBS and blocked for 10min with 2% BSA/PBS. 3mL 48hr retroviral supernatant was added per
well and plates were centrifuged at 2000xg for 1.5hr at room temperature. Supernatant was
removed and 0.5mL (1.5x106) day 1 activated splenocytes were added per well. Cells were
centrifuged for an additional 10min at 1000xg and returned to 37°C . Transduction was repeated
on day 2 post activation using 72hr retroviral supernatant. For untransduced T cells, CM was used
in place of retroviral supernatant.
Surface CAR Expression
Presence of surface CAR expression was measured in transduced T cells on day 5 post-activation
by flow cytometry. P4 and CL10 CAR were measured using biotinylated rabbit anti-human IgG
(H+L) and CD19 CAR was measured using biotinylated goat anti-mouse IgG (H+L) (Jackson
Immunoresearch). Binding of P4 and CL10 CAR to biotinylated recombinant protein antigen was
also evaluated. Recombinant murine FRβ was purchased from R&D. Recombinant human
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mesothelin was produced in yeast as described. Recombinant proteins were biotinylated in-house
using EZ-link-Sulfo-NHS-LC-biotin (Thermo) and purified with dialysis using Tube-O-Dialyzer
Medi (G-Biosciences). T cells were labeled with 300ng biotinylated antibody or 500ng
biotinylated recombinant protein for 30 minutes at 4°C . Cells were washed and secondary
labeling with Streptavidin-APC was conducted for 25min at 4°C . Co-expression of GFP and
APC was used to determine surface CAR expression in transduced T cells.
Cytokine Release
1x105 target cells and 1x105 CAR+ T cells were added in 200µl CM. After overnight (18-24hr)
incubation at 37°C , cell-free supernatant was removed and stored at -20C until assessment. For
assessment of IFNg production in response to immobilized protein antigen, 1:2 dilutions of
recombinant murine FRβ (R&D) in 100µl PBS were plated in 96-well ELISA plates in triplicate
wells per condition (range 31-1000 ng/well). After overnight coating at 4°C , wells were washed
with PBS and 1x105 CAR+ T cells were added in 200µl CM. After 18hr culture, cell-free
supernatant was removed and stored at -20C until assessment. Human and mouse IFNg release
were measured using respective ELISA kits (Biolegend).
Cell Lysis
Cell lines: 1x104 fLuc+ target cells were plated in white 96-well plates. CAR+ T cells were added
at 5:1, 1:1, or 1:5 E:T ratios in triplicate wells and co-cultured at 37°C . After 4hr or overnight
incubation, residual luciferase activity was measured using the Extended-GLO luciferase reporter
assay (Life Technologies) and calculated as follows: Percent Lysis = 100 – [(average fLuc signal
from T cell treated wells)/(average fLuc signal from untreated wells) x100].
in vivo Tumor Models
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6-8 week old female C57BL/6 mice were purchased from Charles River, housed and treated
under University of Pennsylvania IACUC approved protocols. Mice were inoculated
intraperitoneally (IP) with 5x106 ID8-RFP-fLuc, ID8-mFRβ, or ID8-Meso tumor cells. T cells
were injected IP in 200µl PBS at the doses and schedules outlined in the figure legends. In some
cases 150mg/kg cyclophosphamide (Cy) was injected IV one day before T cell transfer and
human IL2 was provided at 15μg/dose in 100µl IP for 3 consecutive days following T cell
transfer (CyIL2 conditioning). Clodronate or PBS liposomes (clodronateliposomes.com) were
provided at the manufacturer’s recommended dose (100µl per 10g mouse weight) IV or IP as
described. Tumor growth was monitored by bioluminescent imaging and/or weight gain. Mice
were euthanized when they had gained >70% of initial body weight (tumor ascites formation) or
lost >20% of pre-treatment body weight (toxicity).
Bioluminescent Imaging
Mice were injected IP with 3mg/kg D-Luciferin and imaged under isoflurane anesthesia using an
IVIS Spectrum imaging system (Perkin Elmer). 5 consecutive images were collected 15-21
minutes following Luciferin injection. Peak luminescence was determined for each individual
mouse using Living Image software and is displayed in photons/second (p/s). Images were
generated with Living Image software using identical luminescent scales for each group.
Tissue Collection and Analysis
Mice were euthanized at the indicated time points following T cell delivery and whole tumor
ascites was isolated by peritoneal wash. 10mL PBS was injected IP and total cells in the wash
were collected. Red blood cells were lysed using ACK lysis buffer. 1-2x106 total cells were
stained and analyzed by flow cytometry as described below. Liver, lung, and/or hearts were
collected, formalin fixed, and paraffin embedded by the University of Pennsylvania Cancer
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Histology Core or the CHOP Pathology Core Laboratory at Children’s Hospital of Philadelphia.
For some mice, sections were H&E stained and evaluated for pathology. Peripheral blood was
collected via retro-orbital blood collection under isoflurane anesthesia. 50µl per sample were
labeled for CD45, CD11b, Ly6G, Ly6C, CD3, and CD8 and cell counts per µl blood were
calculated using Trucount tubes (BD Biosciences). The remaining blood was centrifuged at
4000RPM for 10 minutes at 4°C . Clear serum was removed and stored at -80C until analysis.
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were
measured by the University of Pennsylvania Mouse Phenotyping, Physiology, & Metabolism
Core at the Penn Diabetes Research Center. Luminex was performed by the University of
Pennsylvania Human Immunology Core using the mouse 32-plex cytokine/chemokine magnetic
bead panel (EMD Millipore).
Pathology Scoring
H&E stained liver sections were evaluated by board-certified veterinary pathologists at the
University of Pennsylvania School of Veterinary Medicine Comparative Pathology Core.
Individual pathological indications were given a score of 0-10 to grade the pathological severity
(0=not present, 2=rare/minimal, 4=mild, 6=moderate, 8=severe, 10=marked).
Flow Cytometry
Up to 2x106 cells were labeled per tube in staining buffer (2% FBS/PBS). Human FRβ expression
in human in vitro polarized macrophages and primary ovarian cancer TAMs was evaluated using
biotinylated m923-IgG and Streptavidin-PE as described in Chapter 3. The following marker
antibodies were used in parallel: human CD45-PerCP-Cy5.5, human CD14-APC-Cy7, human
CD14-FITC, human CD206-APC, mouse/human CD11b-PacBlue, human HLA-DR/DP/DQFITC (Biolegend), human CD163-BV421, human CD33-APC (BD Biosciences). Human
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mesothelin expression in ID8-Meso was evaluated using the K1 antibody (Santa Cruz) and
secondary F(ab)2 donkey anti-mouse IgG-APC (eBioscience). Mouse FRβ expression was
evaluated using CL10 IgG (kindly provided by Takami Matsuyama). Cells were preincubated
with 10μg unlabeled mouse IgG (Jackson Immunoresearch) to block Fc receptors, followed by
labeling with CL10 IgG or rat IgG2a isotype (Biolegend) for 30min at 4°C , washed, blocked
with 10μg unlabeled goat IgG (Jackson), labeled with goat anti-rat IgG-APC (Biolegend),
washed, blocked with 5μg rat IgG (Jackson), and labeled with fluorescently labeled mouse
marker antibodies. The following antibodies were using in this study: mouse CD45-FITC, mouse
CD45-PE, mouse CD45-PacBlue, mouse CD3-PE-Cy7, mouse CD8α-APC, mouse CD4-PE,
mouse/human CD11b-PacBlue, mouse Ly6G-PerCP-Cy5.5, mouse Ly6C-APC-Cy7, mouse
F4/80-PE-Cy7 (Biolegend), mouse CD204-PE (Miltenyi). The respective isotypes were also
purchased from Biolegend. eFluor-506 fixable viability dye (eBioscience) was used to assess
viable cells.
FRβ Expression in Healthy Tissue Macrophages
The following organs were collected from healthy 8-12 week old female C57BL/6 mice:
peripheral blood, bone marrow, spleen, peritoneal wash, liver, lung, heart, kidney, brain, and GI
tract. At least 3 mice were analyzed per tissue. Peripheral blood was collected via cardiac
puncture. Bone marrow was flushed from isolated femurs. Peritoneal cells were collected by IP
wash as described above. Spleens were dissociated by squishing and washing through a 70um cell
strainer. All other organs were minced into small pieces and incubated at 37°C for 2 hours with
shaking in the presence of Collagenase IV and DNAseI to gently digest tissues. Single cell
suspensions were generated by washing tissue digests through 70μm cell strainers, and red blood
cells were lysed using ACK lysis buffer. Single cell suspensions were labeled for FRβ using
CL10 IgG and myeloid markers CD45, CD11b, Ly6G, Ly6C, F4/80, and CD204 by flow
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cytometry as described above. CD45+CD11b+Ly6G- cells were gated to analyze expression of
F4/80 and CD204 macrophage markers. The F4/80-CD204 gates used to evaluate FRβ expression
in each tissue are indicated in the figure. (Not all tissue macrophages express F4/80 or CD204.)
F4/80 IHC
Immunohistochemistry (IHC) for F4/80 was performed in formalin-fixed, paraffin-embedded
tissue sections. Sections were baked at 57C overnight before deparaffinization according to
standard IHC protocols. Antigen retrieval was performed using pH6 Citrate buffer (Thermo) and
the pressure cooker method. Serial blocking steps were performed to block endogenous
peroxidases (Dako), Avidin/Biotin (Vector Labs), and protein block (Dako). 1:100 rat anti-mouse
F4/80 antibody (Life Technologies) was incubated for 2 hours at room temperature. Secondary
biotin anti-rat antibody, Vectastain Elite ABC kit, and Immpact DAB (Vector Labs) were used
according to the manufacturer’s instructions. Slides were counterstained with hematoxylin,
dehydrated and mounted. One tissue slide was stained per mouse. 10-12 random 20X fields per
slide were captured on a NikonXMZ microscope in a non-biased blinded manner. We imported
the images into ImageJ and counted the total number of positive cells per field. The mean of 1012 fields per sample was calculated.
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Results
Human M2 polarized macrophages highly express FRβ
First we measured the expression of FRβ in human monocyte derived macrophages with m923IgG by flow cytometry. As previously reported, MCSF induced high levels of FRβ expression in
differentiated macrophages (M0) compared to monocytes pre-culture (Figure 4.1A). Further
polarization with M2 cytokines IL4 and IL10 resulted in slightly increased expression, while M1
polarization with IFNg and LPS slightly decreased FRβ expression (Figure 4.1A). MCSF-M2
polarized macrophages also highly co-expressed FRβ and classic M2 markers CD206 (Figure
4.1B) and CD163 (Figure 4.1C). To test the hypothesis that FRβ-specific CAR T cells could be
used to eliminate M2-polarized macrophages, we co-cultured MCSF-M2 polarized macrophages
and m923 or control CD19 CAR T cells. m923 CAR T cells produced high levels of IFNg
(Figure 4.1D) and dose-dependent lysis (Figure 4.1E) of M2 macrophages after overnight coculture. To create a basic model of TAMs within a tumor microenvironment we co-cultured
SKOV3 ovarian cancer cells with M2 polarized macrophages and CAR T cells in tissue culture
wells. While m923 CAR T cells do not directly lyse SKOV3 alone, when co-cultured in the
presence of M2 macrophages significant bystander lysis of SKOV3 was observed (Figure 4.1F).
P4 CAR T cells, specific for the human ovarian cancer antigen mesothelin, were used as a
positive control for SKOV3 lysis. These findings suggest that targeting TAMs in the tumor
microenvironment with CAR T cells could lead to both indirect and direct anti-tumor effects.
TAMs from ovarian cancer patients highly express FRβ
To confirm the presence of FRβ+ TAMs in ovarian cancer, we measured FRβ expression by flow
cytometry in primary ovarian cancer patient samples (Figure 4.2A-B). CD11b+CD14+ TAMs
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from ovarian cancer patients exhibited high surface expression of FRβ. Data represents 4
individual patients and TAMs from both liquid tumor ascites and solid tumor digests. In addition,
m923 CAR T cells produced high levels of IFNg in the presence of primary ovarian cancer
ascites (Figure 4.2C) and specific lysis of CD11b-bead isolated TAMs from ovarian cancer
patients (Figure 4.2D).
Development and validation of a mouse FRβ-specific CAR T cell platform
While these data confirm the clinical relevance and feasibility of targeting FRβ+ TAMs with CAR
T cells, to model CAR-mediated destruction of TAMs in vivo in a fully immunocompetent,
dynamic tumor microenvironment, we developed a mouse FRβ-specific CAR T cell platform. We
cloned the CL10 rat anti-mouse FRβ scFv into previously validated MSGV retroviral CAR
constructs containing murine CD28, 41BB, and CD3ζ intracellular signaling domains. The CAR
constructs also contained GFP in trans to serve as a marker for transduced cells. Constructs
containing the P4 scFv, specific for human mesothelin, and FMC26 scFv, specific for human
CD19, were created in parallel to serve as controls (Figure 4.3A). After αCD3/CD28 bead
activation of total C57BL/6 mouse splenocytes, retroviral transduction, and expansion with IL2
(Figure 4.3B), cultures contained >98% CD3+ T cells with a usual ratio of 85:15 CD8+:CD4+
(Figure 4.3C). Surface CAR expression was confirmed in GFP+ cells by labeling with
recombinant protein antigen (murine FRβ and human mesothelin to detect CL10 and P4,
respectively) or antibodies that recognize the scFv portion of the CAR by flow cytometry (Figure
4.3D). CAR transduction was reproducibly achieved at 70-80% GFP+ cells (Figure 4.3E). We
next confirmed specific reactivity of CL10 mouse T cells by establishing dose-dependent IFNg
production in the presence of increasing concentrations of immobilized recombinant FRβ (Figure
4.3F).
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Mouse CL10 CAR T cells display potent reactivity against ID8-mFRβ in vitro and in vivo
To create a model of CAR-targetable murine ovarian cancer we engineered the C57BL/6syngeneic ovarian cancer cell line ID8 to stably express CL10 and P4 CAR target antigens
murine FRβ (ID8-mFRβ) and human mesothelin (ID8-Meso) (Figure 4.4A). Mouse CL10 and P4
CAR T cells produced IFNg (Figure 4.4B) and specifically lysed ID8 target cells containing their
respective CAR target antigen (Figure 4.4C). Multiple doses of CL10 mouse CAR T cells
(injected at day 6-7 of T cell expansion) significantly delayed tumor progression in mice
implanted IP with fLuc+ ID8-mFRβ compared to control P4 CAR T cells as measured by tumor
ascites formation (weight gain) (Figure 4.5B), tumor bioluminescence (Figure 4.5C), and
increased long-term survival (Figure 4.5D). Bioluminescent images from 4 representative mice
per group are shown to illustrate tumor progression (Figure 4.5E). These data confirmed high
activity of CL10 CAR T cells in vivo against antigen-positive target cells.
CL10 CAR T cells display in vitro reactivity against TAMs isolated from ID8 tumor-bearing
mice
We next asked whether the TAMs in our ID8 tumor model expressed FRβ. We collected total
cells by peritoneal wash from mice with large ID8 tumor ascites. Using CL10-IgG, we observed
high expression of FRβ in ~50% of CD11b+F4/80+CD204+ TAMs by flow cytometry (Figure
4.6A-B). Non-myeloid lineage (CD45+CD11b-) immune cells were reproducibly negative for FRβ
expression. High reactivity of CL10 CAR T cells against ID8 TAMs was verified using CD11bmicrobead isolation of all CD11b+ TAMs. CL10 CAR T cells produced high levels of IFNg only
when cultured with CD11b+ but not CD11b- ascites containing tumor cells and non-myeloid
immune cells (Figure 4.6C). P4 control CAR T cells did not produce IFNg in either condition.
Multiple doses of CL10 CAR T cells did not influence ID8 tumor growth
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We next tested the hypothesis that elimination of FRβ+ TAMs using CL10 CAR T cells would
inhibit tumor growth in vivo. We implanted mice with fLuc+ ID8 tumor cells (not expressing
CAR target antigens) and treated mice with an identical dosing schedule to our previous ID8mFRβ tumor model (Figure 4.6D). Multiple doses of CL10 CAR T cells (at day 6-7 of T cell
expansion) did not significantly change tumor progression compared to mice treated with control
P4 CAR T cells as measured by tumor ascites formation (weight gain) (Figure 4.6E), tumor
bioluminescence (Figure 4.6F), and survival (Figure 4.6G). Bioluminescent images from 4
representative mice per group are shown to illustrate tumor progression (Figure 4.6H).
ID8-tumor bearing mice treated with multiple doses of CL10 CAR T cells display poor
survival of CAR T cells and no depletion of FRβ+ TAMs
To investigate whether CL10 CAR T cells led to the depletion of TAMs in ID8 tumor-bearing
mice, we euthanized 5 mice per group on day 33 (2 days following the fourth T cell injection) in
the experiment outlined in Figure 4.6. Tumor ascites from both CL10 and P4 control CAR T cell
treated mice contained a very high percentage of CD45+ immune cells (95% and 96% of total
ascites). However, there were no significant differences in the frequency of infiltrating total
CD11b+ myeloid cells (Figure 4.7A), CD11b+F4/80+ TAMs (Figure 4.7B), total CD3+ T cells
(Figure 4.7C), or total CD3+CD8+ T cells (Figure 4.7D). In addition, FRβ+ TAMs had not been
specifically depleted in CL10 CAR T cell treated mice as FRβ expression was not significantly
different from control treated mice (Figure 4.7E). To assess whether the failure of CL10 CAR T
cells to deplete FRβ+ TAMs could be due to poor engraftment or survival of CAR T cells we
measured the frequency of CAR+ T cells in total CD3+CD8+ cells by GFP expression. CL10 CAR
T cells were detectable at a very low frequency (Figure 4.7F) suggesting poor survival of CAR T
cells following transfer.
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One large dose of CL10 CAR T cells leads to increased systemic innate immune cells and
depletion of FRβ+ TAMs
The very low frequency of CL10 CAR+ T cells just two days post transfer led us to modify our
CAR T cell dosing strategy. Instead of 4-5 multiple weekly doses of 5x106 day 6-7 CAR T cells,
we tested delivery of one larger dose (8x106) on day 5 of T cell expansion in mice with 4 week
established ID8 tumor (Figure 4.8A). We hypothesized that the larger dose at day 5 of T cell
expansion would allow for greater in vivo persistence. In addition, if multiple CAR T cell doses
resulted in an immune response boosted by the subsequent deliveries, an anti-CAR adaptive
immune response could have caused the rapid depletion we observed in our previous experiment
following the fourth CAR T cell dose. We rationalized that one large dose may lead to longer
survival of transferred cells.
On day 28 following tumor injection mice were injected IP with 8x106 day 5 CAR+ T cells. Mice
were euthanized on day 34 (6 days following T cell transfer) to assess CAR T cell survival and
impact on peripheral and tumor-localized myeloid cell populations. We noted a mild and transient
weight loss in CL10 treated mice compared to controls (Figure 4.8B). Mice otherwise appeared
healthy. On day 6 post T cell treatment, no differences in peripheral blood CD8+ or CD4+ T cell
counts were observed (Figure 4.8C). At this time point, no CAR+ (GFP+) T cells were detected in
the peripheral blood of either group (data not shown). However, we did observe significant
increases in Ly6G+ granulocytes at day 3 (data not shown) and day 6 (Figure 4.8C) and Ly6CHI
monocyte counts at day 6 (Figure 4.8C) in peripheral blood of CL10 CAR T cell treated mice.
These data suggested that CL10 CAR T cell treatment led to systemic activation of the innate
immune system with higher peripheral levels of activated neutrophils and myeloid precursors.
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Tumor ascites was collected by peritoneal wash and tumor immune cell infiltrates were analyzed
by flow cytometry (Figure 4.8D-H). CL10 CAR T cell treatment induced a significantly
increased immune cell infiltrate compared to P4 control treated mice (Figure 4.8D). As a
frequency of total live ascites cells, the percentage of total CD45+, total CD11b+, CD11b+Ly6G+
granulocytes, CD11b+Ly6CHI monocytes, CD3+CD8+ T cells, and CD3+CD4+ T cells were all
significantly increased in CL10 compared to P4 CAR T cell treated mice (Figure 4.8D). The
frequency of CAR+ (GFP+) CD8+ T cells was ~60% for both P4 and CL10 groups (Figure 4.8E)
signifying a large increase in CAR T cell survival compared to our previous ID8 experiment
(Figure 4.7F). Depletion of FRβ+ TAMs was also clearly evident in CL10 treated mice (<1% of
F4/80+CD204+ TAMs (Figure 4.8G) expressed FRβ compared to ~50% expression in P4 treated
mice) (Figure 4.8F). We also noted significant differences in the phenotype of CD11b+ myeloid
cells between P4 and CL10 CAR T cell treated mice. Plotting Ly6C vs CD204 (Figure 4.8H)
revealed that in P4 treated mice nearly all myeloid cells were Ly6C negative, with 2 populations
of CD204+ or CD204- TAMs. However, CL10 treated mice had significant populations in all four
quadrants with a continuous transition between different quadrants (Figure 4.8H). We believe
this finding reveals a static picture of ongoing dynamic recruitment and differentiation of new
monocytes to the tumor microenvironment. We hypothesize that elimination of FRβ+ TAMs
resulted in increased recruitment of new (Ly6CHI) monocytes to replace the depleted mature
(Ly6C-F4/80+CD204+/-) macrophages.
Cyclophosphamide and IL2 conditioning increases CL10 CAR T cell persistence and
toxicity in ID8 tumor-bearing mice
Previous research in mouse models as well as clinical application of adoptive T cell therapy have
found that non myeloablative preconditioning either with cyclophosphamide or sublethal
irradiation in combination with high dose IL2 can greatly improve adoptive T cell engraftment
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and anti-tumor efficacy. As another means to enhance CL10 CAR T cell persistence we added
150mg/kg cyclophosphamide treatment on day 27 (one day before T cell transfer) and 15μg IL2
on days 28, 29, and 30 to the one-dose CAR T cell ID8 mouse model (CyIL2) (Figure 4.9A).
Mice were euthanized on day 34 (6 days post T cell transfer) to assess peripheral and tumor
myeloid cell phenotype. The addition of CyIL2 greatly enhanced the mild weight loss seen in
non-conditioned (NC) mice. CyIL2 and CL10 CAR T cells resulted in progressive weight loss in
80% of treated mice with some mice losing >15% total body weight within 6 days post T cell
transfer (Figure 4.9B). In addition, visible signs of decreased grooming (ruffled fur) and lethargy
occurred in CyIL2 CL10 CAR T cell treated mice. Phenotypic changes in peripheral and tumor
myeloid cells in CyIL2 CL10 treated mice were similar to those observed in NC CL10 CAR T
cell treated mice. However, CyIL2 conditioning elicited a greater magnitude in the observed
response. On day 6 post T cell treatment, 3/5 CyIL2 CL10 treated mice had very high levels of
Ly6CHI monocytes and Ly6G+ granulocytes compared to the P4 group with 3/5 mice exhibiting
>7000 Ly6G+ cells/µl blood. In peritoneal tumor ascites, >95% of total cells were CD45+ immune
cells in CyIL2 CL10 treated mice (Figure 4.9D) including a large component of CD11b+ myeloid
cells (Figure 4.9D). Ly6G+ neutrophils alone made up 25-30% of total ascites cells compared to
< 2% of total cells in control mice (Figure 4.9D). The frequency of Ly6CHI myeloid cells was
also significantly increased in CL10 mice (Figure 4.9D). In addition, the frequency of CAR+
(GFP+) CD8+ T cells was significantly higher in CL10 treated mice compared to P4 (Figure
4.9E). In one mouse >50% of total ascites cells were CAR+ CD8+ T cells, and this high level of
CAR T cells correlated with increased toxicity in this mouse.
FRβ+ TAMs were also significantly depleted in CyIL2 CL10 compared to P4 to a similar degree
as NC CL10 mice (Figure 4.9F). In CyIL2 CL10 treated mice, Ly6G- myeloid cells exhibited
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almost a completely Ly6CHI phenotype whereas the majority of these cells in P4 group were
Ly6C- (Figure 4.9H).
Tumor-specific CAR T cells do not recapitulate the myeloid activation and toxicity
observed in CL10 CAR T cell treated mice.
To address whether our findings with CL10 CAR T cells could possibly be due to a general CAR
T cell activation phenotype and not specifically related to elimination of FRβ+ macrophages, we
repeated the CyIL2 ID8 tumor model using ID8-Meso tumor cells. In these experiments, P4
control CAR T cells served as a positive control for T cell activation in the tumor
microenvironment and CD19 CAR T cells served as the negative control CAR. A treatment
schedule identical to the ID8 CyIL2 model was used (Figure 4.10A). Again, only CL10 CAR T
cell treatment led to significant weight loss and signs of toxicity in mice (Figure 4.10B).
Although mild changes in immune cell frequencies were observed between P4 tumor-specific
CAR T cells and CD19 control CAR T cells, myeloid cell phenotypes were mostly identical
between these two groups in the peripheral blood (Figure 4.10C) and peritoneal ascites (Figure
4.10D, F-I) on day 7 post T cell transfer. The massive increase in peripheral blood and peritoneal
ascites Ly6G+ granulocytic and Ly6CHI monocytic myeloid cells with CL10 CAR T cells was
highly reproducible in the ID8-Meso tumor model. P4 tumor-specific CAR T cells did not elicit
this same dramatic myeloid cell infiltration. These experiments led us to hypothesize that innate
immune cell activation and toxicity in CL10 CAR T cell treated mice is driven by FRβ-targeted
CAR T cell immunopathology.
Clodronate liposome treatment produced a similar phenotype to CL10 CAR T cells in ID8
tumor-bearing mice
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As a positive control for macrophage depletion we added clodronate liposomes in addition to
CAR T cell treatment in the ID8 tumor model. Clodronate or control PBS liposomes were
injected IV 2 days before and IP one day before a single dose of 8x106 CL10 or P4 control CAR
T cells on day 28 of ID8 tumor growth (Figure 4.11A). Similar to CL10 CAR T cell treatment
alone, addition of clodronate to control P4 CAR T cells resulted in transient, recoverable weight
loss. However, addition of clodronate to CL10 CAR T cells resulted in enhanced weight loss with
2/4 mice requiring euthanasia at day 4 following T cell treatment due to deteriorating condition
(Figure 4.11B). We evaluated peripheral blood phenotype 3 days post T cell transfer (Figure
4.11C). Addition of clodronate to P4 control CAR T cells significantly elevated both T cell
(CD4+ and CD8+) and myeloid cell (Ly6G+ and Ly6CHI) counts. Addition of clodronate to CL10
CAR T cells produced an additive effect on Ly6G+ granulocytes and Ly6CHI monocytes.
Long term tumor growth is promoted in NC but inhibited in CyIL2 CL10 CAR T cell
treated mice
To assess the impact of macrophage depletion by CL10 CAR T cells on tumor growth, we
evaluated long term tumor progression in NC and CyIL2 conditioned ID8-Meso tumor bearing
mice. Mice were treated with a single dose of 8x106 CD19, P4, or CL10 CAR+ T cells on day 28
following tumor inoculation (Figure 4.12A). One group of mice received a mixed dose of 4x106
P4 and 4x106 CL10 CAR T cells (P4/CL10). We monitored tumor progression by progressive
weight gain in NC (Figure 4.12B) and CyIL2 conditioned (Figure 4.12C) mice and
bioluminescence in NC (Figure 4.12D) and CyIL2 conditioned (Figure 4.12E) mice. The weight
loss and signs of toxicity in CL10 CAR T cell treated mice recovered within 10 days of T cell
treatment. We observed a trend for more rapid outgrowth of NC CL10 CAR T cell treated mice
compared to controls (Figure 4.12 B, D) and significantly decreased tumor growth in CyIL2
conditioned CL10 CAR T cell treated mice (Figure 4.12C, E). To evaluate ongoing systemic
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inflammation and CAR T cell persistence we measured peripheral blood cell counts on day 31
after T cell treatment. One month following T cell transfer, the inflammation observed in the first
week following CL10 CAR T cell transfer (Figures 4.8-10) was completely resolved. Peripheral
blood T cell and myeloid cell counts were not significantly different from controls in NC (Figure
4.12F) or CyIL2 conditioned (Figure 4.12G) mice. CAR+ (GFP+) T cells were nearly
undetectable in all groups (range 0-0.3% of peripheral blood CD8+ T cells, data not shown).
Survival curves of NC mice were not different (Figure 4.12H). However, survival of CyIL2
conditioned P4, CL10, and P4/CL10 CAR T cell groups were all significantly enhanced
compared to CD19 control treated mice (Figure 4.12I).
CL10 CAR T cells with CyIL2 conditioning produce toxicity in non-tumor bearing mice.
To ask whether the signs of toxicity revealed by the addition of CyIL2 were dependent on the
presence of tumor, we treated non-tumor bearing C57BL/6 mice according to the same treatment
protocol (CyIL2 and single dose 8x106 CAR+ T cells). We observed a similar loss in weight and
ruffling/lethargy in CyIL2 CL10 treated non-tumor bearing mice (Figure 4.13A). These results
suggested that on-target elimination of non-TAM FRβ+ cells could be responsible for the transient
toxicity of CL10 CAR T cells.
FRβ is highly expressed in healthy liver Kupffer cells
Unlike in humans, FRβ is not expressed in bone marrow myeloid progenitors (data not shown) or
peripheral blood monocytes (Figure 4.14) in C57BL/6 mice. The FRβ literature in rodents has
generally described low expression of FRβ in resting macrophages, with higher expression
induced upon macrophage activation and in inflammatory environments160,198. Nagai and
colleagues used IHC to determine co-expression of FRβ and macrophage marker CD68 in a large
array of healthy mouse tissues. Their findings revealed low-moderate expression in spleen,
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peritoneal, liver, heart and colon macrophages171. To determine whether CL10 CAR T cellmediated toxicity could be due to recognition of macrophages in these normal healthy tissues we
examined FRβ in CD11b+F4/80+CD204+/- macrophage populations in C57BL/6 bone marrow,
spleen, peritoneal cavity, liver, lung, heart, kidney, brain, and GI tract using CL10-IgG and flow
cytometry. Our analyses revealed that most tissue macrophages do not express FRβ, with the
exception of low levels in resting peritoneal macrophages and high expression in liver
macrophages (Kupffer cells) and cardiac macrophages in the heart (Figure 4.14A).
Representative F4/80 vs CD204 expression plots and gates (Figure 4.14B) and FRβ expression
histograms (Figure 4.14C) are shown for each tissue.
F4/80+ Kupffer cells are depleted in the livers of CyIL2 CL10 CAR T cell treated mice
To assess whether liver Kupffer cells were impacted by CL10 CAR T cell treatment, we
evaluated F4/80 expression in fixed liver samples by IHC. Preliminary data suggest the CyIL2
conditioned CL10 CAR T cell treated mice showed depletion of F4/80+ cells in the liver when
analyzed 6-7 days post T cell transfer (Figure 4.15). Interestingly, NC CL10 CAR T cell treated
mice show evidence of increased F4/80 expression, possibly suggesting activation or recovery but
not depletion of Kupffer cells at this time point.
CL10 CAR T cell treatment with CyIL2 conditioning results in liver inflammation and
necrosis
Due to the high expression of FRβ in and evidence for depletion of liver Kupffer cells, we
reasoned that liver-directed tissue pathology could account for toxicity observed in CL10 CAR T
cell treated mice. Liver samples collected 6-7 days post T cell transfer from NC or CyIL2
conditioned mice from experiments outlined in Figures 4.8, 4.9, and 4.10 were analyzed by board
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certified veterinary anatomic pathologists. Representative H&E images are shown for each group
(Figure 4.16A).
While low levels of extramedullary hematopoiesis (EMH) is common in the liver, CL10 CAR T
cell treated mice displayed drastically increased EMH with an unusually strong skewing towards
the myeloid lineage, referred to as extramedullary myelopoiesis (EMM). The severity of EMM
was most notable in CyIL2 conditioned CL10 treated mice (see Figure 4.16F for scoring) with
numerous foci throughout the liver (Figure 4.16D), which is consistent with the increased Ly6G+
and Ly6C+ cells detected by flow cytometry in the peripheral blood and peritoneal cavity. Liver
assessment also revealed increases in circulating and liver infiltrating neutrophils and myeloid
precursor cells in CyIL2 CL10 treated mice. Histologically, these mice also had notably increased
numbers of megakaryocytes throughout the hepatic parenchyma.
Livers from all the groups had multifocal aggregates of neoplastic cells on the peritoneal surface
that occasionally extended into the underlying hepatic parenchyma. Peritoneal spread of injected
carcinoma cells (ID8 tumor cells), termed carcinomatosis, resulted in varying levels of
surrounding hepatocellular necrosis and myeloid cell infiltrate. Histologically in the CyIL2 and
CL10 treated mice the foci of carcinomatosis contained large areas of necrosis with fewer tumor
cells (see Figure 4.16B) as compared to the other groups. Increased tumor cell necrosis in CyIL2
CL10 treated mice supports the finding of delayed tumor progression in this treatment group
(Figure 4.12). There were also increased areas of hepatocyte necrosis (Figure 4.16C). Given the
increased amount of hepatic tissue damage in these mice, there was also prominent hepatocellular
regeneration characterized by increased numbers of mitotic figures (Figure 4.16E).
Hepatocellular necrosis results in the release of liver-specific aminotransferase enzymes into the
bloodstream of affected animals. We evaluated serum alanine aminotransferase (ALT) (Figure
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4.16G) and aspartate aminotransferase (AST) (Figure 4.16H) in NC or CyIL2 CAR T cell treated
mice. Serum ALT and AST were within the normal range for all mice on day 6-7 (Figure 4.11GH) and day 3 (data not shown) post T cell transfer, and there were no significant differences
between any of the groups. It is possible that the moderate hepatocyte necrosis noted during liver
assessment was not extensive enough to cause significant changes in serum enzyme levels.
Luminex analysis reveals increased serum cytokine and chemokine levels in CyIL2
conditioned CAR T cell treated mice
To assess potential correlates of systemic inflammation and toxicity in CL10 CAR T cell treated
mice, we analyzed peripheral blood levels of 32 chemokines and cytokines on day 3 following T
cell transfer. Many chemokines and cytokines were highly increased in CyIL2 conditioned CL10
CAR T cell treated mice (Figure 4.17). Neutrophil growth and activation factor G-CSF was
particularly dramatically increased. Also of substantial note, cytokines IFNg and IL6 and
chemokines IP-10 (CXCL10), MIG (CXCL9), KC (CXCL1), and MCP-1 (CCL2) were
considerably elevated in CyIL2 CL10 groups. Another group of cytokines and chemokines were
also statistically significantly but only moderately increased (Figure 4.18). These included GMCSF, RANTES, TNFα, IL-3, IL-7, IL-10, IL-13, IL-15, MIP-1β, LIF, MIP-1α, MIP-2, and
VEGF. The group of unchanged cytokines (Figure 4.19) included IL-1α, IL-1β, IL-2, IL-4, IL-9,
IL-12, LIX, IL-17, and M-CSF. NC CL10 CAR T cell treated mice and P4 tumor-specific CAR T
cell treated mice generally did not show elevations in most cytokines evaluated.
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Discussion and Future Directions
To our knowledge this is the first reported study describing CAR T cells directed against
macrophages. We established that targeting human FRβ+ macrophages is feasible using human
CAR T cells and confirmed that FRβ could be a clinically relevant target in primary ovarian
cancer TAMs. After some optimization of in vivo application of mouse FRβ-specific CAR T
cells, we did observe a mild delay in tumor progression in CyIL2 conditioned CL10 CAR T cell
treated mice compared to control T cells. Conversely, application of CL10 CAR T cells in nonconditioned mice may have mildly increased tumor progression. While the mechanisms
responsible are unknown, it is possible that the increased engraftment of T cells and exacerbated
inflammation (highlighted by increased signs of toxicity, granulo/monocytosis, and elevated
serum cytokines) in CyIL2 pre-conditioned mice produced a more inhospitable environment for
tumor growth and survival. CAR T cell activation could have even caused bystander lysis of
neighboring tumor cells (analogous to what we demonstrated using human tumor/macrophage cocultures in vitro). A proinflammatory environment could also have resulted in direct tumor cell
lysis by soluble factors or activated proinflammatory (M1) macrophages and infiltrating cytotoxic
neutrophils. CL10 CAR T cell application in NC mice, however, led to decreased engraftment
and less systemic inflammation. It is possible that the mild induction of tumor infiltrating myeloid
cells in this low inflammatory setting actually helped to promote tumor growth by increasing a
source for rapid TAM repopulation. This hypothesis is partially supported by comparing the
myeloid cell phenotype in NC CL10 (Figure 4.8H) and CyIL2 conditioned CL10 mice (Figure
4.9H) 6 days post T cell transfer. Whereas myeloid cells in CyIL2 conditioned CL10 mice show
almost an exclusively Ly6CHI phenotype, in NC mice ongoing differentiation is evident with
increases in Ly6Clow monocytes. Future studies to determine the kinetics and phenotype of
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macrophage differentiation and/or repolarization in the tumor microenvironment following CL10
CAR T cell treatment will be necessary to clarify these hypotheses.
Both NC and CyIL2 conditioned mice ultimately resolved signs of peripheral inflammation,
coinciding with loss of CAR T cells at late stages of tumor progression. It is possible that more
robust effects on tumor growth would have been noted in the setting of long term CAR T cell
persistence and activity. Unfortunately, our earlier mouse model suggested that multiple doses of
CAR T cells led to rapid depletion of T cells following later doses (Figure 4.7) decreasing the
chance that repeat infusions would result in long term persistence. Since the CL10 scFv is derived
from rat171 and the P4 scFv is derived from human176, foreign epitopes in these regions may have
elicited an immune response against the surface CAR. Reports of neutralizing factors directed
against mouse-derived scFvs have been described in CAR T cell treated patients95,128, and may
have been exacerbated by multiple CAR T cell infusions129. Therefore we think it is likely that
antibody-mediated CAR T cell elimination could be partially responsible for poor CAR T cell
persistence. The CD19 control CAR T cells (derived from a mouse scFv) seemed to persist
slightly better than P4 and CL10 in NC (Mean = 0.20% CD19 CAR+ CD8+ vs 0.01% CL10 (P
=.006) and .06% P4 (P=.03)) and CyIL2 conditioned (Mean = 0.18% CD19 CAR+ CD8+ vs
0.01% CL10 (P =.01) and .03% P4 (P=.03)) mice on day 31 post T cell transfer in ID8-Meso
tumor-bearing mice. While activation induced T cell death could also account for lower
persistence of CL10 and P4, lower immunogenicity of mouse-derived CD19 CAR T cells could
account for the slightly increased persistence.
Even if immunogenicity could be avoided and long term CAR T cell persistence achieved, CL10
CAR T cells would likely still have to fight an up-hill battle against constant replenishment of
TAMs from infiltrating Ly6CHI monocytes, especially in light of the increased infiltration of these
cells following CL10 CAR T cell treatment. An alternative approach to enhance CL10 CAR T
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cell efficacy could be to combine CL10 CAR T cells with therapeutic elimination of or blocking
monocyte recruitment into the tumor. Strategies targeting CCL2/CCR2 axis could block
recruitment or MCSF/CD115 axis could hamper differentiation thereby giving CL10 CAR T cells
a moderate advantage in this fight.
Lymphodepleting preconditioning and IL2 drastically increased the signs of toxicity and systemic
inflammation in CL10 CAR T cell treated mice. We believe the major mechanism behind these
observations is the well-described phenomena of improved T cell engraftment and functional
activity following lymphodepletion70,231,235. CD19 control CAR T cells and P4 tumor-specific
CAR T cells did not reproduce the phenotype observed in CL10 treated mice, suggesting the
conditioning regimen alone is not responsible. However, it is possible that cyclophosphamide has
an unappreciated effect on FRβ+ target cells that could be driving some of the increased toxicity.
We did evaluate FRβ expression in peritoneal, spleen, and liver macrophages following
cyclophosphamide treatment of non-tumor bearing mice and did not see any changes in surface
expression (data not shown). These findings support our original hypothesis that increased T cell
function was largely responsible for the increased toxicity observed in CyIL2 conditioned mice.
The striking systemic activation of monocyte and granulocyte output was by far the most
conspicuous observation coinciding with signs of toxicity in CyIL2 conditioned CL10 CAR T
cell treated mice. We noted peripheral increases in Ly6CHI monocytes and Ly6G+ granulocytes in
peripheral blood and peritoneal cavity, as well as marked extramedullary myelopoiesis (EMM) in
the liver. Liver EMM was correlated with on-target depletion of FRβ+ liver Kupffer cells. It is
unknown whether local destruction of nearby cells induced EMM directly or whether spikes in
peripheral cytokines led to induction of EMM in the liver. Systemic cytokine activation would
likely have also induced myelopoietic output from the bone marrow and potentially the spleen,
another common site for extramedullary hematopoiesis. Future studies should evaluate myeloid
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output from these organs in order to determine whether abnormal EMM from the liver was solely
responsible for the systemic surge in myeloid production.
The elevated levels of certain myeloid inducing cytokines in serum from CyIL2 conditioned
CL10 CAR T cell treated mice highly suggests that systemic cytokine levels likely played a major
role in inducing the observed monocytosis and granulocytosis. In particular, exceedingly high
serum concentrations of granulocyte colony stimulating factor (G-CSF) were noted. G-CSF is
considered the master regulator of granulocyte production and release from the bone marrow. GCSF mediates rapid release of neutrophils from the bone marrow through enhancing expression
of surface CXCR4 (Reviewed in (239)). G-CSF can also promote release of other bone marrow
populations, and is used clinically to mobilize HSCs before transplant240. Cells of the
monocyte/macrophage lineage are the major producers of G-CSF although mesenchymal and
endothelial cell expression has also been observed241. Many inflammatory stimuli including
TNFα and LPS can induce G-CSF production from macrophages during inflammation. In
addition to G-CSF, chemokines IP-10 (CXCL10), MIG (CXCL9), KC (CXCL1), and MCP1
(CCL2) are significantly elevated in CL10 CAR T cell treated mice. Production of IP-10242 and
MIG is induced by IFNg in a variety of cell types. IP-10 and MIG are particularly chemotactic for
activated lymphocytes243. Although T cell numbers were not drastically impacted in our mouse
models, these chemokines could have contributed to lymphocyte trafficking in CL10 CAR T cell
treated mice. MCP1 is the classic chemokine driving recruitment of CCR2+ peripheral blood
monocytes into sites of inflammation244 and tumor growth245,246. Therefore, elevated MCP1 likely
influenced the greatly elevated numbers of Ly6CHI monocytes in CyIL2 CL10 CAR T cell treated
mice.
We believe the high serum concentrations of IFNg are likely produced from the activated CL10
CAR T cells. Indeed we observed extraordinarily high production of IFNg upon CL10 CAR
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activation in vitro. However, many of the other chemokines and cytokines elevated in serum from
mice could be derived from either CAR T cells or a variety of other cells including the targeted
macrophages themselves. Evaluating a larger array of cytokines produced using in vitro coculture systems of CAR T cells and TAMs as well as other components of the peritoneal ascites
will be helpful in the future to unravel the sources of cytokine production.
Of note, many of the elevated cytokines in our model have also been described in CD19 CAR T
cell treated patients experiencing cytokine storm following T cell transfer (including IFNg, IL6,
CXCL9, CXCL10, and TNFα)118,121,123. Many parallels have been drawn between the cytokine
release syndrome observed in CAR patients and symptoms of macrophage activation syndrome
(MAS)247,248. The prominent role of IL6 in both scenarios, highlighted by the effective use of
IL6R inhibitor tocilizumab to control cytokine storm in CD19 CAR patients122, suggests that
macrophage activation following CAR T cell transfer could be a prominent factor driving toxicity
of CAR T cell therapy in the clinic. One preclinical study using ErbB-targeted CAR T cells
confirmed macrophage derived IL6 as a correlate of toxicity in mice249. Interestingly, this study
also showed reduced IFNg production by CAR T cells in vivo when macrophages were depleted,
possibly suggesting a feedback system between CAR T cells and activated macrophages. Our
model directly targeting macrophages with CL10 CAR T cells also confirms these similarities
and may be of use to further future understanding of the role of macrophages in CAR therapy.
Of note, we did not observe many significant increases in serum cytokines in P4 CAR T cell
treated ID8-Meso tumor bearing mice. It is technically possible that CL10 is a “better” CAR and
produces higher levels of T cell activation upon target recognition in vivo. Future experiments
directly comparing P4 and CL10 CAR T cell efficacy against ID8-Meso and ID8-mFRβ could
more directly address these potential functional differences. However, we believe that the cells
targeted by CL10 (macrophages) vs P4 (tumor cells) is likely responsible for the major
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phenotypic differences elicited in CL10 CAR T cell treated mice. This hypothesis is supported by
the finding that clodronate liposome-mediated macrophage elimination also produced increased
hematopoietic output visualized by increased peripheral blood cell counts. Like with NC CL10
mice, clodronate caused transient recoverable weight loss in combination with control T cells.
However, combination of CL10 CAR and clodronate synergistically enhanced systemic myeloid
activation and toxicity. We initially hypothesized that clodronate pretreatment would decrease
CL10 CAR T cell toxicity by eliminating FRβ+ target cells before CAR T cell delivery. Instead
we observed additive effects from the two treatments which ultimately produced lethal toxicity in
50% of mice. Several factors could account for these observations. Clodronate may not have
eliminated all FRβ+ macrophages before CL10 CAR T cell transfer. The kinetics of clodronate
and CL10 CAR mediated macrophage depletion will need to be clarified in the future. It is also
possible that FRβ is expressed in a population of cells not targeted by clodronate. Nonmacrophage FRβ expression will need to be investigated further to address this possibility. Future
studies comparing the effects of clodronate and CL10 CAR T cell-mediated macrophage
depletion will help untangle the phenotype of “clean” macrophage depletion to proinflammatory
macrophage depletion in the setting of CAR T cells. For example, evaluating serum cytokine
secretion from clodronate treated mice will be helpful in untangling whether the cytokine release
observed following CL10 CAR T cell treatment was more dependent on T cell activation or
macrophage destruction.
In light of high expression of FRβ in cardiac macrophages, it will be of great interest in the future
to determine whether cardiac macrophages are depleted similarly to liver Kupffer cells in CyIL2
conditioned CL10 treated C57BL/6 mice and whether any evidence of cardiac pathology is
present. In all of our experiments we injected CAR T cells directly IP. This could have allowed
for more direct access to the liver compared to other organs like the heart. In addition, the
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frequency of CAR T cells in the peripheral blood was usually low, especially compared to the
frequency in peritoneal wash, suggesting CAR T cells do not efficiently or rapidly exit the
peritoneal cavity. Future experiments comparing IV delivery of CL10 CAR T cells to IP delivery
are warranted to investigate whether route of delivery impacts the ensuing site and severity of
tissue pathology and overall degree of toxicity.
While our analyses highlighted liver and cardiac macrophage as candidate target cells for CL10
CAR T cell targeting, tissue macrophage FRβ expression was measured in healthy mice. Models
of experimental inflammation have been reported to increase FRβ expression in macrophages at
sites of inflammation and systemically160. It is unknown whether the systemic inflammation
observed in CL10 CAR T cell treated mice could have induced FRβ to higher levels on tissue
macrophages than those observed in healthy mice. In theory, this scenario could create a selfperpetuating model of (CAR T cell activation  systemic inflammation  higher FRβ
expression in previously low/negative macrophages  increased CAR T cell activation and
toxicity).
A recent report of lethal toxicity in mice treated with chimeric NKG2D CAR T cells reported
strain-specific differences in the degree of toxicity with BALBc mice experiencing drastically
increased lethality compared to C57BL/6234. Although this could be due to differential expression
of NKG2D target ligands in BALBc vs C57BL/6 mice, their findings raise an important question
about the variability of CAR T cell therapy in a genetically diverse population. Future
experiments are warranted to evaluate whether FRβ expression is changed and whether CL10
CAR T cells produce similar toxicity in genetically divergent strains of mice.
In summary, we have developed the first model targeting macrophages with CAR T cells. It
appears that CAR T cell-mediated macrophage destruction activates signaling pathways to
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promote increased myeloid output. We have evaluated many of the soluble factors that are likely
involved, but future studies with in vitro systems and genetic knockouts will be necessary to fully
untangle the pathways and cellular mediators of these effects. Encouragingly, elimination of
TAMs with CAR T cells produced a mild anti-tumor effect in our model. However, several
obstacles will need to be overcome to improve CAR T cell persistence and ongoing myeloid
depletion in order to fully evaluate the merits of this approach. Finally, our evaluation of ontarget toxicity in healthy tissue macrophages will help educate future development of FRβdirected CAR T cells for AML.
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Figure 4.1
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Figure 4.1 Human M2 polarized macrophages highly express FRβ and are
efficiently targeted my m923 CAR T cells
(A) FRβ expression in human monocytes (pre-culture), MCSF-differentiated
macrophages (M0, blue), M1 polarized (red), and M2 polarized (green) MCSFdifferentiated macrophages. (B) M2 macrophages co-express FRβ and CD206. (C) M2
macrophages co-express FRβ and CD163. (D) IFNg secretion in supernatants from
overnight co-culture of M2 macrophages and CAR T cells. Error bars represent mean ±
SD of triplicate wells. Representative experiment shown. (E) Specific lysis of M2
macrophages after overnight co-culture with CAR T cells at 3:1, 1:1, or 1:3 E:T ratios.
Lysis was measured by quantitative flow cytometry examination of live target cells
following co-culture. Error bars represent mean ± SD of triplicate wells. One
representative experiment shown. (F) Specific lysis of SKOV3 ovarian carcinoma by
Untransduced (UN), P4, or m923 CAR T cells with (right, SKOV3/MACS) or without
(left, SKOV3/Control) the presence of M2 macrophages present in the culture. SKOV3
and M2 Macrophages were cultured at a 1:1 ratio. Error bars represent mean ± SD of
triplicate wells. One representative experiment shown. Results were repeated 3 times
with similar results. SD – standard deviation. (*** P < .001)
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Figure 4.2

Figure 4.2 Ovarian cancer TAMs highly express FRβ and are targeted by m923
CAR T cells
(A-B) Flow cytometry assessment of FRβ in TAMs from primary ovarian cancer patients.
Whole ascites or tumor digests were washed, labeled, and gated on live,
CD45+CD11b+CD14+ TAMs for assessment of FRβ. m923-IgG (blue) and isotype (gray)
staining was used to determine frequency of FRβ+ TAMs. One representative sample
shown (A). Average frequency in 7 samples is indicated (B). 4 different patients are
represented. TAMs from liquid ascites and solid tumor digests were evaluated. (C) IFNg
secretion from overnight co-culture of CAR T cells with whole ovarian cancer ascites
tumor. Untreated tumor ascites was cultured in the absence of T cells. Media control
wells contained T cells alone. Error bars represent mean ± SD of triplicate wells. (D)
Percent lysis of primary ovarian cancer TAMs by m923 CAR T cells. Whole CD11b+
tumor associated myeloid wells were isolated by CD11b magnetic microbeads from
ovarian patient tumor ascites. After overnight culture at 1:1 E:T, quantitative flow
cytometry was used to assess live CD14+ TAMs following culture. Error bars represent
mean ± SD of 6 replicate wells. Untreated wells were cultured in the absence of T cells.
CL10 control CAR T cells are specific for mouse FRβ. SD – standard deviation. (*** P <
.001)
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Figure 4.3

147

Figure 4.3 Development of a FRβ-specific mouse CAR T cell platform
(A) Schematic representation of MSGV CAR retroviral constructs. (B) T cell expansion
of untransduced (UN), P4 and CL10 mouse CAR T cells. 10 independent experiments
incorporated. Error bars represent mean ± SEM. (C) On day 5 of expansion cultures
contained >98% CD3+ (upper) with 80-90% CD8+ (lower) T cells. (D) Surface CAR
expression in GFP+ cells. T cells were labeled with biotinylated recombinant murine FRβ
(FRβ), human mesothelin (Meso), or α-human (H+L) antibody (CAR) and secondary
streptavidin APC (SA-APC). (E) CAR T cell transduction efficiency across 10
independent experiments as measured by GFP expression on day 4-5 of culture. Error
bars represent mean ± SEM. (F) IFNg production from mouse CAR T cells cultured
overnight in 96-well plates coated with recombinant FRβ. Error bars represent mean ±
SEM. GFP – green fluorescent protein, VH – variable heavy change, L – linker, VL –
variable light chain, TM – transmembrane, SEM – standard error.
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Figure 4.4

Figure 4.4 CL10 mouse CAR T cells display potent reactivity against ID8-mFRβ in
vitro
(A) Expression of mouse FRβ (left, red) and human mesothelin (right, blue) in
engineered cell lines ID8-mFRβ and ID8-Meso, respectively. Isotype staining is shown in
gray histograms. (B) IFNg secretion following overnight co-culture of mouse CAR T
cells and ID8 cell lines. Error bars represent mean ± SD of three replicate wells.
Representative experiment shown. (C) Specific lysis of fLuc+ ID8 cell lines after 5hr coculture with CAR T cells. Error bars represent mean ± SD of 3 replicate wells. One
representative experiment is shown. UN – unstransduced, E:T – effector: target.
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Figure 4.5
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Figure 4.5 CL10 mouse CAR T cells significantly inhibit ID8-mFRβ tumor growth
in vivo
(A) Treatment schedule of C57BL/6 mice implanted IP with 5x106 fLuc+ ID8-mFRβ
tumor cells with 5x106 P4 or CL10 CAR+ T cells on days 4, 10, 17, 31, and 38 following
tumor injection. n=8 mice per group. Tumor progression was monitored by (B)
progressive weight gain and (C) bioluminescent imaging. (D) Survival. (*** P < .001,
log-rank (Mantel-Cox) test). (E) Representative bioluminescent images of 4 mice per
group. Error bars represent mean ± SEM. IP – intraperitoneal. fLuc – firefly luciferase.
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Figure 4.6
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Figure 4.6 CL10 CAR T cells display in vitro reactivity against ID8 TAMs but fail to
impact ID8 tumor growth in vivo
(A-B) FRβ expression in CD45+CD11b+F4/80+CD204+ TAMs in mice bearing large ID8
tumor ascites. (A) Representative histogram. Blue – CL10 IgG. Gray – rat IgG2a isotype.
(B) Expression across n=3 mice. CD45+CD11b- immune cells do not express FRβ. (C)
IFNg production following overnight co-culture of CAR T cells and ID8 ascites CD11b+
or CD11b- magnetic bead-isolated fractions. (D) Treatment schedule of C57BL/6 mice
implanted IP with 5x106 fLuc+ ID8 tumor cells and 5x106 P4 or CL10 CAR+ T cells on
days 4, 10, 17, 31, and 38 following tumor injection. 10 mice per group (5mice per group
were euthanized on d33). Tumor progression was monitored by (E) progressive weight
gain and (F) bioluminescent imaging. (G) Survival. (H) Representative bioluminescent
images of 4 mice per group. Error bars represent mean ± SEM. IP – intraperitoneal. fLuc
– firefly luciferase.
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Figure 4.7

Figure 4.7 ID8-tumor bearing mice treated with multiple doses of CL10 CAR T cells
display poor survival of CAR T cells and no depletion of FRβ+ TAMs
5 mice/group treated in the experiment outlined in Figure 4.6 were euthanized on day 33.
Tumor ascites was collected by peritoneal wash and analyzed by flow cytometry. The
relative frequency of (A) CD45+CD11b+ cells, (B) CD45+CD11b+ F4/80+ TAMs, (C)
CD3+ and (D) CD3+CD8+ T cells was determined. (E) FRβ expression in CD45+CD11b+
F4/80+ TAMs. Black histogram – CL10 IgG. Gray histogram – rat IgG2a isotype.
Representative FRβ plots are shown for one mouse per group. Total results are quantified
to the right (n=5). Error bars represent mean ± SEM. (F) Survival of CAR+ T cells on d33
(2 days following the fourth T cell injection) as measured by GFP expression in
CD3+CD8+ T cells. One representative histogram per group. Total expression for n=5
mice per group is shown to the right. Error bars represent mean ± SEM. (*** P < .001)
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Figure 4.8
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Figure 4.8 One large dose of CL10 CAR T cells leads to increased systemic innate
immune cells and depletion of FRβ+ TAMs
(A) Treatment schedule of C57BL/6 mice implanted IP with 5x106 fLuc+ ID8 and 8x106
CAR+ T cells on day 28 following tumor injection. Mice were euthanized for analysis 6
days later. n=5 mice per group. (B) Transient weight loss in CL10 CAR T cell treated
mice. Weight change is indicated as a percentage of pre-treatment (day (-1)) body weight.
(C) Peripheral blood cell counts at time of euthanasia (day 6 post T cell treatment).
CD3+CD8+ T cells, CD3+CD8- (CD4) T cells, CD11b+Ly6GHI and CD11b+Ly6CHI
myeloid cells. (D) Relative frequency of indicated immune cell populations as a
percentage of total live ascites cells. From left to right: Total CD45+, CD45+CD11b+,
CD45+CD11b+Ly6G+, CD45+CD11b+Ly6G-Ly6CHI, CD45+CD3+CD8+, and
CD45+CD3+CD4+. (E) Survival of CAR+ T cells in peritoneal cavity on day 6 post T cell
treatment as measured by GFP expression in CD3+CD8+ T cells. One representative GFP
fluorescence histogram per group. Total expression for n=5 mice per group is shown to
the right. (F) FRβ expression in F4/80+CD204+ ascites TAMs. One representative FRβ
expression histogram per group. Black – CL10 IgG. Gray – rat IgG2a isotype. Total
expression for n=5 mice per group is shown to the right. (G) Representative flow
cytometry plots to indicate F480 and CD204 populations in CL10 or control P4 CAR T
cell treated mice. Gated on CD45+CD11b+Ly6G- cells. (H) Representative flow
cytometry plots to highlight different Ly6C and CD204 populations in CL10 or control
P4 CAR T cell treated mice. Gated on CD45+CD11b+Ly6G- cells. All error bars represent
mean ± SEM of n=5 mice per group. (* P < .05, ** P < .01, *** P < .001) IP –
intraperitoneal, fLuc – firefly luciferase.
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Figure 4.9
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Figure 4.9 Cyclophosphamide and IL2 conditioning increases CL10 CAR T cell
persistence and toxicity in ID8 tumor-bearing mice
(A) Treatment schedule of C57BL/6 mice implanted IP with 5x106 fLuc+ ID8 and 8x106
CAR+ T cells on day 28 following tumor injection. 150mg/kg cyclophosphamide (Cy)
was given IV on day 27. 15μg IL2 was given IP on days 28, 29, and 30. (CyIL2
conditioning). Mice were euthanized for analysis 6 days later. n= 5 mice per group. (B)
Progressive weight loss in CL10 CAR T cell treated mice. Weight change is indicated as
a percentage of pre-treatment (day (-1)) body weight. (C) Peripheral blood cell counts at
time of euthanasia (day 6 post T cell treatment). CD3+CD8+ T cells, CD3+CD8- (CD4) T
cells, CD11b+Ly6GHI and CD11b+Ly6CHI myeloid cells. (D) Relative frequency of
indicated immune cell populations as a percentage of total live ascites cells. From left to
right: Total CD45+, CD45+CD11b+, CD45+CD11b+Ly6G+, CD45+CD11b+Ly6G-Ly6CHI,
CD45+CD3+CD8+, and CD45+CD3+CD4+. (E) Frequency of CAR+ T cells in peritoneal
cavity on day 6 post T cell treatment as measured by GFP expression in CD3+CD8+ T
cells. One representative GFP fluorescence histogram per group. Total expression for n=5
mice per group is shown to the right. (F) FRβ expression in F4/80+CD204+ ascites
TAMs. One representative FRβ expression histogram per group. Black – CL10 IgG. Gray
– rat IgG2a isotype. Total expression for n=5 mice per group is shown to the right. (G)
Representative flow cytometry plots to indicate F480 and CD204 populations in CL10 or
control P4 CAR T cell treated mice. Gated on CD45+CD11b+Ly6G- cells. (H)
Representative flow cytometry plots to highlight different Ly6C and CD204 populations
in CL10 or control P4 CAR T cell treated mice. Gated on CD45+CD11b+Ly6G- cells. All
error bars represent mean ± SEM of n=5 mice per group. (* P < .05, ** P < .01, *** P <
.001) IP – intraperitoneal, IV – intravenous, fLuc – firefly luciferase.
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Figure 4.10
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Figure 4.10 Tumor-specific CAR T cells do not recapitulate the immune cell
activation and toxicity observed in CL10 CAR T cell treated mice
(A) Treatment schedule of C57BL/6 mice implanted IP with 5x106 fLuc+ ID8-Meso and
8x106 CAR+ T cells on day 28 following tumor injection. P4 CAR T cells are specific for
ID8-Meso and serve as a positive control for T cell activation, and CD19 CAR T cells
serve as a negative control. 150mg/kg cyclophosphamide (Cy) was given IV on day 27.
15μg IL2 was given IP on days 28, 29, and 30 (CyIL2 conditioning). Mice were
euthanized for analysis 7 days later. n= 4 or 5 mice per group. (B) Progressive weight
loss only in CL10 CAR T cell treated mice. Weight change is indicated as a percentage of
pre-treatment (day (-2)) body weight. (C) Peripheral blood cell counts at time of
euthanasia (day 7 post T cell treatment). CD3+CD8+ T cells, CD3+CD8- (CD4) T cells,
CD11b+Ly6G+ and CD11b+Ly6CHI myeloid cells. (D) Relative frequency of indicated
immune cell populations as a percentage of total live ascites cells. From left to right:
Total CD45+, CD45+CD11b+, CD45+CD11b+Ly6G+, CD45+CD11b+Ly6G-Ly6C+,
CD45+CD11b+Ly6G-F4/80+CD204+ TAMs, CD45+CD3+CD4+, and CD45+CD3+CD8+.
(E) Frequency of CAR+ T cells in peritoneal cavity on day 7 post T cell treatment as
measured by GFP expression in CD3+CD8+ T cells. One representative GFP fluorescence
histogram per group. Total GFP expression (left) and GFP MFI (right) for n=4 or 5 mice
per group is shown below. (F) FRβ expression in F4/80+CD204+ ascites TAMs. One
representative FRβ expression histogram per group. Black – CL10 IgG. Gray – rat IgG2a
isotype. Total expression for n=4 or 5 mice per group is shown to the left. (G)
Representative flow cytometry plots to indicate F4/80 and CD204 populations in CL10,
P4, or CD19 control CAR T cell treated mice. Gated on CD45+CD11b+Ly6G- cells. (H)
Representative flow cytometry plots to highlight different Ly6C and CD204 populations
in CL10, P4, or CD19 control CAR T cell treated mice. Gated on CD45+CD11b+Ly6Gcells. (I) Representative flow cytometry plots to highlight the large frequency of
infiltrating Ly6G+ neutrophils only in CL10 treated mice. Gated on CD45+CD11b+ cells.
All error bars represent mean ± SEM of n=4 or 5 mice per group. (* P < .05, ** P < .01,
*** P < .001) IP – intraperitoneal, IV – intravenous, fLuc – firefly luciferase, MFI –
median fluorescence intensity.
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Figure 4.11

Figure 4.11 Clodronate liposome-mediated macrophage depletion causes a similar
increase in myelopoiesis and synergizes with CL10 CAR T cells
(A) Treatment schedule of C57BL/6 mice implanted IP with 5x106 fLuc+ ID8 and 8x106
CAR+ T cells on day 28 following tumor injection. Clodronate liposomes (Clod) or PBS
control liposomes (PBL) were provided IV on day 26 and IP on day 27. Mice were
euthanized for analysis 6 days later. n=5 mice per group. (B) Rapid weight loss in 50% of
CL10-clodronate treated mice. Weight change is indicated as a percentage of pretreatment (day (-2)) body weight. Each line represents one mouse. (C) Peripheral blood
cell counts at day 3 post T cell treatment. CD3+CD8+ T cells, CD3+CD8- (CD4) T cells,
CD11b+Ly6G+ granulocytes and CD11b+Ly6CHI monocytes. Error bars represent mean ±
SEM of n=3 to 5 mice per group. (* P < .05, ** P < .01) IP – intraperitoneal, IV –
intravenous.
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Figure 4.12
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Figure 4.12 CL10 CAR T cells enhances tumor progression in NC mice and inhibits
tumor growth in CyIL2 conditioned mice
(A) Treatment schedule of C57BL/6 mice implanted IP with 5x106 fLuc+ ID8-Meso and
8x106 CAR+ T cells on day 28 following tumor injection. P4 CAR T cells are specific for
ID8-Meso and CD19 CAR T cells serve as a negative control. P4/CL10 groups received
4x106 each of P4 and CL10 CAR+ T cells. In CyIL2 conditioned mice, 150mg/kg
cyclophosphamide (Cy) was given IV on day 27 and 15μg IL2 was given IP on days 28,
29, and 30. Non-conditioned (NC) mice were treated in the absence of Cy or IL2. Mice
were monitored long term for tumor progression. Weight changes in (B) NC and (C)
CyIL2 conditioned mice following transfer of CAR T cells. Tumor luminescence in (D)
NC and (E) CyIL2 conditioned mice following T cell transfer. Peripheral blood cell
counts on day 31 following T cell transfer in (F) NC and (G) CyIL2 conditioned mice.
Survival in (H) NC and (I) CyIL2 conditioned mice following T cell transfer. Error bars
represent mean ± SEM of n=5 mice per group.
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Figure 4.13

Figure 4.13 CL10 CAR T cells produce toxicity in non-tumor bearing mice
(A) Increased weight loss in 6-week old non-tumor bearing C57BL/6 mice treated
according to the CyIL2 protocol with 8x106 CL10 or control P4 CAR+ T cells. Error bars
represent mean ± SEM of n=5 mice per group. (* P < .05).
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Figure 4.14
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Figure 4.14 Expression of FRβ in healthy mouse tissue macrophages
(A) FRβ expression in tissue macrophages from different organs in healthy untreated
C57BL/6 mice. At least 3 mice were analyzed for each tissue. Error bars represent mean
± SEM of n=3 to 8 mice per tissue. (B) F4/80 and CD204 expression of tissue resident
myeloid (CD45+CD11b+Ly6G-) cells in the indicated organs. The F4/80 vs CD204 gates
shown were used to assess FRβ expression. (C) Representative macrophage FRβ
expression histograms for each tissue. Frequency of FRβ+ cells is indicated in tissues with
significant expression compared to isotype. Blue – CL10 IgG. Gray – rat IgG2a isotype.
PB – peripheral blood, BM – bone marrow, GI – gastrointestinal tract.
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Figure 4.15

Figure 4.15 Liver Kupffer cells are depleted in CL10 CyIL2 treated mice
Kupffer cell depletion in CyIL2 CL10 treated mice as indicated by depletion of F4/80+
cells. Left – representative 20X images of F4/80 IHC. Right – F4/80+ cell quantification.
n=1 to 5 mice per group. (** P < .01)
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Figure 4.16

Figure 4.16 CL10 CAR T cell treatment leads to significant liver inflammation and
necrosis
Fixed liver samples and serum from mice treated in experiments outlined in Figures 4.8,
4.9, and 4.10 were further analyzed for liver pathology. (A) Representative 4X H&E liver
images from treated mice highlighting areas of carcinomatosis. (B) 10X image
highlighting carcinomatosis with areas of tumor necrosis in CL10 CyIL2 treated mice.
(C) 10X image highlighting liver necrosis in CL10 CyIL2 treated mice. (D) 10X image
highlighting severe EMM in CL10 CyIL2 treated mice. (E) 40X image highlighting areas
of hepatocyte regeneration (arrows point to multiple mitotic figures) surrounding severe
EMM in CL10 CyIL2 treated mice. (F) EMM score (0=normal to 10=marked) from n=914 mice per treatment group. Error bars represent mean ± SEM. (*** P < .001) (G)
Serum ALT 6-7 days post T cell transfer. (H) Serum AST 6-7 days post T cell transfer.
Error bars represent mean ± SEM of n=9-14 mice per group. Control groups incorporate
both CD19 and P4 CAR T cell treated mice from both ID8 and ID8-Meso tumor models.
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Figure 4.17

Figure 4.17 Chemokines and cytokines highly increased in CL10 CyIL2 treated mice
Luminex analysis of serum cytokine and chemokine levels were evaluated on day 3
following T cell transfer from mice treated in experiments outlined in Figures 4.8, 4.9,
and 4.10. Cytokines that were substantially increased in CyIL2 conditioned CL10 CAR T
cell treated mice include (A) G-CSF, (B) IL6, (C) IFNg, (D) IP-10, (E) MIG, (F) KC,
(G) MCP-1, and (H) Eotaxin. (I) Serum IL-5 is highly increased likely due to
cyclophosphamide/IL2 conditioning (CyIL2). Error bars represent mean ± SEM of n=5 to
10 mice per group. (* P < .05, ** P < .01, *** P < .001). P values were calculated to
compare CyIL2 Control to CyIL2 CL10 CAR T cell treated groups. Control mice
incorporate both CD19 in ID8-Meso and P4 in ID8 tumor models. P4-Meso designates
P4 CAR T cell treated ID8-Meso tumor bearing mice.
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Figure 4.18
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Figure 4.18 Chemokines and cytokines low/moderately increased in CL10 CyIL2
treated mice
Luminex analysis of serum cytokine and chemokine levels were evaluated on day 3
following T cell transfer from mice treated in experiments outlined in Figures 4.8, 4.9,
and 4.10. Cytokines that were significantly but moderately (range < 200pg/mL) increased
in CyIL2 conditioned CL10 CAR T cell treated mice include (A) GM-CSF, (B)
RANTES, (C) TNFα, (D) IL-3, (E) IL-7, (F) IL-10, (G) IL-13, (H) IL-15, (I) MIP-1β,
(J) LIF, (K) MIP-1α, (L) MIP-2, and (M) VEGF. Error bars represent mean ± SEM of
n=5 to 10 mice per group. (* P < .05, ** P < .01, *** P < .001). P values were calculated
to compare CyIL2 Control to CyIL2 CL10 CAR T cell treated groups. Control mice
incorporate both CD19 in ID8-Meso and P4 in ID8 tumor models. P4-Meso designates
P4 CAR T cell treated ID8-Meso tumor bearing mice.
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Figure 4.19

Figure 4.19 Chemokines and cytokines not changed in CL10 CyIL2 treated mice
Luminex analysis of serum cytokine and chemokine levels were evaluated on day 3
following T cell transfer from mice treated in experiments outlined in Figures 4.8, 4.9,
and 4.10. Cytokines that were mostly unchanged between all groups include (A) IL-1a,
(B) IL-1b, (C) IL-2, (D) IL-4, (E) IL-9, (F) IL-12p40, (G) IL-12p70, (H) LIX, (I) IL-17,
(J) M-CSF. Error bars represent mean ± SEM of n=5 to 10 mice per group. Control mice
incorporate both CD19 in ID8-Meso and P4 in ID8 tumor models. P4-Meso designates
P4 CAR T cell treated ID8-Meso tumor bearing mice.
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CHAPTER 5: FRβ CAR T cells: The Road Ahead
Other CAR T cells for AML
Since the inception of this thesis work, other CAR targets for AML have been evaluated and are
currently in clinical development. To compare the potential benefits and limitations of FRβ CAR
T cell therapy for AML, we will briefly summarize preclinical and clinical experience with other
CARs currently in development to treat AML.
Expression of the carbohydrate tumor antigen, Lewis Y (LeY), has been reported in many types
of cancer, and in 2010, Peinert and colleagues assessed its expression in AML and myeloma250.
46% of AML and 52% of MM patients expressed LeY. LeY CAR T cells were able to
significantly lyse LeY+ AML and MM cells. This group has previously published that although
neutrophils express low levels of LeY, they were not significantly targeted by LeY CAR T cells,
suggesting a favorable safety profile against normal tissues251. These findings led to the first CAR
T cell trial for AML patients utilizing LeY CAR T cells252. Of the 4 patients treated, 3 had
minimal residual disease (MRD) and one had active detectable disease in blood and BM before
treatment. Infusions were well tolerated without high grade toxicity or cytokine storm. Transient
decreases in blasts of the patient with detectable disease were observed. Trafficking to the BM
and spleen and persistence of CAR T cells by PCR were also observed, however, all four patients
relapsed with LeY+ AML. These findings suggest that LeY CAR T cell therapy is feasible in
AML patients, however, due to other contributing factors, possible suppression of T cells in
patients, clinical efficacy is limited.
CD33 (or Siglec-3) is a sialic acid binding surface antigen of the myelomonocytic lineage253. It is
expressed throughout myeloid differentiation, including in some CD34+ HSCs. CD33 is widely
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and highly expressed in the vast majority of AML patient tumors, and gemtuzumab ozogamicin, a
toxin linked to a CD33-specific monoclonal antibody, was given accelerated FDA approval for
use in AML patients in 2000. Unfortunately, after 9 years of experience with demonstrated
suboptimal efficacy and the incidence of hepatotoxicity in a large percentage of patients254,
gemtuzumab ozogamicin was discontinued in 2010. Hepatotoxicity was likely related to the
targeting of CD33+ cells in the liver, such as liver Kupffer cells. Nevertheless, CD33 remained a
target of interest for developing other immunotherapies for AML. In the first report of CD33directed CARs, CD33 CARs were introduced into cytokine-induced killer (CIK) cells enriched
for CD3+CD56+CD8+ cells188. Addition of CD33 CAR significantly enhanced the anti-leukemic
activity of CIK cells in vitro, however, increased cytotoxicity of CD33 CAR+ CIKs was also
noted against healthy CD34+ HSCs. Follow-up experiments showed that CD33 CAR transduced
EBV-specific T cells also displayed anti-leukemic activity in vitro and in vivo, however, colony
formation following culture with CD34+ HSCs was still impaired189. O’Hear and colleagues
recently reported the use of a different CD33 CAR construct255. These CAR T cells also showed
efficacy against primary AML and AML cell lines in vitro, and greatly improved survival of
Molm13 xenograft tumor bearing mice in vivo. Again, CD33 CAR T cells significantly inhibited
HSC colony formation in vitro. Kenderian et al created a CD33 CAR using the scFv from
gemtuzumab and evaluated in vivo efficacy against primary AML and healthy human BM
xenografts in mice208. CD33 CAR T cells display potent antitumor activity in vivo against AML
cell line Molm14 and primary AML xenografts. In addition, the authors confirm the CD33 CARspecific bone marrow toxicity suggested in the other studies with an in vivo model using human
HSC xenografts. Despite the toxicity with gemtuzumab and preclinical evidence for normal HSC
recognition in vitro and in mouse models, the Chinese PLA General Hospital is currently
conducting a CD33 CAR trial for AML patients (NCT01864902). Results have been reported
from one patient256 with relapsed, refractory AML and pancytopenia. The patient experienced a
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significant but transient decrease in CD33+ blasts which was accompanied by fever and cytokine
spikes that were manageable. Although CAR+ T cells were still detectable by PCR, the disease
rapidly progressed. Of interest, no hepatotoxic effects were observed. Although the antitumor
effects were mild, the infusion of CD33 CAR T cells was reasonably well tolerated in this patient.
More patients will need to be evaluated before safety concerns about CD33 targeting by CAR T
cells can be alleviated.
CD123, the IL3 receptor α chain, is also highly expressed in AML and HSCs but has decreased
expression in mature myeloid lineage cells. CD123 antibody-based therapies have not resulted in
BM suppression, but efficacy against AML has been limited257. Like CD33, many groups have
now evaluated CD123 CAR T cells in preclinical models. Tettamanti and colleagues found that
CD123 CAR CIK cells showed comparable antitumor activity to CD33 but had a somewhat
decreased inhibition of HSC colony formation207. CD123 CIK cells also targeted CD14+
monocytes at roughly the same level as CD33. Mardiros et al compared the activity of two
different anti-CD123 scFvs in CAR T cells190. Both CARs displayed potent anti-leukemic effects
in vitro and in vivo and were capable of eliminating CD123+CD34+ cells from both leukemic and
normal BM. Pizzitola also compared CD33 to CD123 CAR CIKs in vivo using primary AML and
healthy CD34+ HSCs in mouse models258. CD123 CAR T cells displayed comparable antileukemia activity and improved safety profile compared to CD33 against healthy CD34+ cells in
vitro and in vivo. On the other hand, Gill and colleagues described CD34+ bone marrow
destruction in humanized mice using CD123 CAR T cells191. Differences in these outcomes may
be the result of the different CAR T cell constructs used (including scFv and costimulation),
transduction and expansion methods, and T cell doses used for in vivo models. While some
studies showed an improved safety profile for CD123 compared to CD33 in terms of the potential
for healthy BM HSC elimination, this is still a major concern in applying CD123 CAR T cells in
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the clinic. CD123 may have a better safety profile when considering expression in mature
myeloid cells, like liver Kupffer cells. In a setting where BM transplant is available, CD123 CAR
T cells may be a safer alternative to CD33. A clinical trial (NCT02159495) is planned, but not yet
recruiting patients, to evaluate CD123 CAR T cells in AML.
CAR T cells specific for CD44v6, an isoform of the cell adhesion molecule CD44, have also been
evaluated in preclinical models of AML and MM259. This target is particularly intriguing because
it was demonstrated to be necessary for tumor growth and engraftment in vivo, minimizing the
chance of tumor escape due to antigen loss. In addition CD44v6 is not expressed in hematopoietic
progenitors and colony formation was not inhibited in vitro or in vivo. If successfully applied
without toxicity, CD44v6 could be a promising CAR target for many indications including
hematological and solid tumors. However, a large percentage of patients treated with
bivatuzumab, a CD44v6-specific monoclonal antibody tested in clinical trials for head and neck
squamous cell carcinoma260 and metastatic breast cancer261, experienced skin disorders including
one fatal report of epidermal necrolysis260. These off-tumor effects, likely due to expression of
CD44v6 in keratinocytes, resulted in discontinuation of clinical development of bivatuzumab.
Interestingly, Casucci and colleagues report that while CD44v6 CAR T cells show high activity
against AML, MM, and healthy monocytes, they were not reactive against primary human
keratinocytes in vitro. While this finding is encouraging, it is unknown whether the low toxicity
profile against keratinocytes in vitro will hold up during clinical use of CD44v6 CAR T cells in
patients.

FRβ CAR T cells show a reduced likelihood to produce BM HSC toxicity
Although LeY and CD44v6 CAR T cells have been evaluated for AML, they are not myeloid
restricted and their respective toxicities would likely result from recognition of antigen in non176

myeloid tissues. CD123, CD33, and FRβ have all been described as nearly exclusive to the
myeloid lineage. However, there are noteworthy distinctions in expression of these molecules
during myeloid lineage differentiation. CD123 is highly expressed on CD34+ HSCs and myeloid
progenitors in the bone marrow with reduced expression on mature monocytes and macrophages.
CD33 is expressed on some CD34+ HSCs, myeloid progenitors, peripheral monocytes and some
tissue macrophages, including liver Kupffer cells and lung alveolar macrophages208. FRβ is not
co-expressed with CD34 or CD123 in bone marrow HSCs and myeloid progenitors but shows
high expression in CD33+ and CD14+ monocytes (Figure 5.1).

Figure 5.1 Co-expression of FRβ and CD34, CD123, CD33, and CD14 in healthy
donor bone marrow
Due to demonstrated expression in HSCs, both CD33 and CD123 CAR T cells show the potential
to eliminate healthy CD34+ HSCs in the bone marrow microenvironment. Our experiments with
FRβ reveal its expression is induced at a later phase of myeloid differentiation. These findings,
coupled with our in vivo model using humanized mice engrafted with human CD34+ BM, highly
suggest a decreased risk of BM HSC toxicity in AML patients treated with FRβ CAR T cells
compared to CD123 or CD33. CD123 and CD33 CAR T cells could potentially be safely applied
in patients who are eligible for BM transplant following CAR T cell therapy. However, many
patients are not eligible due to age262 or lack of an appropriate donor.
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FRβ CAR T cells recognize healthy monocytes
Like CD33 and CD44v6, FRβ is highly expressed in healthy peripheral monocytes.
Monocytopenia would be an expected dose limiting toxicity in patients treated with CAR T cells
targeting these antigens. We and Kenderian208 have demonstrated the efficacy of transient mRNA
CAR T cells for FRβ+ and CD33+ AML, and Casucci259 showed that incorporation of an inducible
caspase 9 suicide gene allowed for the return of monocytes in vivo following selective elimination
of CD44v6 CAR T cells. These preclinical models suggest that transient CAR expression could
be applied to eliminate tumor cells in the short term, following which CAR T cell deletion could
allow for repopulation of peripheral monocytes.
Another consideration is that high levels of antigen positive monocytes in patients would provide
an alternative source for T cell activation, which could contribute to cytokine release syndrome
observed in some CAR T cell treated patients. A higher tumor burden seemed to correlate with
the severity of cytokine storm in at least one study263. Therefore, pre-conditioning with
myeloablative regimens could be added to clinical protocols to essentially “de-bulk” the patient
of antigen positive target cells before CAR T cell transfer. These considerations could increase
the chances for safe application of FRβ and other myeloid-directed CAR T cells.

Combination therapy with FRβ CAR T cells: couldn’t we all work
together?
A growing array of potential CAR T cell targets in AML will likely benefit patients in the future
as we learn to safely implement CAR T cells. Not all patients’ tumors will express any one
antigen, and heterogeneity within a given patient increases the likelihood that someone treated
with one CAR T cell specificity could relapse with antigen-negative disease. CD19 is one of the
most ubiquitously expressed antigens in ALL, and CD19-negative disease relapse has been
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observed following CAR therapy122. While the safety profiles of each CAR target antigen must be
thoroughly investigated individually, parallel or sequential treatment could eventually be applied
to target multiple AML tumor antigens in the same patient. Combined therapy of safe and
effective CAR T cells of multiple specificities will likely improve CAR T cell efficacy and long
term survival of patients in the future.
FRβ CAR T cells could also be beneficial in combination with other types of AML therapy.
Already noted, myeloablative therapy and FRβ CAR T cells could be applied before stem cell
transplant to increase the safety of FRβ CAR T cells and promote longer remissions following
BM transplant. As highlighted in Chapter 2, combination with ATRA (already FDA approved for
use in AML patients) would likely provide augmented activity of FRβ CAR T cells through
antigen upregulation on AML blasts.

FRβ CAR T cells: what about tissue macrophages?
While FRβ has been observed on mature macrophages at sites of inflammation and tumor growth,
expression in healthy tissue macrophages is not well characterized. We attempted to optimize our
high affinity m923-IgG for use in IHC to evaluate FRβ expression in tissue sections from healthy
organs, however, we were unable to achieve consistent staining. Another group recently
published FRβ IHC expression in over 900 sections from human malignancies168, but
unfortunately, this did not include any non-tumor tissue sections. While this study supports the
rationale for applying FRβ-directed therapy to eliminate tumor associated macrophages (TAMs),
expression in healthy tissue macrophages should be investigated more thoroughly to evaluate the
relative specificity of FRβ to tumor localized macrophages. This question will need to be more
adequately addressed in order to accurately predict off-tumor toxicity in patients treated with FRβ
CAR T cells. Although no hepatotoxicity was observed in one patient treated with CD33 CAR T
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cells, the high liver toxicity in patients treated with gemtuzumab was attributed to destruction of
CD33+ cells (most likely Kupffer cells) in the liver. The strong correlation between CD33 and
FRβ in bone marrow and peripheral blood monocytes suggests that tissue macrophage expression
of these antigens may overlap as well.

FRβ CAR T cells: Lessons from mouse models
Our mouse model of FRβ-directed CAR T cell therapy also highlights the potential for toxicity
associated with recognition of macrophages in otherwise healthy organs. In the setting of CyIL2
preconditioning, CL10 CAR T cells caused systemic aberrant myelopoiesis and on-target
depletion of liver Kupffer cells. Although inflammation and toxicity ultimately resolved in CL10
treated C57BL/6 mice, even transient elimination of mature macrophages elicited a dramatic and
potentially dangerous degree of systemic immune activation. It is possible that longer survival of
CL10 CAR T cells would have ultimately led to mortality of the animals. As discussed in Chapter
4, future experiments will be needed to fully understand the nature of the toxicity produced using
CL10 CAR T cells. We could then utilize the phenotype in our mouse model to evaluate which
potential intervening therapies, such as neutralizing systemic cytokines IL6 or TNFα, are likely to
improve the safety profile of macrophage-specific CAR T cells.
Our experiments with CL10 CAR T cells warrant caution for clinical development of FRβ CAR T
cells in patients, particularly in the setting of non-myeloablative lymphodepletion and IL2.
However, the relevance of FRβ-directed CAR T cells in mice to their application in humans is
difficult to gauge because of the disparate distribution of FRβ during myeloid differentiation in
mice and humans (Figure 5.2).
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Figure 5.2 Expression of mouse and human FRβ during myeloid differentiation
Expression of FRβ in humans begins at the myeloid progenitor cell stage, with increasing
expression along differentiation to monocytes. AML derived from these myeloid progenitor cells
also expresses FRβ in humans. As discussed above, evidence for high expression in mature
macrophages has also been suggested, however, the tissue distribution of macrophage FRβ
expression in healthy individuals is not well characterized. In C57BL/6 mice, FRβ expression is
absent in bone marrow myeloid progenitor cells, Trib2 induced AML (data not shown), bone
marrow and peripheral blood monocytes, and most tissue macrophages. Therefore, the potential
for bone marrow and monocyte toxicity could not be assessed using FRβ CAR T cells in mice.
Like in humans, mouse and rat macrophages in models of inflammation and tumor growth show
increased expression of FRβ. We also confirmed high expression of FRβ in liver and cardiac
macrophages in healthy mice that was absent in macrophages from many other tissues. These
findings suggest distinct control of FRβ expression in different tissue microenvironments. Future
experiments will be needed to understand how the different tissue environments mediate
macrophage phenotype. Again, in-depth analyses of tissue macrophages in humans are needed to
evaluate whether differential FRβ tissue macrophage expression is reproducible in humans and
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whether liver and cardiac macrophages show similarly high FRβ expression. An understanding of
the potential sources of off-tumor CAR T cell attack will be invaluable for designing safe and
effective FRβ CAR T cell therapies. For example, myeloablation or macrophage-specific
elimination could be used in preconditioning therapies to decrease off-tumor T cell activation in
healthy organs.
For consideration of CAR T cell therapy for TAM elimination in solid tumors, our experiments in
the ID8 tumor model suggest that CL10 CAR T cells can eliminate FRβ+ TAMs in the tumor
microenvironment and provide a significant but short survival benefit. However, due to the
combination of short term persistence of CAR T cells in our mouse model and increased
recruitment of Ly6CHI monocytes we were unable to fulfill our goal of modeling long term
depletion of TAMs with CAR T cells for the duration of tumor growth. Human peripheral blood
monocytes, unlike in mice, highly express FRβ. The limitations associated with modeling FRβ in
mice would not apply. Since FRβ is expressed earlier in myeloid differentiation, FRβ-specific
CAR T cells would eliminate both mature TAMs and TAM precursor monocytes in humans.
Therefore, long term depletion of human TAMs would likely be possible. Another population of
immunosuppressive tumor associated myeloid cells known as MDSCs have been described in
mouse tumor models and human patients. They resemble immature myeloid cells of either
granulocytic (Ly6G+) or monocytic (Ly6C+) origin in mice, and both granulocytic (CD66b+) and
monocytic (CD14+) MDSCs have been described in human cancer patients. Since FRβ is not
expressed in immature Ly6C+ myeloid cells in mice, we would not be able to assess CARmediated MDSC elimination in our mouse model. However, in humans, CD14+ monocytic
MDSCs would likely express FRβ. We hypothesize that FRβ-targeted CAR T cells have the
potential to disrupt the tumor-myeloid cell axis of immunosuppression in human cancer patients
with the potential to eliminate FRβ+ TAMs, systemic and tumor-localized MDSCs, and inhibit
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repopulation of TAMs by elimination of peripheral monocytes. Unfortunately we are unable to
model these aspects of FRβ CAR T cells in mouse models due to the differences in FRβ
expression along myeloid-lineage differentiation. In addition, the major safety concerns for CAR
T cells redirected against myeloid antigens would need to be addressed before clinical application
for solid tumors.
With the excitement and potential of CAR T cells in cancer therapy, the field is constantly
innovating new ideas for finer control of CAR T cell activity. Drug-inducible suicide genes200 and
newly described “ON-switches” for CAR induction264 are likely only the beginning in the modern
era of genome engineering, which will soon allow for precision network control and fine-tuned
manipulation of engineered T cells.
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